WO2022242703A1 - 抗msln抗体及其应用 - Google Patents

抗msln抗体及其应用 Download PDF

Info

Publication number
WO2022242703A1
WO2022242703A1 PCT/CN2022/093759 CN2022093759W WO2022242703A1 WO 2022242703 A1 WO2022242703 A1 WO 2022242703A1 CN 2022093759 W CN2022093759 W CN 2022093759W WO 2022242703 A1 WO2022242703 A1 WO 2022242703A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
sequence shown
antibody
antigen
cells
Prior art date
Application number
PCT/CN2022/093759
Other languages
English (en)
French (fr)
Inventor
杨翠青
邵小慧
廖敬礼
付雅媛
曹卓晓
唐任宏
任晋生
Original Assignee
江苏先声药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏先声药业有限公司 filed Critical 江苏先声药业有限公司
Priority to CN202280035947.9A priority Critical patent/CN117396515A/zh
Publication of WO2022242703A1 publication Critical patent/WO2022242703A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Definitions

  • the present invention relates to the field of antibodies, in particular to anti-MSLN antibodies and applications thereof.
  • MSLN Mesothelin
  • Mesothelin is a differentiation antigen present on normal mesothelial cells, and can be expressed in mesothelial cells of normal pleura, pericardium and peritoneum. Limited expression in normal tissues, but MSLN was found to be expressed in 90% of epithelioid malignant pleural mesothelioma cells, 69% of lung adenocarcinoma cells, 60% of breast cancer cells, 46% of esophageal cancer cells, pancreatic tumor cells and ovarian cancer cells (Morello A et al., Cancer Discov.2016; 6(2):133-146; Baldo P et al., Onco Targets Ther.2017; 10:5337-5353; Argani P et al., Clin Cancer Res.2001; 7 (12):3862-3868; Hassan R et al., Clin Cancer Res. 2004; 10(12Pt 1):3937-3942). Therefore, MSLN may become
  • the MSLN gene is located on chromosome 16p13.3, the full length of the gene is 8kb, the cDNA size is 2138bp, contains an open reading frame of 1884bp, 17 exons, and encodes 628 amino acids.
  • the MSLN gene encodes a 71KDa precursor protein.
  • the MSLN precursor protein is anchored on the cell membrane by Glycosylphosphatidylinositol (GPI), and can be hydrolyzed by furin into two parts: the N-terminal soluble protein with a molecular weight of 31 kDa, known as megakaryocyte enhancement Factor (megakaryocyte-potentiating factor, MPF) and a cell surface glycoprotein with a molecular weight of 40kDa are mature MSLN (Chang K et al., Proc Natl Acad Sci US A.1996; 93(1):136-140; Manzanares et al., Hepatol Commun. 2017;2(2):155-172).
  • GPI Glycosylphosphatidylinositol
  • mice The biological function of mesothelin has not been fully elucidated.
  • researchers have studied mice that knocked out the MSLN gene and found that the mice showed no abnormalities in development, reproduction, and blood cell counts, indicating that it did not affect the normal growth and development of mice. (Bera TK et al., Mol Cell Biol. 2000; 20(8):2902-2906).
  • MSLN The abnormal expression of MSLN plays an important role in the proliferation, differentiation, adhesion and drug resistance of tumor cells.
  • Overexpression of MSLN can activate multiple signaling pathways of NF- ⁇ B (nuclear factor kappa-light-chain-enhancer of activated B cells), MAPK (mitogen-activated protein kinase) and PI3K (Phosphoinositide 3-kinases), thereby inducing cell apoptosis Promoting cell proliferation, migration and metastasis by inducing the activation and expression of MMP7 (matrix metalloproteinase 7, matrix metalloproteinase-7) and MMP9 (matrix metalloproteinase 9, matrix metalloproteinase-9).
  • MSLN can block paclitaxel-induced tumor cell apoptosis and increase cancer cell resistance to drugs by simultaneously activating PI3K/AKT (Protein Kinase B, PKB) and MAPK/ERK (extracellular regulated protein kinases) signaling pathways (Bharadwaj U et al. Mol Cancer. 2011; 10:106; Cheng WF et al. Br J Cancer. 2009; 100(7):1144-1153).
  • PI3K/AKT Protein Kinase B, PKB
  • MAPK/ERK extracellular regulated protein kinases
  • Drug development targeting MSLN includes immunotoxins, vaccines, chimeric monoclonal antibodies, ADC (antibody-drug conjugate) and CAR-T (Chimeric Antigen Receptor T-Cell).
  • Antibody drugs mainly through antibody neutralization, antibody-dependent cell-mediated cytotoxicity (Antibody-dependent cell-mediated cytotoxicity, ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), antibody and effector molecules (toxins or inhibitors) ) combined with other methods to mediate tumor cell apoptosis or inhibit tumor cell proliferation, targeting and killing tumor cells.
  • Amatuximab (MORAb-009) is a chimeric high-affinity antibody composed of an anti-MSLN antibody SS1 single-chain variable region fragment and a human IgG1/ ⁇ constant region, which can prevent MSLN-expressing tumor cells from adhering to CA125 and pass ADCC It can kill tumor cells (Hassan R et al., Cancer Immun. 2007; 7:20).
  • Anetumab Ravtansine (BAY94-9343) is a fully human anti-MSLN antibody (MF-T) and maytansine derivative DM4 (tubulin polymerase inhibitor) linked by a reducing disulfide linker Drug Conjugation (Grosso F et al., Future Oncol. 2012; 8(3):293-305).
  • BAY94-9343 binds to tumor cells and can be internalized into lysosomes to release DM4 to kill tumor cells.
  • MSLN CAR-T Cell Therapy Shows Encouraging Results in Mesothelioma, Ovarian Cancer, Lung Cancer Mouse Transplant Models, Pancreatic, Ovarian, and Pleural Tumor Adaptations Underway at University of Pennsylvania and Memorial Sloan Kettering Cancer Center (Beatty GL et al. Cancer Immunol Res. 2015 Feb; 3(2):217; Adusumilli PS presented in 11th Annual PEGS Europe Summit, Portugal).
  • the present invention provides an anti-MSLN antibody, a nucleic acid encoding the same, a method for preparing the antibody, a pharmaceutical composition containing the antibody, and related uses of the pharmaceutical composition for treating tumors.
  • the invention provides an antibody or antigen-binding fragment that specifically binds MSLN, said antibody or antigen-binding fragment comprising:
  • the HCDR1-3 and/or LCDR1-3 are determined according to the Kabat numbering system, more preferably, the HCDR1-3 and/or the LCDR1-3 comprise the sequences shown in Table 23.
  • the HCDR1-3 are selected from any sequence combination of the following VH1-VH77 or have at least 70% identity with the sequence combination or have 1, 2, 3 or more amino acids
  • the LCDR1-3 is selected from any sequence combination of the following VL1-VL67 or has at least 70% identity or a sequence with 1, 2, 3 or more amino acid insertions, deletions and/or substitutions compared with the sequence combination combination, the replacement is preferably a conservative amino acid replacement:
  • the antibody or antigen-binding fragment comprises a sequence combination selected from: VH1+VL1, VH2+VL2, VH3+VL3, VH4+VL4, VH5+VL5, VH6+VL6, VH7+ VL7, VH8+VL8, VH9+VL9, VH10+VL10, VH11+VL11, VH12+VL12, VH13+VL13, VH14+VL14, VH15+VL15, VH16+VL16, VH17+VL17, VH18+VL18, VH19+VL19, VH19+VL20, VH20+VL21, VH21+VL22, VH22+VL23, VH23+VL24, VH24+VL25, VH25+VL26, VH26+VL27, VH27+VL28, VH28+VL29, VH29+V
  • the antibody or antigen-binding fragment comprises: (1) with SEQ ID NO: 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 569-571, 581-584, 593-596, 604-607, 615-618 or 626-631 any one of VH has Sequences that are at least 80%, 85%, 90%, 91%, 92%, 93%, 9
  • the antibody or antigen-binding portion comprises: (1) the sequence shown in SEQ ID NO: 16 and the sequence shown in SEQ ID NO: 17;
  • SEQ ID NO: the sequence shown in 44 and the sequence shown in SEQ ID NO: 45;
  • (123) is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence shown in (1) to (122) above sexual sequence.
  • the antibody or antigen-binding fragment comprises or does not comprise an antibody heavy chain constant region and/or a light chain variable region; optionally, the antibody heavy chain constant region can be selected from human, Alpaca, mouse, rat, rabbit or sheep; alternatively, the antibody heavy chain constant region can be selected from IgG, IgM, IgA, IgE or IgD, and the IgG can be selected from IgG1, IgG2, IgG3 or IgG4
  • the heavy chain constant region can be selected from Fc region, CH3 region, heavy chain constant region without CH1 fragment or complete heavy chain constant region; preferably, the heavy chain constant region has such as SEQ ID NO Amino acid sequence shown in: 158;
  • the light chain constant region has the amino acid sequence shown in SEQ ID NO: 159.
  • the antibody or antigen-binding fragment specifically binds to human MSLN protein; preferably, the dissociation constant (KD) with human MSLN is not greater than 8.00E-7M.
  • the antibody or antigen-binding fragment is:
  • the antibody or antigen-binding fragment is selected from monoclonal antibodies, polyclonal antibodies, natural antibodies, engineered antibodies, monospecific antibodies, multispecific antibodies (such as bispecific antibodies), Monovalent antibody, multivalent antibody, whole antibody, fragment of whole antibody, naked antibody, conjugated antibody, chimeric antibody, humanized antibody, fully human antibody, Fab, Fab', Fab'-SH, F(ab') 2. Fd, Fv, scFv, diabody or single domain antibody.
  • the antibody or antigen-binding fragment is also coupled with a therapeutic agent or tracer; preferably, the therapeutic agent is selected from drugs, toxins, radioisotopes, chemotherapeutics or immunomodulators,
  • the tracer is selected from radiological contrast agents, paramagnetic ions, metals, fluorescent labels, chemiluminescent labels, ultrasound contrast agents and photosensitizers.
  • the present invention provides a multispecific molecule comprising the antibody or antigen-binding fragment described in the first aspect; preferably, the multispecific molecule further comprises a specific binding An antigen other than MSLN or an antibody or antigen-binding fragment that binds a different epitope of MSLN than the antibody or antigen-binding fragment of the first aspect.
  • the antigen other than the MSLN is an antigen on the surface of T cells, B cells, natural killer cells, dendritic cells, macrophages, monocytes or neutrophils; preferably , the antigens other than MSLN are selected from: CD3, CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD16, CD16A, CD32B, PD-1, PD-2, PD-L1, VEGF, NKG2D, CD19, CD20, CD40, CD47, 4-1BB, CD137, EGFR, EGFRvIII, TNF-alpha, CD33, HER2, HER3, HAS, CD5, CD27, EphA2, EpCAM, MUC1, MUC16, CEA, Claudin18.2, folate receptor, Claudin6, WT1, NY- ESO-1, MAGE3, ASGPR1 or CDH16.
  • the multispecific molecule is a tandem scFv, a diabody (Db), a single chain diabody (scDb), a dual affinity retargeting (DART) antibody, F(ab') 2.
  • the present invention provides a chimeric antigen receptor (CAR), said chimeric antigen receptor at least comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signaling domain, said The extracellular antigen-binding domain comprises an antibody or antigen-binding fragment optionally selected from the first aspect.
  • CAR chimeric antigen receptor
  • the present invention provides an immune effector cell expressing the chimeric antigen receptor described in the third aspect, or comprising a nucleic acid fragment encoding the chimeric antigen receptor described in the third aspect;
  • the immune effector cells are selected from T cells, NK cells (natural killer cell), NKT cells (natural killer T cell), DNT cells (double negative T cell), monocytes, macrophages, dendritic cells or mast cells, the T cells are preferably selected from cytotoxic T cells, regulatory T cells or helper T cells; preferably, the immune effector cells are autoimmune effector cells or allogeneic immune effector cells.
  • the present invention provides an isolated nucleic acid fragment encoding the antibody or antigen-binding fragment of the first aspect, the multispecific molecule of the second aspect, or the chimeric molecule of the third aspect antigen receptor.
  • the present invention provides a vector comprising the nucleic acid fragment of the fifth aspect.
  • the present invention provides a host cell comprising the vector described in the sixth aspect; preferably, the cell is a prokaryotic cell or a eukaryotic cell, such as bacteria (Escherichia coli), fungi (yeast ), insect cells or mammalian cells (CHO cell line or 293T cell line).
  • the cell is a prokaryotic cell or a eukaryotic cell, such as bacteria (Escherichia coli), fungi (yeast ), insect cells or mammalian cells (CHO cell line or 293T cell line).
  • the present invention also provides a method for preparing an antibody or an antigen-binding fragment or a multispecific molecule, the method comprising culturing the cells described in the seventh aspect above, and isolating the cells expressing Antibodies or antigen-binding fragments, or isolated multispecific molecules expressed by said cells.
  • the present invention also provides a method for preparing immune effector cells, the method comprising introducing the nucleic acid fragment encoding the CAR described in the third aspect into the immune effector cells, optionally, the method further includes Enabling the immune effector cells to express the CAR described in the third aspect.
  • the present invention also provides a pharmaceutical composition, characterized in that the pharmaceutical composition comprises the antibody or antigen-binding fragment optionally selected from the first aspect, or the antibody or antigen-binding fragment optionally selected from the second aspect. or the immune effector cell described in the fourth aspect, or the nucleic acid fragment described in the fifth aspect, or the carrier described in the sixth aspect; or the product prepared by the methods described in the eighth and ninth aspects;
  • the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, diluent or adjuvant; optionally, the pharmaceutical composition further comprises an additional antineoplastic agent.
  • the present invention also provides an antibody or antigen-binding fragment optionally selected from the first aspect, or a multispecific antibody optionally selected from the second aspect, or the immune antibody described in the fourth aspect.
  • the present invention provides a method for preventing and/or treating tumors, comprising administering an effective amount of the antibody or antigen-binding fragment optionally selected from the first aspect, or optionally From the multispecific antibody described in the second aspect, or the immune effector cell described in the fourth aspect, or the nucleic acid fragment described in the fifth aspect, or the carrier described in the sixth aspect; or the eighth and ninth aspects or the pharmaceutical composition described in the tenth aspect;
  • the tumor is preferably mesothelioma, lung cancer, breast cancer, esophageal cancer, pancreatic cancer, ovarian cancer or pleural cancer; more preferably epithelioid malignant pleural mesothelium tumor, lung adenocarcinoma.
  • the present invention provides a kit comprising the antibody or antigen-binding fragment optionally selected from the first aspect, or the multispecific antibody optionally selected from the second aspect, or the fourth aspect
  • the present invention provides a method for detecting the expression of MSLN, under the condition that a complex can be formed between the antibody or antigen-binding fragment optionally selected from the first aspect and MSLN, the sample to be detected is mixed with Optionally contacting an antibody or antigen-binding fragment from the first aspect.
  • the present invention provides a method for inhibiting the proliferation or migration of cells expressing MSLN in vitro, under the condition that a complex can be formed between the antibody or antigen-binding fragment optionally selected from the first aspect and MSLN, The cells are contacted with an antibody or antigen-binding fragment optionally selected from the first aspect.
  • compositions including A and B should be understood as the following technical scheme: a composition composed of A and B, and a composition containing other components in addition to A and B, all fall into Into the scope of the aforementioned "a composition”.
  • MSLN Mesothelin
  • MSLN Mesothelin
  • an antigen-binding molecule eg, an antibody
  • an antigen-binding molecule specifically binds an antigen and substantially the same antigen with high affinity, typically, but does not bind an unrelated antigen with high affinity. Affinity is usually reflected in an equilibrium dissociation constant (KD), where a lower KD indicates a higher affinity.
  • KD equilibrium dissociation constant
  • high affinity generally refers to having about 1 ⁇ 10 -6 M or lower, about 1 ⁇ 10 -7 M or lower, about 1 ⁇ 10 -8 M or lower, about 1 ⁇ 10 -9 M or less, a KD of about 1 ⁇ 10 -10 M or less, 1 ⁇ 10 -11 M or less, or 1 ⁇ 10 -12 M or less.
  • KD KD/Ka, where Kd represents the dissociation rate and Ka represents the on-rate.
  • the equilibrium dissociation constant KD can be measured by methods known in the art, such as surface plasmon resonance (eg, Biacore) or equilibrium dialysis. For example, refer to the method for obtaining the KD value shown in Example 5 herein.
  • antigen binding molecule is used herein in the broadest sense to refer to a molecule that specifically binds an antigen.
  • antigen binding molecules include, but are not limited to, antibodies or antibody mimetics.
  • Antibody mimic refers to an organic compound or binding domain that can specifically bind to an antigen, but has nothing to do with the structure of an antibody.
  • antibody mimics include but are not limited to affibody, affitin, affilin, designed ankyrin repeat proteins (DARPins), aptamers or Kunitz-type domain peptides.
  • antibody is used herein in the broadest sense to refer to a polypeptide comprising sufficient sequence from the variable region of an immunoglobulin heavy chain and/or sufficient sequence from the variable region of an immunoglobulin light chain to be capable of specifically binding to an antigen or peptide combinations.
  • Antibody herein encompasses various forms and various structures as long as they exhibit the desired antigen-binding activity.
  • Antibody herein includes alternative protein scaffolds or artificial scaffolds with grafted complementarity determining regions (CDRs) or CDR derivatives. Such scaffolds include antibody-derived scaffolds comprising mutations introduced, eg, to stabilize the three-dimensional structure of the antibody, as well as fully synthetic scaffolds comprising, eg, biocompatible polymers.
  • Such scaffolds may also include non-antibody-derived scaffolds, such as scaffold proteins known in the art to be useful for grafting CDRs, including but not limited to tenascin, fibronectin, peptide aptamers, and the like.
  • Antibody herein includes a typical "four-chain antibody”, which belongs to the immunoglobulins composed of two heavy chains (HC) and two light chains (LC); In the N-terminal to C-terminal direction, it consists of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a hinge region (HR), a heavy chain constant region CH2 domain, a heavy chain constant region CH3 domain; and, When the full-length antibody is of the IgE isotype, it optionally also includes a heavy chain constant region CH4 domain; the light chain is composed of a light chain variable region (VL) and a light chain constant in the N-terminal to C-terminal direction.
  • VH heavy chain variable region
  • CH1 domain a heavy chain constant region
  • HR hinge region
  • CH2 domain a heavy chain constant region CH2 domain
  • CH3 domain heavy chain constant region
  • the full-length antibody is of the IgE isotype, it optionally also includes a heavy chain constant region CH4 domain
  • the light chain is
  • immunoglobulins can be divided into five classes, or isotypes of immunoglobulins, namely IgM, IgD, IgG, IgA, and IgE, and their corresponding heavy chains are respectively the ⁇ chain and the delta chain , ⁇ chain, ⁇ chain and ⁇ chain.
  • IgG can be divided into IgG1, IgG2, IgG3, IgG4, and IgA can be divided into IgA1 and IgA.
  • IgA2 Light chains are classified as either kappa chains or lambda chains by difference in the constant region.
  • Each of the five Ig classes can have either a kappa chain or a lambda chain.
  • an “antibody” herein may be derived from any animal, including but not limited to humans and non-human animals selected from primates, mammals, rodents and vertebrates, such as camelids, llamas , proto-ostrich, alpaca, sheep, rabbit, mouse, rat or cartilaginous fishes (eg sharks).
  • Antibody herein includes, but is not limited to, monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), monovalent antibodies, multivalent antibodies, intact antibodies, fragments of intact antibodies, naked antibodies , conjugated antibody, chimeric antibody, humanized antibody or fully human antibody.
  • the term "monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., except for possible variants (such as containing naturally occurring mutations or arising during the manufacture of a formulation, such variants typically appear as In addition to being present in small amounts), the individual antibodies comprising the population are identical and/or bind the same epitope. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), in monoclonal antibody preparations each monoclonal antibody is directed against a single determinant on the antigen.
  • monoclonal antibodies can be produced by a variety of techniques including, but not limited to, hybridoma technology, recombinant DNA methods, phage library display technology and the use of transgenic animals containing all or part of the human immunoglobulin loci methods and other methods known in the art.
  • natural antibody herein refers to antibodies produced and paired by the immune system of a multicellular organism.
  • engineered antibody herein refers to a non-natural antibody obtained through genetic engineering, antibody engineering and other techniques.
  • engineered antibody includes humanized antibodies, small molecule antibodies (such as scFv, etc.), specific antibodies, etc.
  • the term "monospecific” herein refers to having one or more binding sites, wherein each binding site binds the same epitope of the same antigen.
  • multispecific antibody herein refers to an antibody having at least two antigen-binding sites, each of which is associated with a different epitope of the same antigen or with a different epitope of a different antigen. bit binding.
  • terms such as “bispecific”, “trispecific”, “tetraspecific” and the like refer to the number of different epitopes to which an antibody/antigen binding molecule can bind.
  • valence herein refers to the presence of a defined number of binding sites in an antibody/antigen binding molecule. Accordingly, the terms “monovalent”, “bivalent”, “tetravalent” and “hexavalent” denote one binding site, two binding sites, four binding sites and six binding sites in an antibody/antigen binding molecule, respectively. point of existence.
  • full-length antibody intact antibody
  • intact antibody intact antibody
  • Antigen-binding fragment and “antibody fragment” are used interchangeably herein, and do not possess the full structure of an intact antibody, but only include partial or partial variants of an intact antibody that possess the ability to bind Antigen capacity.
  • Antigen-binding fragment or “antibody fragment” herein includes, but is not limited to, Fab, Fab', Fab'-SH, F(ab') 2 , Fd, Fv, scFv, diabody and single domain antibody.
  • Papain digestion of intact antibodies yields two identical antigen-binding fragments, termed "Fab” fragments, each containing the variable domains of the heavy and light chains, as well as the constant domain of the light chain and the first constant domain of the heavy chain (CH1 ).
  • Fab fragment herein refers to a light chain fragment comprising the VL domain and the constant domain (CL) of the light chain, and an antibody fragment comprising the VH domain and the first constant domain (CH1) of the heavy chain.
  • Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy-terminus of the CH1 domain of the heavy chain, including one or more cysteines from the antibody hinge region.
  • Fab'-SH is a Fab' fragment in which the cysteine residues of the constant domains bear a free thiol group. Pepsin treatment yields an F(ab') 2 fragment with two antigen-combining sites (two Fab fragments) and part of the Fc region.
  • Fd refers to an antibody consisting of VH and CH1 domains.
  • Fv refers to an antibody fragment consisting of a single-armed VL and VH domain.
  • the Fv fragment is generally considered to be the smallest antibody fragment capable of forming a complete antigen-binding site. It is generally believed that the six CDRs confer antigen-binding specificity to an antibody. However, even a variable region (such as the Fd fragment, which contains only three CDRs specific for an antigen) is able to recognize and bind antigen, although perhaps with a lower affinity than the full binding site.
  • scFv single-chain variable fragment
  • scFv single-chain variable fragment
  • Such scFv molecules may have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH.
  • Suitable prior art linkers consist of the repeated GGGGS amino acid sequence or variants thereof.
  • a linker having the amino acid sequence (GGGGS) 4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448).
  • Other linkers useful in the present invention are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur.J. Immunol.31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, described by Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001) Cancer Immunol.
  • diabody herein, whose VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow pairing between the two domains of the same chain, thus forcing the domains to The complementary domains of the other chain pair and create two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak R.J. et al., Structure 2:1121-1123 (1994)).
  • naked antibody refers to an antibody that is not conjugated to a therapeutic agent or tracer
  • conjugated antibody refers to an antibody conjugated to a therapeutic agent or tracer
  • Chimeric antibody herein refers to an antibody whose light chain and/or heavy chain are partly derived from an antibody (which may be derived from a specific species or belong to a specific class or subclass of antibodies). class), and the other part of the light chain or/and heavy chain is derived from another antibody (which may be derived from the same or different species or belong to the same or different antibody class or subclass), but in any case, it still retains the Binding activity to target antigen (U.S.P 4,816,567 to Cabilly et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851 6855 (1984)).
  • chimeric antibody may include antibodies (e.g., human-mouse chimeric antibodies) in which the antibody's heavy and light chain variable regions are derived from a primary antibody (e.g., a murine antibody), and the antibody's heavy and light chains are The light chain constant region is from a second antibody (eg, a human antibody).
  • a primary antibody e.g., a murine antibody
  • the light chain constant region is from a second antibody (eg, a human antibody).
  • humanized antibody herein refers to a genetically engineered non-human antibody whose amino acid sequence has been modified to increase sequence homology with a human antibody.
  • all or part of the CDR region of a humanized antibody is derived from a non-human antibody (donor antibody), and all or part of the non-CDR region (for example, variable region FR and/or constant region) is derived from a human Immunoglobulin (receptor antibody).
  • Humanized antibodies usually retain or partially retain the expected properties of the donor antibody, including but not limited to, antigen specificity, affinity, reactivity, ability to increase immune cell activity, ability to enhance immune response, etc.
  • Fully human antibody refers to antibodies having variable regions in which both the FRs and CDRs are derived from human germline immunoglobulin sequences. Furthermore, if the antibody comprises a constant region, the constant region also is derived from human germline immunoglobulin sequences. Fully human antibodies herein may include amino acid residues not encoded by human germline immunoglobulin sequences (eg, mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, "fully human antibodies” herein do not include antibodies in which CDR sequences derived from the germline of another mammalian species (eg, mouse) have been grafted onto human framework sequences.
  • another mammalian species eg, mouse
  • variable region herein refers to the region in the heavy or light chain of an antibody that is involved in making the antibody bind to an antigen
  • “heavy chain variable region” is used interchangeably with “VH” and “HCVR”
  • “light chain variable region” can be used interchangeably with “VL” and “LCVR”.
  • the variable domains (VH and VL, respectively) of the heavy and light chains of natural antibodies generally have similar structures, and each domain contains four conserved framework regions (FR) and three hypervariable regions (HVR). See, eg, Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., p.91 (2007). A single VH or VL domain may be sufficient to confer antigen binding specificity.
  • complementarity determining region and “CDR” are used interchangeably herein, and generally refer to the hypervariable region (HVR) of the heavy chain variable region (VH) or the light chain variable region (VL). It can form a precise complementarity with the antigen epitope, so it is also called complementarity determining region.
  • the CDR of the variable region of the heavy chain can be abbreviated as HCDR
  • the CDR of the variable region of the light chain can be abbreviated as LCDR.
  • framework region or “FR region” are used interchangeably and refer to those amino acid residues in an antibody heavy chain variable region or light chain variable region other than the CDRs.
  • CDRs For further descriptions of CDRs, refer to Kabat et al., J.Biol.Chem., 252:6609-6616 (1977); Kabat et al., U.S. Department of Health and Human Services, "Sequences of proteins of immunological interest” (1991); People such as Chothia, J.Mol.Biol.196:901-917 (1987); People such as Al-Lazikani B., J.Mol.Biol., 273:927-948 (1997); People such as MacCallum, J.Mol .Biol.262:732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45:3832-3839 (2008); Lefranc M.P.
  • CDR herein can be marked and defined by methods known in the art, including but not limited to Kabat numbering system, Chothia numbering system or IMGT numbering system, and the tool websites used include but not limited to AbRSA website (http://cao.labshare.
  • CDRs herein include overlaps and subsets of amino acid residues defined in different ways.
  • Kabat numbering system herein generally refers to the immunoglobulin alignment and numbering system proposed by Elvin A. Kabat (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991).
  • heavy chain constant region herein refers to the carboxy-terminal portion of the heavy chain of an antibody that is not directly involved in binding the antibody to an antigen, but exhibits effector functions, such as interaction with Fc receptors, which are relative to the antibody's available Variable domains have more conserved amino acid sequences.
  • the "heavy chain constant region” at least includes: CH1 domain, hinge region, CH2 domain, CH3 domain, or variants or fragments thereof.
  • Heavy chain constant region includes "full-length heavy chain constant region” and “heavy chain constant region fragment", the former has a structure substantially similar to that of a natural antibody constant region, while the latter only includes “full-length heavy chain constant region” part".
  • a typical "full-length antibody heavy chain constant region” consists of a CH1 domain-hinge region-CH2 domain-CH3 domain; when the antibody is IgE, it also includes a CH4 domain; when the antibody is a heavy chain In the case of an antibody, it does not include a CH1 domain.
  • a typical "heavy chain constant region segment" can be selected from CH1, Fc or CH3 domains.
  • light chain constant region refers to the carboxy-terminal part of the antibody light chain, which is not directly involved in the binding of the antibody to the antigen, and the light chain constant region can be selected from a constant kappa domain or a constant lambda domain.
  • Fc refers to the carboxy-terminal part of the antibody obtained by papain hydrolysis of the whole antibody, which typically includes the CH3 and CH2 domains of the antibody.
  • Fc regions include, for example, native sequence Fc regions, recombinant Fc regions and variant Fc regions.
  • the boundaries of the Fc region of an immunoglobulin heavy chain can vary slightly, the Fc region of a human IgG heavy chain is generally defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxyl terminus.
  • the C-terminal lysine of the Fc region (residue 447 according to the Kabat numbering system) can be removed, for example, during the production or purification of the antibody, or by recombinant engineering of the nucleic acid encoding the heavy chain of the antibody, thus the Fc region can comprise or excluding Lys447.
  • amino acid herein generally refers to amino acids that belong to the same class or have similar characteristics (eg, charge, side chain size, hydrophobicity, hydrophilicity, backbone conformation, and rigidity).
  • amino acids in each of the following groups belong to each other's conservative amino acid residues, and the substitution of amino acid residues in the group belongs to the conservative amino acid substitution:
  • identity may be calculated by aligning said sequences for optimal comparison purposes in order to determine the percent "identity" of two amino acid sequences or two nucleic acid sequences (for example, may be optimal alignment to introduce gaps in one or both of the first and second amino acid sequences or nucleic acid sequences or non-homologous sequences may be discarded for comparison purposes).
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
  • the percent identity between two sequences will vary with the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap that need to be introduced to optimally align the two sequences.
  • the comparison of sequences and the calculation of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, using the Needlema and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm in the GAP program that has been integrated into the GCG software package (available at www.gcg.com), using the Blossum 62 matrix or The PAM250 matrix and gap weights of 16, 14, 12, 10, 8, 6 or 4 and length weights of 1, 2, 3, 4, 5 or 6 determine the percent identity between two amino acid sequences.
  • the GAP program in the GCG software package (available at www.gcg.com), using the NWSgapdna.CMP matrix with gap weights of 40, 50, 60, 70, or 80 and length weights of 1, 2, 3, 4, 5 or 6, determining the percent identity between two nucleotide sequences.
  • a particularly preferred parameter set (and one that should be used unless otherwise stated) is the Blossum62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.
  • nucleic acid and protein sequences described herein may further be used as "query sequences" to perform searches against public databases, eg to identify other family member sequences or related sequences.
  • search can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul et al., (1990) J. Mol. Biol. 215:403-10.
  • Gapped BLAST can be used as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402.
  • the default parameters of the respective programs eg, XBLAST and NBLAST
  • XBLAST and NBLAST the default parameters of the respective programs. See www.ncbi.nlm.nih.gov.
  • chimeric antigen receptor herein refers to an artificial cell surface receptor engineered to be expressed on immune effector cells and to specifically bind an antigen, comprising at least (1) an extracellular antigen-binding domain, such as an antibody The variable heavy or light chain, (2) the transmembrane domain that anchors the CAR into immune effector cells, and (3) the intracellular signaling domain.
  • CARs are able to redirect T cells and other immune effector cells to a target of choice, such as cancer cells, in a non-MHC-restricted manner using an extracellular antigen-binding domain.
  • nucleic acid includes any compound and/or substance comprising a polymer of nucleotides.
  • Each nucleotide consists of a base, especially a purine or pyrimidine base (i.e. cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e. deoxyribose or ribose) and phosphate groups.
  • cytosine C
  • G guanine
  • A adenine
  • T thymine
  • U uracil
  • nucleic acid molecules are described by a sequence of bases, whereby the bases represent the primary structure (linear structure) of the nucleic acid molecule.
  • the sequence of bases is usually expressed 5' to 3'.
  • nucleic acid molecule encompasses deoxyribonucleic acid (DNA), including for example complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), especially messenger RNA (mRNA), synthetic forms of DNA or RNA, and synthetic forms of DNA or RNA comprising both Mixed polymers of one or more of these molecules.
  • Nucleic acid molecules can be linear or circular.
  • nucleic acid molecule includes both sense and antisense strands, as well as single- and double-stranded forms.
  • nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides.
  • Nucleic acid molecules also encompass DNA and RNA molecules suitable as vectors for direct expression of antibodies of the invention in vitro and/or in vivo, for example in a host or patient.
  • DNA eg cDNA
  • RNA eg mRNA
  • Such DNA (eg cDNA) or RNA (eg mRNA) vectors may be unmodified or modified.
  • mRNA can be chemically modified to enhance the stability of the RNA vector and/or the expression of the encoded molecule, so that the mRNA can be injected into a subject to generate antibodies in vivo (see e.g.
  • An "isolated" nucleic acid herein refers to a nucleic acid molecule that has been separated from components of its natural environment.
  • An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but which is present extrachromosomally or at a chromosomal location other than its natural chromosomal location.
  • vector refers to a nucleic acid molecule capable of amplifying another nucleic acid to which it has been linked.
  • the term includes vectors that are self-replicating nucleic acid structures as well as vectors that integrate into the genome of a host cell into which the vector has been introduced.
  • Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors”.
  • host cell herein refers to a cell into which exogenous nucleic acid has been introduced, including the progeny of such a cell.
  • Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom, regardless of the number of passages. Progeny may not be identical to the parental cell in nucleic acid content, but may contain mutations. Mutant progeny having the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
  • the term "pharmaceutical composition” refers to a preparation that is present in a form that permits the biological activity of the active ingredients contained therein to be effective and that does not contain substances that are unacceptably toxic to the subject to which the pharmaceutical composition is administered. additional ingredients.
  • treatment refers to surgical or therapeutic treatment, the purpose of which is to prevent, slow down (reduce) an undesired physiological change or pathology, such as the progression of cancer, in the subject being treated.
  • beneficial or desired clinical outcomes include, but are not limited to, alleviation of symptoms, diminished extent of disease, stable disease state (i.e., not worsening), delay or slowing of disease progression, amelioration or palliation of disease state, and remission (whether partial response or complete response), whether detectable or undetectable.
  • Those in need of treatment include those already with the condition or disease as well as those prone to have the condition or disease or those in which the condition or disease is to be prevented.
  • slow down lessen, weaken, moderate, alleviate, etc., the meaning of eliminate, disappear, not occur, etc. is also included.
  • subject refers to an organism receiving treatment for a particular disease or condition as described herein.
  • subjects and patients include mammals, such as humans, primate (eg, monkeys) or non-primate mammals, receiving treatment for a disease or disorder.
  • an effective amount herein refers to an amount of a therapeutic agent effective to prevent or alleviate a disease condition or the progression of the disease when administered alone or in combination with another therapeutic agent to a cell, tissue or subject.
  • Effective amount also refers to an amount of a compound sufficient to relieve symptoms, eg, treat, cure, prevent or alleviate the associated medical condition, or to increase the rate of treatment, cure, prevent or alleviate such condition.
  • a therapeutically effective dose refers to that ingredient alone.
  • a therapeutically effective dose refers to the combined amounts of the active ingredients that produce a therapeutic effect, whether administered in combination, sequentially or simultaneously.
  • cancer refers to or describes the physiological condition in mammals typically characterized by unregulated cell growth. Both benign and malignant cancers are included in this definition.
  • tumor or “neoplastic” herein refers to all neoplastic cell growth and proliferation, whether malignant or benign, and to all pre-cancerous and cancerous cells and tissues.
  • cancer and “tumor” are not mutually exclusive when referred to herein.
  • EC50 refers to the half-maximal effective concentration, which includes the concentration of antibody that induces a response halfway between baseline and maximum after a specified exposure time. EC50 essentially represents the concentration of antibody at which 50% of its maximal effect is observed and can be measured by methods known in the art.
  • Fig. 1 is the purity situation of human MSLN protein determined by SDS-PAGE
  • Figure 2 A shows the binding activity of human MSLN-R3-rFc protein and control antibody detected by ELISA
  • B is ELISA to detect the binding activity of human MSLN-FL-his protein and control antibody
  • C is ELISA to detect the binding activity of human MSLN-R1-his protein and control antibody
  • D is ELISA to detect the binding activity of human MSLN-R2-his protein and control antibody
  • E is ELISA to detect the binding activity of human MSLN-R3-his protein and control antibody
  • Figure 3 is the ELISA detection of the binding activity of the control antibody to the MSLN protein
  • Figure 4 A is the FACS result of detecting the expression of MSLN in Hela cells by the control antibody Tab106
  • B is the FACS result of the control antibody Tab131 detecting the expression of MSLN in Hela cells
  • C is the FACS result of the control antibody Tab142 detecting the expression of MSLN in Hela cells
  • Figure 5 A is the FACS result of the control antibody Tab106 detecting the expression of MSLN in OVCAR3 cells
  • B is the FACS result of the control antibody Tab131 detecting the expression of MSLN in OVCAR3 cells
  • C is the FACS result of detecting the expression of MSLN in OVCAR3 cells by the control antibody Tab142
  • Figure 6 A is the FACS screening results of CHO-K1-hMSLN-2C8 cells transfected with human MSLN protein detected by the control antibody Tab020
  • B is the FACS screening results of CHO-K1-Hmsln-2D11 cells transfected with human MSLN protein detected by the control antibody Tab020
  • C is the FACS screening results of CHO-K1-hMSLN-2C5 cells transfected with human MSLN protein detected by the control antibody Tab020
  • Figure 7 is the FACS result of NB149 antiserum detection of HEK293T-monkey MSLN cell expression
  • Figure 8 A is the FACS screening results of HEK293T-hMSLN-B8 cells transfected with human MSLN protein detected by the control antibody Tab020
  • B is the FACS screening results of HEK293T-hMSLN-2A4 cells transfected with human MSLN protein detected by the control antibody Tab020
  • C is the FACS screening results of HEK293T-hMSLN-2A7 cells transfected with human MSLN protein detected by the control antibody Tab020
  • Figure 9 is the FACS screening results of HEK293T cells transfected with human MSLN-R3 protein detected by the control antibody Tab106
  • Figure 10 A is the FACS detection of the binding reaction of the control antibody to human tumor cells OVCAR3 tumor cells
  • B is the binding reaction of control antibody to CHO-K1-hMSLN-2C8 recombinant cells detected by FACS
  • C is the FACS detection of the binding reaction of the control antibody to HEK293T-monkey MSLN recombinant cells
  • Figure 11 A is human MSLN-FL-his, MSLN-R3-his, MSLN-R3-3 protein detection of serum antibody titers after immunization of mice;
  • B, C are human MSLN-FL-his protein detection of serum antibody titers of mice after immunization Valence
  • Figure 12 A and B are human MSLN-R1-his protein detection serum antibody titers after immunization of mice
  • Figure 13 A and B are human MSLN-R2-his protein detection serum antibody titers after immunization of mice
  • Figure 14 A and B are human MSLN-R3-his protein detection serum antibody titers after immunization of mice
  • Figure 15 A and B are human MSLN-R3-3 protein detection serum antibody titers after immunization of mice
  • Figure 16 A, B, C are the serum antibody titers detected by different cells after immunization of mice
  • Figure 17 A is the detection of serum antibody titers by OVCAR3 cells after immunization of mice
  • mice C is the detection of serum antibody titer with HEK293T-monkey MSLN cells after immunization of mice
  • Figure 18 A and B are the detection of serum antibody titers with different cells after immunization of mice
  • Figure 19 A. ELISA detection of the binding reaction of F1 chimeric antibody to human MSLN-FL-his protein
  • Figure 20 A ELISA detection of the binding reaction of F2 chimeric antibody to human MSLN-FL-his protein
  • Figure 21 A ELISA detection of the binding reaction of F3 chimeric antibody to human MSLN-FL-his protein
  • Figure 22 A ELISA detection of the binding reaction of F4,5,6 chimeric antibody to human MSLN-FL-his protein
  • Figure 23 A, B ELISA detection of the binding reaction of F7 chimeric antibody to human MSLN-FL-his protein
  • Figure 24 A, B ELISA detection of the binding reaction of F8 chimeric antibody to human MSLN-FL-his protein
  • Figure 25 A FACS detection of the binding reaction of F1 chimeric antibody to OVCAR3 cells
  • FIG. 26 A FACS detection of the binding reaction of F2 chimeric antibody to OVCAR3 cells
  • FIG. 27 A FACS detection of the binding reaction of F3 chimeric antibody to OVCAR3 cells
  • FIG. 28 A FACS detection of the binding reaction of F4, F5, F6 chimeric antibodies to OVCAR3 cells
  • Figure 29 A, B FACS detection of the binding reaction of F7 chimeric antibody to OVCAR3 cells
  • FIG. 30 A, B FACS detection of the binding reaction of F8 chimeric antibody to OVCAR3 cells
  • Figure 31 to Figure 37 are the competitive ELISA method to detect the inhibition rate between chimeric antibodies
  • a to H in Figure 38 are ELISA detection of the binding reaction of the humanized antibody to the full-length human MSLN protein
  • a to F in Figure 39 are ELISA detection of the binding reaction of humanized antibody to human MSLN-R3 protein
  • a to J in Figure 40 are FACS detection of the binding reaction of the humanized antibody to HEK293T-hMSLN-R3 cells
  • a to J in Figure 41 are FACS detection of the binding reaction of humanized antibody to HEK293T empty cells
  • a to J in Figure 42 are FACS detection of the binding reaction of the humanized antibody to OVCAR3 cells
  • a to J in Figure 43 are FACS detection of the binding reaction of the humanized antibody to A431 cells
  • a to J in Figure 44 are FACS detection of the binding reaction of the humanized antibody to HEK293T-monkey MSLN cells
  • sequences of YP218, YP3 and YP223 are from patent US2015252118A1
  • the sequence of m912 is from patent WO2009120769A1
  • the sequence of Amatuximab is from patent US20140127237A1.
  • VH and VL sequences of clone YP218 recognizing human MSLN R3 epitope and clone YP3 recognizing human MSLN conformational epitope were recombined into human IgG1 CH and CL expression vectors; the VH and VL sequences of clone YP223 recognizing human MSLN R2 epitope were recombined into Rabbit IgG1 CH and CL expression vectors; the VH and VL of clones m912 and YP218 that recognize the human MSLN R3 epitope were connected through 3 GGGGS linkers and then recombined into the human IgG1Fc expression vector to obtain recombinant plasmids. Plasmid construction and antibody expression and purification were completed by Taizhou Baiying Biotechnology Co., Ltd.
  • YP218 human IgG1 format antibody YP223 rabbit IgG1 format antibody, YP3 human IgG1 format antibody, YP218scFv-human IgG1 Fc (hFc) format antibody, and m912scFv-human IgG1 Fc (hFc) format antibody were named Tab142 respectively (Amatuximab), Tab106 (YP218, hIgG1 format), Tab020 (YP223, rabbit IgG1 format), Tab107 (YP3, hIgG1 format), Tab108 (YP218, scFv-hIgG1Fc format) and Tab131 (m912, scFv-hIgG1Fc format).
  • MSLN protein has three IgG-like domains extracellularly, of which Region1 (R1) is located at the farthest membrane end, Region3 (R3) is located at the proximal membrane end, the antigen-binding epitope of Amatuximab is located at R1, and YP218 is located at R3.
  • HEK293E cells purchased from Suzhou Yiyan Biotechnology Co., Ltd.
  • PI Polysciences, catalog number: 24765-1
  • FreeStyle TM 293 Thermofisher scientific, catalog number: 12338018
  • the cell culture fluid was collected, centrifuged to remove cell components, and the culture supernatant containing the extracellular region of human MSLN protein was obtained.
  • the culture supernatant was loaded onto a nickel ion affinity chromatography column HisTrap TM Excel (GE Healthcare, product number: GE17-3712-06), and an ultraviolet (UV) detector was used to monitor changes in ultraviolet absorbance (A280nm).
  • UV ultraviolet
  • the culture supernatant was loaded onto the protein A chromatography column (Protein A filler AT Protein A Diamond and the chromatography column BXK16/26 were both purchased from Bogeron), washed with PBS phosphate buffer (pH7.4) and then Wash with 20mM PB, 1M NaCl, pH 7.2, and finally use citrate buffer with pH 3.4 for elution, and collect the human MSLN protein with rabbit Fc (rFc) tag eluted from the protein A chromatography column. Dialyze with PBS phosphate buffered saline (pH 7.4) overnight at 4°C.
  • the dialyzed protein was sterile-filtered at 0.22 microns and stored at -80°C to obtain purified human MSLN extracellular domain protein.
  • the target bands of samples detected by SDS-PAGE reducing gel and non-reducing gel are shown in Figure 1.
  • the prepared above-mentioned human MSLN protein was detected by ELISA using positive control antibodies that recognize different epitopes.
  • the detection results are shown in Figure 2 and Tables 2 to 6.
  • -his, MSLN-R2-his, MSLN-R3-his proteins can bind to anti-human MSLN antibody (purchased from Acro, Cat. No. #MSN-M30) or control antibody, and Tab142 (Amatuximab ), Tab106 (YP218), Tab020 (YP223) and Tab107 (YP3) have consistent binding epitopes, indicating that the above proteins with binding activity have been prepared.
  • nucleotide sequence encoding the full-length amino acid sequence of human MSLN (NCBI: AAH09272.1) was cloned into the pcDNA3.1 vector and a plasmid was prepared (completed by General Biosystems (Anhui) Co., Ltd.).
  • the CHO-K1 cell line (purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) was transfected with plasmids ( 3000 Transfection Kit, purchased from Invitrogen, product number: L3000-015), and selectively cultured in DMEM/F12 medium containing 10 ⁇ g/mL puromycin and 10% (w/w) fetal bovine serum for 2 weeks, and used Rabbit anti-human MSLN antibody (Tab020) and goat anti-rabbit IgG Fab antibody (cell signaling, product number: 4414S) sorted positive monoclonal cells on the flow cytometer FACSAria II (purchased from BD Biosciences) to 96-well plates, placed in 37 Cultivate in 5% (v/v) CO 2 , and select some monoclonal wells for expansion after about 2 weeks.
  • the amplified clones were screened by flow cytometry. Cell lines with better growth, higher fluorescence intensity, and monoclonality were selected to continue to be
  • Table 9 shows that a series of CHO-K1 monoclonal cell lines positively expressing human MSLN have been prepared.
  • the abscissa is the fluorescence intensity of cells, and the ordinate is the number of cells.
  • the results showed that 2C8, 2D11, and 2C5 were recombinant CHO-K1 cell lines expressing human MSLN protein at a high level.
  • the nucleotide sequence encoding the full-length amino acid sequence of monkey MSLN (NCBI: XP_028696439.1) was cloned into the pcDNA3.1 vector and a plasmid was prepared.
  • HEK293T cell line (purchased from ATCC) was transfected with plasmid ( 3000 Transfection Kit, purchased from Invitrogen, product number: L3000-015), and selectively cultured in DMEM/F12 medium containing 10 ⁇ g/ml puromycin and 10% (w/w) fetal bovine serum for 2 weeks, and used Subcloning was carried out in a 96-well culture plate by the limiting dilution method, and cultured at 37° C., 5% (v/v) CO 2 .
  • the nucleotide sequence encoding the full-length amino acid sequence of human MSLN was cloned into pcDNA3.1 vector and a plasmid was prepared.
  • HEK293T cell line purchased from ATCC
  • plasmid 3000 Transfection Kit
  • DMEM medium containing 5 ⁇ g/mL puromycin and 10% (w/w) fetal bovine serum for 2 weeks
  • rabbit antibody Human MSLN antibody (Tab020) and goat anti-rabbit IgG Fab antibody (cell signaling, product number: 4414S) were used to sort positive monoclonal cells on the flow cytometer FACSAriaII (purchased from BD Biosciences) to 96-well plates, and placed at 37°C , 5% (v/v) CO 2 culture, after about 2 weeks, select some monoclonal wells for expansion.
  • the amplified clones were detected and analyzed by FACS flow cytometry with the Tab020 antibody, and the cell lines with better growth and higher fluorescence intensity were selected for further expansion and cultured and frozen in liquid nitrogen.
  • the results of expression levels are shown in Table 11 and Figure 8, showing that HEK293T-human MSLN after puromycin pressure selection has a single positive peak, and B8, 2A4, and 2A7 are recombinant HEK293T cell lines expressing human MSLN protein at a high level, available The binding activity of the antibody to human MSLN protein was detected by FACS.
  • the nucleotide sequence encoding the amino acid sequence of human MSLN-R3 (Met487-Ser606 of NCBI: AAH09272.1) was cloned into pcDNA3.1 vector and a plasmid was prepared.
  • HEK293T cell line (purchased from ATCC) was transfected with plasmid ( 3000 Transfection Kit (purchased from Invitrogen, product number: L3000-015), selectively culture in DMEM medium containing 5 ⁇ g/mL puromycin and 10% (w/w) fetal bovine serum for 2 weeks, and use anti-human MSLN-R3 antibody (Tab106) and goat anti-human IgG H+L antibody (Jackson, catalog number: 109605088) sorted positive monoclonal cells into 96-well plates on the flow cytometer FACSAriaII (purchased from BD Biosciences), and placed Culture at 37°C, 5% (v/v) CO 2 , and select some monoclonal wells for expansion after about 2 weeks.
  • plasmid 3000 Transfection Kit
  • DMEM medium containing 5 ⁇ g/mL puromycin and 10% (w/w) fetal bovine serum for 2 weeks
  • the amplified clones were detected and analyzed by FACS flow cytometry with the Tab106 antibody, and the cell lines with better growth and higher fluorescence intensity were selected to continue to be expanded and cultured and frozen in liquid nitrogen.
  • the expression results are shown in Table 12 and Figure 9, which shows that HEK293T-human MSLN-R3 after puromycin pressure selection has a relatively single positive peak, which can be used to detect the binding activity of the antibody to human MSLN-R3 protein by FACS.
  • the binding activity of the control antibody to cells expressing human MSLN or monkey MSLN is shown in Table 13 to Table 15 and Figure 10, and the IgG subtype control is human IgG1.
  • Tab142, Tab020, Tab106, and Tab107 have good binding activity to OVCAR3 tumor cells expressing human MSLN protein and CHO-K1-hMSLN-2C8 recombinant cells, while the binding activity of Tab131 is relatively weak.
  • Tab142, Tab106, and Tab107 have binding activity to HEK293T-monkey MSLN recombinant cells, and Tab020 and Tab131 have almost no cross-binding activity to monkey MSLN detected under the same experimental conditions.
  • Anti-human MSLN monoclonal antibodies were produced by immunizing mice.
  • BALB/c AnNCrl mice purchasedd from Victoria Lihua Company
  • SJL/JorllcoCrl mice purchasedd from Shanghai Slack Company
  • Breeding environment SPF grade. After the mice were purchased, they were raised in a laboratory environment for 1 week, with a 12/12 hour light/dark cycle adjustment, a temperature of 20-25° C., and a humidity of 40-60%.
  • the acclimatized mice were immunized according to the following scheme.
  • the immune antigen is (1) protein immunogen: human MSLN-FL-hFc protein, MSLN-FL-his protein, MSLN-R3-rFc protein (made by the company), (2) 293T cells transferred with different MSLN proteins as immunogen : 293T-hMSLN, 293T-hMSLN R3, 293T-hMSLN R3/mMSLN R1-2 (made by the company). Mice in 6 groups were immunized with the above antigens alone or in combination (see Table 16 for the immunization scheme).
  • the immunogen was emulsified with TiterMax (purchased from Sigma, product number T2684) and injected 0.1 ml subcutaneously and intraperitoneally respectively, namely Each mouse was injected with 50 micrograms of immunogenic protein or 5E6 cells.
  • the immunogen was injected subcutaneously and intraperitoneally with 0.1 ml of Imject Alum Adjuvant (purchased from Thermofisher scientific, product number: 77161), that is, each mouse was injected with 25 micrograms of the immunogen.
  • the frequency of immunization was once a week, blood was collected before fusion, and the antibody titer in mouse serum was detected by ELISA and FACS methods.
  • Add ACK Lysing Buffer (purchased from Gibco, product number: A1049201) to lyse the red blood cells doped in the splenocytes to obtain a splenocyte suspension.
  • Use DMEM (purchased from Gibco, article number: 11995-073) basal medium to centrifuge and wash the cells 3 times at 1000 rpm, and then mix with mouse myeloma cell SP2/0 (purchased from ATCC, CRL -1581) were mixed, and cell fusion was performed using BTX ECM2001+ high-efficiency electrofusion method (see METHODS IN ENZYMOLOGY, VOL.220).
  • the fused cells were diluted into DMEM medium containing 20% fetal bovine serum (ExCell Bio, product number FSD500) and 1 ⁇ HAT (purchased from Sigma, product number: H0262), and the percentages are mass percentages. Then add 2 ⁇ 10 4 /200 microliters per well into a 96-well cell culture plate, put it in a 5% CO 2 , 37° C. incubator, and the percentages are volume percentages.
  • the supernatant on the cell fusion plate was screened by ELISA, and the ELISA-positive clones were amplified into a 24-well plate, in DMEM containing 10% (w/w) HT (purchased from Sigma, product number: H0137) fetal bovine serum, at 37 ° C, Expand the culture under the condition of 5% (v/v) CO 2 .
  • DMEM fetal bovine serum
  • the hybridoma cells in the positive group in the ELISA and FACS experiments were selected as qualified positive clones, and the qualified hybridoma cells were selected to be subcloned in a 96-well plate by limiting dilution method, containing 10% ( w/w) FBS DMEM medium (purchased from Gibco), cultured at 37° C., 5% (v/v) CO 2 .
  • ELISA and FACS were used for preliminary screening, and a single positive clone was selected and amplified to a 24-well plate for further culture.
  • the optimal clone was selected and cultured in DMEM medium containing 10% (w/w) FBS (purchased from Gibco) at 37°C, 5% (v/v) CO 2 conditions
  • the optimal clone is expanded and cultured under liquid nitrogen cryopreservation to obtain the hybridoma cells of the present invention.
  • the hybridoma cells in the logarithmic growth phase were collected, and the cells were fully lysed with Trizol (Invitrogen, Cat No. 15596-018) and stored at -80 degrees Celsius for testing.
  • the samples were entrusted to Suzhou Jinweizhi Biotechnology Co., Ltd. to complete the amino acid sequence determination of the variable regions of the light and heavy chains of the hybridoma positive clones.
  • the sequencing results were analyzed using MOE software, and an evolutionary tree was constructed according to the amino acid sequence of the protein encoded by the variable region.
  • the heavy chain variable region sequences of 71 clones were cloned by Taizhou Baiying Biotechnology Co., Ltd. into the expression vector pcDNA3.4-B1HH1 (heavy chain constant region sequence: ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQGNVFSCSVMHEALHNHYTQKSLSPGK,SEQ ID NO:158)
  • the light chain variable region sequences of 71 clones were cloned into the expression vector pcDNA3.4-B1HLK containing the signal peptide and the Kappa light chain constant region of human antibody IgG1 (light chain constant region sequence: RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVNOCEVTHQGLSSPVT5KSFNRIDGEC) , the expression vector of human-mouse chimeric antibody was obtained and the antibody was prepared according to the method of Example 1.1.
  • Enzyme-linked immunosorbent assay to detect the binding of chimeric antibody to human MSLN protein
  • MSLN human-mouse chimeric antibody to human MSLN full-length protein
  • MSLN-R1 protein, MSLN-R2 protein, MSLN-R3 protein, MSLN-R3-3 protein the purified proteins obtained in Example 2 It was diluted with PBS to a final concentration of 2 ⁇ g/mL, and then added to a 96-well ELISA plate at 50 ⁇ l/well. Seal with a plastic film and incubate at 4°C overnight, wash the plate twice with PBST the next day, add blocking solution [PBS+2% (w/w) BSA] to block at room temperature for 2 hours.
  • Table 24-51 shows that the chimeric antibodies after purification and production have different degrees of binding to human MSLN full-length protein, MSLN-R1 protein, MSLN-R2 protein, MSLN-R3 protein, and MSLN-R3-3 protein at the ELISA level , according to the different combination of antigen and antibody in vitro ELISA experiments, F1-F8 chimeric antibodies can be divided into five categories:
  • the negative control antibody hIgG1 is the antibody anti-hel-hIgG1 against chicken egg lysozyme (purchased from Baiying, product number: B117901), and the data in the table are OD 450nm values.
  • the chimeric antibody has binding activity to most of the 293T cells overexpressing monkey MSLN,
  • Anti-human MSLN chimeric antibodies were captured using a Protein A chip (GE Healthcare; 29-127-558).
  • Sample and running buffer was HBS-EP+(10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P20) (GE Healthcare; BR-1006-69).
  • the flow-through cell was set to 25°C.
  • the sample block was set to 16°C. Both were pretreated with running buffer.
  • the antibody to be tested was first captured with a Protein A chip, and then a single concentration of human MSLN-FL-his protein was injected to record the binding and dissociation process of the antibody and antigen protein, and finally Glycine pH1.5 (GE Healthcare; BR-1003-54) complete chip regeneration.
  • Binding was measured by injecting different concentrations of human MSLN-FL-his in solution for 240 s with a flow rate of 30 ⁇ L/min starting from 200 nM (see detailed results for actual concentrations tested) diluted 1:1 for a total of 5 concentration.
  • the dissociation phase is monitored for up to 600 seconds and is triggered by switching from sample solution to running buffer.
  • the MSLN chimeric antibody was grouped by competition ELISA. Referring to the method of Example 5 (5.1), 2 ⁇ g/mL chimeric antibody was used to coat the ELISA plate, human MSLN protein was serially diluted starting from 30 ⁇ g/mL, and EC80 was calculated as the concentration in the competitive ELISA.
  • the CDRs of the murine antibody were grafted into corresponding human templates to form a variable region sequence in the order of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
  • the buried residues, the residues that directly interact with the CDR region, and the residues in the framework region that have an important impact on the conformation of VL and VH are back mutated to obtain a humanized monoclonal antibody .
  • the CDR amino acid residues of the antibody are determined and annotated by the Kabat numbering system.
  • the humanized light chain templates of antibody S009-F2.39.3 are IGKV4-1*01/IGKV2-29*02 and IGKJ4*01, the humanized heavy chain templates are IGHV1-46*01 and IGHJ1*01, and the mouse
  • the CDRs of the antibody S009-F2.39.3 were transplanted into its human template respectively, that is, the corresponding humanized version was obtained.
  • the key amino acids in the FR region sequence of the humanized antibody of S009-F2.39.3 were back-mutated to the corresponding amino acids of the mouse antibody to ensure the original affinity.
  • the specific back mutation design is shown in Table 60.
  • Graft means that the murine antibody CDR is implanted into the FR region sequence of the human germline template; P49S means that the 49th P of Graft is mutated into an S, and so on.
  • the numbering of backmutated amino acids is the natural sequence numbering.
  • amino acid sequence of S009-F2.39.3.VL1 is shown in SEQ ID NO: 565:
  • amino acid sequence of S009-F2.39.3.VL2 is shown in SEQ ID NO: 566:
  • amino acid sequence of S009-F2.39.3.VL3 is shown in SEQ ID NO: 567:
  • amino acid sequence of S009-F2.39.3.VL4 is shown in SEQ ID NO: 568:
  • amino acid sequence of S009-F2.39.3.VH1 is shown in SEQ ID NO: 569:
  • S009-F2.39.3.VH2 The amino acid sequence of S009-F2.39.3.VH2 is shown in SEQ ID NO: 570:
  • amino acid sequence of S009-F2.39.3.VH3 is shown in SEQ ID NO: 571:
  • amino acid sequence of the humanized light chain template IGKV4-1*01 is shown in SEQ ID NO: 572:
  • amino acid sequence of the humanized light chain template IGKV2-29*02 is shown in SEQ ID NO: 573:
  • amino acid sequence of the humanized light chain template IGKJ4*01 is shown in SEQ ID NO: 574:
  • amino acid sequence of the humanized heavy chain template IGHV1-46*01 is shown in SEQ ID NO: 575:
  • amino acid sequence of the humanized heavy chain template IGHJ1*01 is shown in SEQ ID NO: 576:
  • the humanized light chain templates of antibody S009-F2.23.12 are IGKV1-33*01 and IGKJ4*01, the humanized heavy chain templates are IGHV1-46*01 and IGHJ6*01, and the mouse antibody S009-F2.23.12
  • the CDRs of each gene were transplanted into their human templates respectively, that is, the corresponding humanized versions were obtained.
  • the key amino acids in the FR region sequence of the humanized antibody of S009-F2.23.12 were back-mutated to the corresponding amino acids of the mouse antibody to ensure the original affinity (the antibody has a site that is prone to chemical modification, we Point mutations were performed at these sites to eliminate the risk of modification).
  • the specific back mutation design is shown in Table 62.
  • Graft means that the murine antibody CDR is implanted into the FR region sequence of the human germline template; Y49H means that the 49th position of Graft is mutated from Y to H, and so on.
  • the numbering of backmutated amino acids is the natural sequence numbering.
  • amino acid sequence of S009-F2.23.12.VL1 is shown in SEQ ID NO: 577:
  • amino acid sequence of S009-F2.23.12.VL2 is shown in SEQ ID NO: 578:
  • amino acid sequence of S009-F2.23.12.VL3 is shown in SEQ ID NO: 579:
  • amino acid sequence of S009-F2.23.12.VL4 is shown in SEQ ID NO: 580:
  • amino acid sequence of S009-F2.23.12.VH1 is shown in SEQ ID NO: 581:
  • amino acid sequence of S009-F2.23.12.VH2 is shown in SEQ ID NO: 582:
  • amino acid sequence of S009-F2.23.12.VH3 is shown in SEQ ID NO: 583:
  • amino acid sequence of S009-F2.23.12.VH4 is shown in SEQ ID NO: 584:
  • amino acid sequence of the humanized light chain template IGKV1-33*01 is shown in SEQ ID NO: 585:
  • amino acid sequence of the humanized light chain template IGKJ4*01 is shown in SEQ ID NO: 574:
  • amino acid sequence of the humanized heavy chain template IGHV1-46*01 is shown in SEQ ID NO: 575:
  • amino acid sequence of the humanized heavy chain template IGHJ6*01 is shown in SEQ ID NO: 586:
  • the humanized light chain templates of antibody S009-F7.44.20 are IGKV3-11*01/IGKV6-21*01 and IGKJ4*01, the humanized heavy chain templates are IGHV1-46*01 and IGHJ6*01, and the mouse
  • the CDRs of the antibody S009-F7.44.20 were transplanted into their human templates respectively, that is, the corresponding humanized versions were obtained.
  • the key amino acids in the FR region sequence of the humanized antibody of S009-F7.44.20 were back-mutated to the corresponding amino acids of the mouse antibody to ensure the original affinity (the antibody has a site that is prone to chemical modification, we Point mutations at these sites have eliminated the risk of modification).
  • the specific back mutation design is shown in Table 64.
  • Table 64 The humanized antibody reverse mutation design of S009-F7.44.20
  • Graft means that the murine antibody CDR is implanted into the FR region sequence of the human germline template; K50Y means that the 50th K of Graft is mutated into Y, and so on.
  • the numbering of backmutated amino acids is the natural sequence numbering.
  • variable region of S009-F7.44.20 humanized antibody is as follows:
  • amino acid sequence of S009-F7.44.20.VL1 is shown in SEQ ID NO: 589:
  • amino acid sequence of S009-F7.44.20.VL2 is shown in SEQ ID NO: 590:
  • amino acid sequence of S009-F7.44.20.VL3 is shown in SEQ ID NO: 591:
  • amino acid sequence of S009-F7.44.20.VL4 is shown in SEQ ID NO: 592:
  • amino acid sequence of S009-F7.44.20.VH1 is shown in SEQ ID NO: 593:
  • amino acid sequence of S009-F7.44.20.VH1a is shown in SEQ ID NO: 594:
  • amino acid sequence of S009-F7.44.20.VH2 is shown in SEQ ID NO: 595:
  • amino acid sequence of S009-F7.44.20.VH2a is shown in SEQ ID NO: 596:
  • amino acid sequence of the humanized light chain template IGKV3-11*01 is shown in SEQ ID NO: 597:
  • amino acid sequence of the humanized light chain template IGKV6-21*01 is shown in SEQ ID NO: 598:
  • amino acid sequence of the humanized light chain template IGKJ4*01 is shown in SEQ ID NO: 574:
  • amino acid sequence of the humanized heavy chain template IGHV1-46*01 is shown in SEQ ID NO: 575:
  • amino acid sequence of the humanized heavy chain template IGHJ6*01 is shown in SEQ ID NO: 586:
  • the humanized light chain templates of antibody S009-F7.33.24 are IGKV2-29*02/IGKV4-1*01 and IGKJ4*01, the humanized heavy chain templates are IGHV1-3*01 and IGHJ1*01, and the mouse
  • the CDRs of the antibody S009-F7.33.24 were transplanted into its human template respectively, that is, the corresponding humanized version was obtained.
  • the key amino acids in the FR region sequence of the humanized antibody of S009-F7.33.24 were back-mutated to the corresponding amino acids of the mouse antibody to ensure the original affinity (antibody has a site that is prone to chemical modification, we Point mutations at these sites have eliminated the risk of modification).
  • the specific back mutation design is shown in Table 66.
  • Graft means that the murine antibody CDR is implanted into the FR region sequence of the human germline template; P43S means that the 43rd P of Graft is mutated into an S, and so on.
  • the numbering of backmutated amino acids is the natural sequence numbering.
  • variable region of the S009-F7.33.24 humanized antibody is as follows:
  • amino acid sequence of S009-F7.33.24.VL1 is shown in SEQ ID NO: 601:
  • amino acid sequence of S009-F7.33.24.VL2 is shown in SEQ ID NO: 602:
  • amino acid sequence of S009-F7.33.24.VL3 is shown in SEQ ID NO: 603:
  • amino acid sequence of S009-F7.33.24.VH1 is shown in SEQ ID NO: 604:
  • amino acid sequence of S009-F7.33.24.VH1a is shown in SEQ ID NO: 605:
  • amino acid sequence of S009-F7.33.24.VH2 is shown in SEQ ID NO: 606:
  • amino acid sequence of S009-F7.33.24.VH2a is shown in SEQ ID NO: 607:
  • amino acid sequence of the humanized light chain template IGKV2-29*02 is shown in SEQ ID NO: 573:
  • amino acid sequence of the humanized light chain template IGKV4-1*01 is shown in SEQ ID NO: 572:
  • amino acid sequence of the humanized light chain template IGKJ4*01 is shown in SEQ ID NO: 574:
  • amino acid sequence of the humanized heavy chain template IGHV1-3*01 is shown in SEQ ID NO: 608:
  • amino acid sequence of the humanized heavy chain template IGHJ1*01 is shown in SEQ ID NO: 576:
  • the humanized light chain templates of antibody S009-F3.80.22 are IGKV2-40*01 and IGKJ2*01, the humanized heavy chain templates are IGHV1-69-2*01 and IGHJ6*01, and the mouse antibody S009-F3
  • the CDRs of .80.22 were respectively transplanted into their human source templates, that is, the corresponding humanized versions were obtained.
  • the key amino acids in the FR region sequence of the humanized antibody of S009-F3.80.22 were back-mutated to the corresponding amino acids of the mouse antibody to ensure the original affinity (the antibody has a site that is prone to chemical modification, we Point mutations at these sites have eliminated the risk of modification).
  • the specific back mutation design is shown in Table 68.
  • Graft means that the mouse antibody CDR is implanted into the FR region sequence of the human germline template; Y41F means that the 41st position of Graft is mutated from Y to F, and so on.
  • the numbering of backmutated amino acids is the natural sequence numbering.
  • variable region of the humanized antibody S009-F3.80.22 is as follows:
  • amino acid sequence of S009-F3.80.22.VL1 is shown in SEQ ID NO: 611:
  • amino acid sequence of S009-F3.80.22.VL1a is shown in SEQ ID NO: 612:
  • amino acid sequence of S009-F3.80.22.VL2 is shown in SEQ ID NO: 613:
  • amino acid sequence of S009-F3.80.22.VL2a is shown in SEQ ID NO: 614:
  • amino acid sequence of S009-F3.80.22.VH1 is shown in SEQ ID NO: 615:
  • amino acid sequence of S009-F3.80.22.VH2 is shown in SEQ ID NO: 616:
  • amino acid sequence of S009-F3.80.22.VH3 is shown in SEQ ID NO: 617:
  • amino acid sequence of S009-F3.80.22.VH4 is shown in SEQ ID NO: 618:
  • amino acid sequence of the humanized light chain template IGKV2-40*01 is shown in SEQ ID NO: 619:
  • amino acid sequence of the humanized light chain template IGKJ2*01 is shown in SEQ ID NO: 620:
  • amino acid sequence of the humanized heavy chain template IGHV1-69-2*01 is shown in SEQ ID NO: 621:
  • amino acid sequence of the humanized heavy chain template IGHJ6*01 is shown in SEQ ID NO: 586:
  • the humanized light chain templates of antibody S009-F3.38.10 are IGKV4-1*01/IGKV2-40*01 and IGKJ2*01, the humanized heavy chain templates are IGHV1-3*01 and IGHJ6*01, and the mouse
  • the CDRs of the antibody S009-F3.38.10 were transplanted into its human template respectively, that is, the corresponding humanized version was obtained.
  • the key amino acids in the FR region sequence of the humanized antibody of S009-F3.38.10 were back-mutated to the corresponding amino acids of the mouse antibody to ensure the original affinity, (antibody has a site that is prone to chemical modification, We performed point mutations at these sites to eliminate the risk of modification).
  • the specific back mutation design is shown in Table 70.
  • Table 70 The humanized antibody reverse mutation design of S009-F3.38.10
  • Graft means that the murine antibody CDR is implanted into the FR region sequence of the human germline template; P48S means that the 48th P of Graft is mutated into an S, and so on.
  • the numbering of backmutated amino acids is the natural sequence numbering.
  • amino acid sequence of S009-F3.38.10.VL1 is shown in SEQ ID NO: 624:
  • amino acid sequence of S009-F3.38.10.VL2 is shown in SEQ ID NO: 625:
  • amino acid sequence of S009-F3.38.10.VH1 is shown in SEQ ID NO: 626:
  • amino acid sequence of S009-F3.38.10.VH2 is shown in SEQ ID NO: 627:
  • amino acid sequence of S009-F3.38.10.VH3 is shown in SEQ ID NO: 628:
  • amino acid sequence of S009-F3.38.10.VH3a is shown in SEQ ID NO: 629:
  • amino acid sequence of S009-F3.38.10.VH4 is shown in SEQ ID NO: 630:
  • amino acid sequence of S009-F3.38.10.VH5 is shown in SEQ ID NO: 631:
  • amino acid sequence of the humanized light chain template IGKV4-1*01 is shown in SEQ ID NO: 572:
  • amino acid sequence of the humanized light chain template IGKV2-40*01 is shown in SEQ ID NO: 619:
  • amino acid sequence of the humanized light chain template IGKJ2*01 is shown in SEQ ID NO: 620:
  • amino acid sequence of the humanized heavy chain template IGHV1-3*01 is shown in SEQ ID NO: 608:
  • amino acid sequence of the humanized heavy chain template IGHJ6*01 is shown in SEQ ID NO: 586:
  • Both the positive control antibody and the negative control antibody were constructed by Taizhou Baiying Biotechnology Co., Ltd. and the production and purification of antibodies were completed.
  • Positive control YP218 sequence from patent US2015252118A1 (VH-SEQ ID NO: 13; VL-SEQ ID NO: 15), constructed as VH-(G4S)3-VL-his and VL-(G4S)3-VH-his Antibodies were named Tab110 and Tab111, respectively.
  • Negative control The isotype negative control of the MSLN humanized antibody is an irrelevant antibody m971 that does not bind to the MSLN protein, and its heavy chain variable region and light chain variable region sequences are from the patent US 8591889B (VH-SEQ ID NO: 3, No. 1 -124 positions; VL-SEQ ID NO: 4, 1-107 positions), constructed into the form of VH-(G4S)3-VL-his, named Tab084(NC).
  • the Anti-MSLN humanized antibody is expressed in the form of VH-(G4S)3-VL-his or VL-(G4S)3-VH-his.
  • Antibody expression and purification was undertaken by Taizhou Baiying Biotechnology Co., Ltd.
  • the purified humanized antibody was tested and analyzed for protein concentration, purity, endotoxin (Lonza kit), etc.
  • the purity of the humanized antibody varied greatly, and antibodies with a purity >50% were selected for more activity verification.
  • the present invention respectively selects different light chain and heavy chain sequences from the reverse mutation design of the light chain and heavy chain variable regions of the above-mentioned Anti-MSLN humanized antibody for cross combination, and uses VH-(G4S)3-VL-his or VL-(G4S)3-VH-his form, and finally obtain the following Anti-MSLN humanized antibody.
  • human MSLN-hFc protein (Acro, CAT#MSN-H5253) was diluted with PBS to a final concentration of 2 ⁇ g/mL, and then added to 96 Well ELISA plates were sealed with plastic film and incubated overnight at 4°C. The next day, the plates were washed twice with PBST, and blocking solution [PBS+2% (w/w) BSA] was added to block at room temperature for 2 hours. Pour off the blocking solution, wash the plate twice with PBST, and add the test antibody or control antibody with an initial concentration of 100nM and a 1:10 gradient dilution at 50 ⁇ l/well.
  • the negative control is an irrelevant antibody m971 that does not bind to MSLN protein.
  • Its heavy chain variable region and light chain variable region sequences are from the patent US8591889B, constructed in the form of VH-(G4S)3-VL-his, named Tab084 (NC ); positive controls were YP218 antibodies constructed in the form of VH-(G4S)3-VL-his and VL-(G4S)3-VH-his, named Tab110 and Tab111, respectively.
  • the data in the table are OD450nm values. The results showed that, except for F3.38.10 which had no binding activity to human MSLN full-length protein, the other tested Anti-MSLN humanized antibodies had binding activity to human MSLN full-length protein and human MSLN-R3 protein.
  • Expand the desired cells to the logarithmic growth phase in T-175 cell culture flasks aspirate the medium, wash twice with PBS buffer, digest the cells with trypsin, then stop the digestion with complete medium, and pipette the cells to a single cell suspension. After counting cells, centrifuge, wash the cell pellet twice with PBS, resuspend the cell pellet with FACS buffer (PBS+2% fetal calf serum) to 2 ⁇ 10 6 cells/mL, add 50 ⁇ l per well to 96-well FACS In the reaction plate, add the antibody to be tested or the control antibody (200nM as the initial concentration, 5-fold serial dilution) at 50 ⁇ l/well, mix with the cell suspension, and incubate at 4°C for 1 hour.
  • FACS buffer PBS+2% fetal calf serum
  • the preparation of detection cells and antibodies to be tested and the detection method refer to Example 2.2.
  • the analysis results are shown in A ⁇ J in Fig. 42, A ⁇ J in Fig. 43 and Tables 86-90, wherein Tab084 is a negative control (NC); Tab110 and Tab111 are positive controls.
  • the results show that the F3.80.22 humanized antibody has no binding activity, the F3.38.10 humanized antibody has weak (no) binding activity, and the other detected Anti-MSLN humanized antibodies have binding activity to OVCAR3 tumor cells expressing human MSLN protein , and does not bind to A431 cells that do not express human MSLN protein, indicating that the Anti-MSLN humanized antibody can specifically bind to OVCAR3 cells.
  • HEK293T-monkey MSLN cells were collected, and FACS detection and data analysis were performed according to the method in Example 2.2.
  • the analysis results are shown in A ⁇ J in Figure 44 and Tables 91-95, wherein Tab084 is a negative control (NC); Tab110 and Tab110 are positive controls.
  • the results showed that the F3.80.22 humanized antibody had no binding activity, the F3.38.10 humanized antibody had weak binding activity, and the other detected Anti-MSLN humanized antibodies had good binding activity to HEK293T-monkey MSLN cells.
  • the BIAcore 8K instrument was used to detect the binding strength of the antibody to the antigen by the anti-human antibody capture method.
  • the Anti-Human IgG antibody was immobilized on the CM5 chip (Cytiva; 29-1496-03) by amino coupling method, and the HBS -EP+pH7.4 (10mM HEPES, 150mM NaCl, 3mM EDTA, 0.05% surfactant P20) (Cytiva; BR-1006-69) as the mobile phase, mix NHS and EDC, activate the chip for about 600s, and use 10mM sodium acetate Dilute the Anti-Human IgG antibody to 15 ⁇ g/mL at pH 5.0, inject for 420 seconds, and finally block the remaining activation sites with ethanolamine.
  • the affinity of the antibody to the antigen was determined using a multi-cycle kinetic method.
  • the MSLN-hFc or CD3e-hFc recombinant protein was first captured with an anti-human antibody, and then a single concentration of the antibody to be tested was injected, and the antibody and antigen were recorded.
  • the chip was regenerated with 3M MgCl 2 at the end.
  • the mobile phase was HBS-EP+pH7.4, the flow rate was 30 ⁇ L/min, the regeneration time was 30s, and the detection temperature was 25°C.
  • analyze the data and fit the kinetic parameters of antibody antigen binding including the association rate constant ka, the dissociation rate constant kd, the equilibrium dissociation constant KD, and the maximum binding signal Rmax.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

一种抗MSLN抗体及其制备方法和应用。所述MSLN抗体与MSLN蛋白具有高度亲和力，能够运用于治疗肿瘤等药物的制备中。

Description

抗MSLN抗体及其应用 技术领域
本发明涉及抗体领域，具体而言，涉及抗MSLN抗体及其应用。
背景技术
间皮素(Mesothelin，MSLN)是一种存在于正常间皮细胞上的分化抗原，可表达于正常胸膜、心包和腹膜的间皮细胞中。在正常组织中表达有限，但MSLN被发现表达在90％的上皮样恶性胸膜间皮瘤细胞、69％的肺腺癌细胞、60％的乳腺癌细胞、46％的食管癌细胞、胰腺肿瘤细胞和卵巢癌细胞(Morello A等，Cancer Discov.2016；6(2):133-146；Baldo P等，Onco Targets Ther.2017；10:5337-5353；Argani P等，Clin Cancer Res.2001；7(12):3862-3868；Hassan R等，Clin Cancer Res.2004；10(12Pt 1):3937-3942)。因此MSLN有可能成为癌症治疗的重要靶点。
MSLN基因位于染色体16p13.3，其基因全长8kb，cDNA大小为2138bp，含有1884bp的开放阅读框，17个外显子，编码628个氨基酸。MSLN基因编码一个71KDa的前体蛋白。MSLN前体蛋白由糖磷脂酰肌醇(Glycosylphosphatidylinositol，GPI)锚定在细胞膜上，可被弗林蛋白酶(furin)水解为两个部分：分子量为31kDa的N端可溶性蛋白，被称为巨核细胞增强因子(megakaryocyte-potentiating factor，MPF)和分子量为40kDa的细胞表面糖蛋白，即为成熟的MSLN(Chang K等，Proc Natl Acad Sci U S A.1996；93(1):136-140；Manzanares
Figure PCTCN2022093759-appb-000001
等，Hepatol Commun.2017；2(2):155-172)。
间皮素的生物学功能尚未完全阐明。研究人员曾对敲除MSLN基因的小鼠进行研究，发现小鼠在发育、繁殖和血细胞计数方面均未表现出异常，表明其不影响小鼠正常的生长发育。(Bera TK等，Mol Cell Biol.2000；20(8):2902-2906)。
MSLN的异常表达在肿瘤细胞的增殖分化、黏附及耐药性方面起着重要作用。MSLN的过表达可激活NF-κB(nuclear factor kappa-light-chain-enhancer of activated B cells)，MAPK(mitogen-activated protein kinase)和PI3K(Phosphoinositide 3-kinases)多条信号通路，从而诱导细胞凋亡或者通过诱导MMP7(matrix metalloproteinase 7，基质金属蛋白酶-7)和MMP9(matrix metalloproteinase 9，基质金属蛋白酶-9)的激活和表达促进细胞增殖，迁移和转移。研究表明MSLN通过同时激活PI3K/AKT(Protein Kinase B，PKB)和MAPK/ERK(extracellular regulated protein kinases)信号通路可以阻断紫杉醇诱导的肿瘤细胞凋亡，增加癌细胞对药物的耐受性(Bharadwaj U等，Mol Cancer.2011；10:106；Cheng WF等，Br J Cancer.2009；100(7):1144-1153)。
靶向MSLN的药物研发方向包含免疫毒素、疫苗、嵌合单克隆抗体、ADC(antibody-drug conjugate)和CAR-T(Chimeric Antigen Receptor T-Cell)。抗体类药物主要通过抗体中和、抗体依赖细胞介导的细胞毒性(Antibody-dependent cell-mediated cytotoxicity,ADCC)、抗体依赖细胞介导的吞噬作用(ADCP)、抗体与效应分子(毒素或抑制剂)结合等方式来介导肿瘤细胞凋亡或抑制肿瘤细胞增殖，靶向杀伤肿瘤细胞。
Amatuximab(MORAb-009)是一种嵌合的高亲和力抗体，由抗MSLN抗体SS1单链可变区片段与人IgG1/κ恒定区组成，可防止表达MSLN的肿瘤细胞与CA125黏附，并通过ADCC作用杀伤肿瘤细胞(Hassan R等，Cancer Immun.2007；7:20)。
Anetumab Ravtansine(BAY94-9343)是一种全人源抗MSLN抗体(MF-T)和美登素衍生物DM4(微管蛋白聚合酶抑制剂)由还原性的二硫醚连接物连接而成的抗体偶联药物(Grosso F等，Future Oncol.2012；8(3):293-305)。BAY94-9343与肿瘤细胞结合，可被内化进入溶酶体释放DM4杀伤肿瘤细胞。
MSLN CAR-T细胞治疗在间皮瘤、卵巢癌、肺癌小鼠移植模型中取得了令人鼓舞的结果，Pennsylvania大学和纪念斯隆-凯瑟琳癌症中心正在开展胰腺癌、卵巢癌和胸膜肿瘤等适应症的临床试验(Beatty GL等Cancer Immunol Res.2015 Feb；3(2):217；Adusumilli PS presented in 11th Annual PEGS Europe Summit,Lisbon)。
发明内容
本发明提供抗MSLN抗体，编码其的核酸，抗体制备方法，含有所述抗体的药物组合物，以及药物组合物用于治疗肿瘤的相关用途。
在第一个方面，本发明提供了一种特异性结合MSLN的抗体或抗原结合片段，所述抗体或抗原结合片段包含：
(a)SEQ ID NO：594-596、604-607、615-618、626-631、569-571、581-584、593、16、18、20、22、24、26、28、30、32、34、36、38、40、42、44、46、48、50、52、54、56、58、60、62、64、66、68、70、72、74、76、78、80、82、84、86、88、90、92、94、96、98、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、136、138、140、142、144、146、148、150、152、154或156任一项所示VH的HCDR1、HCDR2和HCDR3，或与所述HCDR1、HCDR2和/或HCDR3具有至少70％同一性或具有1、2、3或更多个氨基酸插入、缺失和/或替换，所述替换优选为保守氨基酸的替换；
和/或，(b)SEQ ID NO：589-592、601-603、611-614、624-625、565-568、577-580、17、19、21、23、25、27、29、31、33、35、37、39、41、43、45、47、49、51、53、55、57、59、61、63、65、67、69、71、73、75、77、79、81、83、85、87、89、91、93、95、97、99、101、103、105、107、109、111、113、115、117、119、121、123、125、127、129、131、133、135、137、139、141、143、145、147、149、151、153、155或157任一项所示VL的LCDR1、LCDR2和LCDR3，或与所述LCDR1、LCDR2和/或LCDR3具有至少70％同一性或具有1、2、3或更多个氨基酸插入、缺失和/或替换，所述替换优选为保守氨基酸的替换。
优选地，所述HCDR1～3和/或LCDR1～3根据Kabat编号系统确定，更优选地，所述HCDR1～3和/或所述LCDR1～3包含表23所示序列。
在一些实施例中，优选地，所述HCDR1～3选自以下VH1-VH77的任意序列组合或者与所述序列组合相比具有至少70％同一性或具有1、2、3或更多个氨基酸插入、缺失和/或替换的序列组合，所述替换优选为保守氨基酸的替换：
Figure PCTCN2022093759-appb-000002
Figure PCTCN2022093759-appb-000003
所述LCDR1～3选自以下VL1-VL67的任意序列组合或者与所述序列组合相比具有至少70％同一性或具有1、2、3或更多个氨基酸插入、缺失和/或替换的序列组合，所述替换优选为保守氨基酸的替换：
Figure PCTCN2022093759-appb-000004
在一些实施例中，优选地，所述抗体或抗原结合片段包括选自以下的序列组合：VH1+VL1、VH2+VL2、VH3+VL3、VH4+VL4、VH5+VL5、VH6+VL6、VH7+VL7、VH8+VL8、VH9+VL9、VH10+VL10、VH11+VL11、VH12+VL12、VH13+VL13、VH14+VL14、VH15+VL15、VH16+VL16、VH17+VL17、VH18+VL18、VH19+VL19、VH19+VL20、 VH20+VL21、VH21+VL22、VH22+VL23、VH23+VL24、VH24+VL25、VH25+VL26、VH26+VL27、VH27+VL28、VH28+VL29、VH29+VL30、VH30+VL31、VH31+VL32、VH32+VL33、VH33+VL34、VH34+VL35、VH35+VL36、VH36+VL37、VH37+VL38、VH38+VL39、VH39+VL38、VH40+VL40、VH41+VL38、VH42+VL41、VH43+VL42、VH44+VL43、VH45+VL38、VH46+VL44、VH47+VL45、VH48+VL46、VH49+VL47、VH50+VL48、VH51+VL49、VH52+VL50、VH53+VL51、VH54+VL52、VH55+VL14、VH56+VL53、VH57+VL54、VH58+VL55、VH59+VL56、VH60+VL57、VH61+VL58、VH62+VL59、VH63+VL14、VH64+VL60、VH65+VL60、VH66+VL61、VH67+VL62、VH68+VL63、VH69+VL64、VH70+VL65、VH72+VL13、VH73+VL43、VH74+VL43、VH75+VL41、VH76+VL41、VH26+VL66或VH77+VL22、以及与所述序列组合之序列相比具有至少70％同一性或具有1、2、3或更多个氨基酸插入、缺失和/或替换的序列组合，所述替换优选为保守氨基酸的替换。
在一些实施例中，优选地，所述抗体或抗原结合片段包含：(1)与SEQ ID NO：16、18、20、22、24、26、28、30、32、34、36、38、40、42、44、46、48、50、52、54、56、58、60、62、64、66、68、70、72、74、76、78、80、82、84、86、88、90、92、94、96、98、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、136、138、140、142、144、146、148、150、152、154、156、569-571、581-584、593-596、604-607、615-618或626-631任一项所示VH相比具有至少80％、85％、90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或100％同一性的序列，或具有至多20个、19个、18个、17个、16个、15个、14个、13个、12个、11个、10个、9个、8个、7个、6个、5个、4个、3个、2个或1个突变的序列；所述突变可选自插入、缺失和/或替换，所述替换优选为保守氨基酸的替换；
和/或，(2)与SEQ ID NO：17、19、21、23、25、27、29、31、33、35、37、39、41、43、45、47、49、51、53、55、57、59、61、63、65、67、69、71、73、75、77、79、81、83、85、87、89、91、93、95、97、99、101、103、105、107、109、111、113、115、117、119、121、123、125、127、129、131、133、135、137、139、141、143、145、147、149、151、153、155、157、565-568、577-580、589-592、601-603、611-614或624-625任一项所示VL相比具有至少80、85％、90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或100％同一性的序列，或具有至多20个、19个、18个、17个、16个、15个、14个、13个、12个、11个、10个、9个、8个、7个、6个、5个、4个、3个、2个或1个突变的序列；所述突变可选自插入、缺失和/或替换，所述替换优选为保守氨基酸的替换。
在一些实施例中，优选地，所述抗体或抗原结合部分包含：(1)SEQ ID NO：16所示序列和SEQ ID NO：17所示序列；
(2)SEQ ID NO：18所示序列和SEQ ID NO：19所示序列；
(3)SEQ ID NO：20所示序列和SEQ ID NO：21所示序列；
(4)SEQ ID NO：22所示序列和SEQ ID NO：23所示序列；
(5)SEQ ID NO：24所示序列和SEQ ID NO：25所示序列；
(6)SEQ ID NO：26所示序列和SEQ ID NO：27所示序列；
(7)SEQ ID NO：28所示序列和SEQ ID NO：29所示序列；
(8)SEQ ID NO：30所示序列和SEQ ID NO：31所示序列；
(9)SEQ ID NO：32所示序列和SEQ ID NO：33所示序列；
(10)SEQ ID NO：34所示序列和SEQ ID NO：35所示序列；
(11)SEQ ID NO：36所示序列和SEQ ID NO：37所示序列；
(12)SEQ ID NO：38所示序列和SEQ ID NO：39所示序列；
(13)SEQ ID NO：40所示序列和SEQ ID NO：41所示序列；
(14)SEQ ID NO：42所示序列和SEQ ID NO：43所示序列；
(15)SEQ ID NO：44所示序列和SEQ ID NO：45所示序列；
(16)SEQ ID NO：46所示序列和SEQ ID NO：47所示序列；
(17)SEQ ID NO：48所示序列和SEQ ID NO：49所示序列；
(18)SEQ ID NO：50所示序列和SEQ ID NO：51所示序列；
(19)SEQ ID NO：52所示序列和SEQ ID NO：53所示序列；
(20)SEQ ID NO：54所示序列和SEQ ID NO：55所示序列；
(21)SEQ ID NO：56所示序列和SEQ ID NO：57所示序列；
(22)SEQ ID NO：58所示序列和SEQ ID NO：59所示序列；
(23)SEQ ID NO：60所示序列和SEQ ID NO：61所示序列；
(24)SEQ ID NO：62所示序列和SEQ ID NO：63所示序列；
(25)SEQ ID NO：64所示序列和SEQ ID NO：65所示序列；
(26)SEQ ID NO：66所示序列和SEQ ID NO：67所示序列；
(27)SEQ ID NO：68所示序列和SEQ ID NO：69所示序列；
(28)SEQ ID NO：70所示序列和SEQ ID NO：71所示序列；
(29)SEQ ID NO：72所示序列和SEQ ID NO：73所示序列；
(30)SEQ ID NO：74所示序列和SEQ ID NO：75所示序列；
(31)SEQ ID NO：76所示序列和SEQ ID NO：77所示序列；
(32)SEQ ID NO：78所示序列和SEQ ID NO：79所示序列；
(33)SEQ ID NO：80所示序列和SEQ ID NO：81所示序列；
(34)SEQ ID NO：82所示序列和SEQ ID NO：83所示序列；
(35)SEQ ID NO：84所示序列和SEQ ID NO：85所示序列；
(36)SEQ ID NO：86所示序列和SEQ ID NO：87所示序列；
(37)SEQ ID NO：88所示序列和SEQ ID NO：89所示序列；
(38)SEQ ID NO：90所示序列和SEQ ID NO：91所示序列；
(39)SEQ ID NO：92所示序列和SEQ ID NO：93所示序列；
(40)SEQ ID NO：94所示序列和SEQ ID NO：95所示序列；
(41)SEQ ID NO：96所示序列和SEQ ID NO：97所示序列；
(42)SEQ ID NO：98所示序列和SEQ ID NO：99所示序列；
(43)SEQ ID NO：100所示序列和SEQ ID NO：101所示序列；
(44)SEQ ID NO：102所示序列和SEQ ID NO：103所示序列；
(45)SEQ ID NO：104所示序列和SEQ ID NO：105所示序列；
(46)SEQ ID NO：106所示序列和SEQ ID NO：107所示序列；
(47)SEQ ID NO：108所示序列和SEQ ID NO：109所示序列；
(48)SEQ ID NO：110所示序列和SEQ ID NO：111所示序列；
(49)SEQ ID NO：112所示序列和SEQ ID NO：113所示序列；
(50)SEQ ID NO：114所示序列和SEQ ID NO：115所示序列；
(51)SEQ ID NO：116所示序列和SEQ ID NO：117所示序列；
(52)SEQ ID NO：118所示序列和SEQ ID NO：119所示序列；
(53)SEQ ID NO：120所示序列和SEQ ID NO：121所示序列；
(54)SEQ ID NO：122所示序列和SEQ ID NO：123所示序列；
(55)SEQ ID NO：124所示序列和SEQ ID NO：125所示序列；
(56)SEQ ID NO：126所示序列和SEQ ID NO：127所示序列；
(57)SEQ ID NO：128所示序列和SEQ ID NO：129所示序列；
(58)SEQ ID NO：130所示序列和SEQ ID NO：131所示序列；
(59)SEQ ID NO：132所示序列和SEQ ID NO：133所示序列；
(60)SEQ ID NO：134所示序列和SEQ ID NO：135所示序列；
(61)SEQ ID NO：136所示序列和SEQ ID NO：137所示序列；
(62)SEQ ID NO：138所示序列和SEQ ID NO：139所示序列；
(63)SEQ ID NO：140所示序列和SEQ ID NO：141所示序列；
(64)SEQ ID NO：142所示序列和SEQ ID NO：143所示序列；
(65)SEQ ID NO：144所示序列和SEQ ID NO：145所示序列；
(66)SEQ ID NO：146所示序列和SEQ ID NO：147所示序列；
(67)SEQ ID NO：148所示序列和SEQ ID NO：149所示序列；
(68)SEQ ID NO：150所示序列和SEQ ID NO：151所示序列；
(69)SEQ ID NO：152所示序列和SEQ ID NO：153所示序列；
(70)SEQ ID NO：154所示序列和SEQ ID NO：155所示序列；
(71)SEQ ID NO：156所示序列和SEQ ID NO：157所示序列；
(72)SEQ ID NO：569所示序列和SEQ ID NO：565所示序列；
(73)SEQ ID NO：569所示序列和SEQ ID NO：566所示序列；
(74)SEQ ID NO：570所示序列和SEQ ID NO：565所示序列；
(75)SEQ ID NO：570所示序列和SEQ ID NO：566所示序列；
(76)SEQ ID NO：570所示序列和SEQ ID NO：568所示序列；
(77)SEQ ID NO：571所示序列和SEQ ID NO：565所示序列；
(78)SEQ ID NO：581所示序列和SEQ ID NO：577所示序列；
(79)SEQ ID NO：581所示序列和SEQ ID NO：580所示序列；
(80)SEQ ID NO：582所示序列和SEQ ID NO：577所示序列；
(81)SEQ ID NO：582所示序列和SEQ ID NO：580所示序列；
(82)SEQ ID NO：584所示序列和SEQ ID NO：577所示序列；
(83)SEQ ID NO：584所示序列和SEQ ID NO：580所示序列；
(84)SEQ ID NO：593所示序列和SEQ ID NO：589所示序列；
(85)SEQ ID NO：593所示序列和SEQ ID NO：590所示序列；
(86)SEQ ID NO：593所示序列和SEQ ID NO：591所示序列；
(87)SEQ ID NO：593所示序列和SEQ ID NO：592所示序列；
(88)SEQ ID NO：594所示序列和SEQ ID NO：589所示序列；
(89)SEQ ID NO：594所示序列和SEQ ID NO：590所示序列；
(90)SEQ ID NO：594所示序列和SEQ ID NO：591所示序列；
(91)SEQ ID NO：594所示序列和SEQ ID NO：592所示序列；
(92)SEQ ID NO：595所示序列和SEQ ID NO：589所示序列；
(93)SEQ ID NO：595所示序列和SEQ ID NO：590所示序列；
(94)SEQ ID NO：595所示序列和SEQ ID NO：591所示序列；
(95)SEQ ID NO：595所示序列和SEQ ID NO：592所示序列；
(96)SEQ ID NO：596所示序列和SEQ ID NO：589所示序列；
(97)SEQ ID NO：596所示序列和SEQ ID NO：590所示序列；
(98)SEQ ID NO：596所示序列和SEQ ID NO：591所示序列；
(99)SEQ ID NO：596所示序列和SEQ ID NO：592所示序列；
(100)SEQ ID NO：604所示序列和SEQ ID NO：601所示序列；
(101)SEQ ID NO：604所示序列和SEQ ID NO：602所示序列；
(102)SEQ ID NO：604所示序列和SEQ ID NO：603所示序列；
(103)SEQ ID NO：605所示序列和SEQ ID NO：601所示序列；
(104)SEQ ID NO：605所示序列和SEQ ID NO：602所示序列；
(105)SEQ ID NO：605所示序列和SEQ ID NO：603所示序列；
(106)SEQ ID NO：606所示序列和SEQ ID NO：601所示序列；
(107)SEQ ID NO：606所示序列和SEQ ID NO：602所示序列；
(108)SEQ ID NO：606所示序列和SEQ ID NO：603所示序列；
(109)SEQ ID NO：607所示序列和SEQ ID NO：601所示序列；
(110)SEQ ID NO：607所示序列和SEQ ID NO：602所示序列；
(111)SEQ ID NO：607所示序列和SEQ ID NO：603所示序列；
(112)SEQ ID NO：611所示序列和SEQ ID NO：615所示序列；
(113)SEQ ID NO：611所示序列和SEQ ID NO：616所示序列；
(114)SEQ ID NO：611所示序列和SEQ ID NO：617所示序列；
(115)SEQ ID NO：611所示序列和SEQ ID NO：618所示序列；
(116)SEQ ID NO：612所示序列和SEQ ID NO：615所示序列；
(117)SEQ ID NO：612所示序列和SEQ ID NO：616所示序列；
(118)SEQ ID NO：612所示序列和SEQ ID NO：617所示序列；
(119)SEQ ID NO：612所示序列和SEQ ID NO：618所示序列；
(120)SEQ ID NO：613所示序列和SEQ ID NO：616所示序列；
(121)SEQ ID NO：624所示序列和SEQ ID NO：631所示序列；
(122)SEQ ID NO：625所示序列和SEQ ID NO：629所示序列；
(123)与上述(1)至(122)所示序列具有至少70％、75％、80％、85％、90％、95％、96％、97％、98％、99％或更高一致性的序列。
进一步的，在一些实施例中，所述抗体或抗原结合片段包含或不包含抗体重链恒定区和/或轻链可变区；可选的，所述抗体重链恒定区可选自人、羊驼、小鼠、大鼠、兔或羊；可选地，所述抗体重链恒定区可选自IgG、IgM、IgA、IgE或IgD，所述IgG可选自IgG1，IgG2，IgG3或IgG4；可选地，所述重链恒定区可选自Fc区、CH3区、不存在CH1片段的重链恒定区或完整重链恒定区；优选地，所述重链恒定区具有如SEQ ID NO：158所示氨基酸序列；优选地，所述轻链恒定区具有如SEQ ID NO：159所示氨基酸序列。
进一步的，在一些实施例中，所述抗体或抗原结合片段特异性结合人MSLN蛋白；优选地，与人MSLN的解离常数(KD)不大于8.00E-7M。
进一步的，在一些实施例中，所述抗体或抗原结合片段为：
(1)嵌合抗体或其片段；
(2)人源化抗体或其片段；或，
(3)全人抗体或其片段。
进一步的，在一些实施例中，所述抗体或抗原结合片段选自单克隆抗体、多克隆抗体、天然抗体、工程化抗体、单特异性抗体、多特异性抗体(例如双特异性抗体)、单价抗体、多价抗体、完整抗体、完整抗体的片段、裸抗体、缀合抗体、嵌合抗体、人源化抗体、全人抗体、Fab、Fab’、Fab’-SH、F(ab’)2、Fd、Fv、scFv、双抗体(diabody)或单域抗体。
进一步的，在一些实施例中，所述抗体或抗原结合片段还偶联有治疗剂或示踪剂；优选地，所述治疗剂选自药物、毒素、放射性同位素、化疗药或免疫调节剂，所述示踪剂选自放射学造影剂、顺磁离子、金属、荧光标记、化学发光标记、超声造影剂和光敏剂。
在第二个方面，本发明提供了一种多特异性分子，所述多特异性分子包含第一方面所述的抗体或抗原结合片段；优选地，所述多特异性分子进一步包含特异性结合MSLN以外的抗原或结合与第一方面所述抗体或抗原结合片段不同的MSLN表位的抗体或抗原结合片段。
在一些实施例中，优选地，所述MSLN以外的抗原为T细胞、B细胞、自然杀伤细胞、树突状细胞、巨噬细胞、单核细胞或嗜中性细胞表面上的抗原；优选地，所述MSLN以外的抗原选自：CD3、CD3γ、CD3δ、CD3ε、CD3ζ、CD16、CD16A、CD32B、PD-1、PD-2、PD-L1、VEGF、NKG2D、CD19、CD20、CD40、CD47、4-1BB、CD137、EGFR、EGFRvIII、TNF-alpha、CD33、HER2、HER3、HAS、CD5、CD27、EphA2、EpCAM、MUC1、MUC16、CEA、Claudin18.2、叶酸受体、Claudin6、WT1、NY-ESO-1、MAGE3、ASGPR1或CDH16。
在一些实施例中，优选地，所述多特异性分子为串联scFv、双功能抗体(Db)、单链双功能抗体(scDb)、双重亲和力再靶向(DART)抗体、F(ab')2、双重可变域(DVD)抗体、臼包杵(KiH)抗体、对接及锁定(DNL)抗体、化学交联抗体、杂多聚抗体或异结合物抗体。
在第三个方面，本发明提供一种嵌合抗原受体(CAR)，所述嵌合抗原受体至少包含细胞外抗原结合结构域、跨膜结构域和胞内信号传导结构域，所述细胞外抗原结合结构域包含任选自第一方面所述抗体或抗原结合片段。
在第四个方面，本发明提供一种免疫效应细胞，所述免疫效应细胞表达第三方面所述的嵌合抗原受体，或包含编码第三方面所述嵌合抗原受体的核酸片段；优选地，所述免疫效应细胞选自T细胞、NK细胞(natural killer cell)、NKT细胞(natural killer T cell)、DNT细胞(double negative T cell)、单核细胞、巨噬细胞、树突状细胞或肥大细胞，所述T细胞优选自细胞毒性T细胞、调节性T细胞或辅助性T细胞；优选地，所述免疫效应细胞为自体免疫效应细胞或同种异体免疫效应细胞。
在第五个方面，本发明提供一种分离的核酸片段，所述核酸片段编码第一方面所述抗体或抗原结合片段，第二方面所述多特异性分子，或第三方面所述嵌合抗原受体。
在第六个方面，本发明提供一种载体(vector)，所述载体包含第五方面所述核酸片段。
在第七个方面，本发明提供一种宿主细胞，所述宿主细胞包含第六方面所述载体；优选地，所述细胞为原核细胞或真核细胞，例如细菌(大肠杆菌)、真菌(酵母)、昆虫细胞或哺乳动物细胞(CHO细胞系或293T细胞系)。
在第八个方面，本发明还提供一种制备抗体或抗原结合片段或多特异性分子的方法，所述方法包括培养上述第七方面所述细胞，以及在适合的条件下分离所述细胞表达的抗体或抗原结合片段，或分离所述细胞表达的多特异性分子。
在第九个方面，本发明还提供一种制备免疫效应细胞的方法，所述方法包括将编码第三方面所述CAR的核酸片段导入所述免疫效应细胞，可选地，所述方法还包括启动所述免疫效应细胞表达第三方面所述CAR。
在第十个方面，本发明还提供一种药物组合物，其特征在于，所述药物组合物包含任选自第一方面所述的抗体或抗原结合片段，或任选自第二方面所述的多特异性抗体，或第四方面所述免疫效应细胞，或第五方面所述的核酸片段，或第六方面所述的载体；或第八 和第九方面所述方法制备获得的产品；可选地，所述药物组合物还包含药学上可接受的运载体(carrier)、稀释剂或助剂；可选地，所述药物组合物还包含额外的抗肿瘤剂。
在第十一个方面，本发明还提供一种任选自第一方面所述的抗体或抗原结合片段，或任选自第二方面所述的多特异性抗体，或第四方面所述免疫效应细胞，或第五方面所述的核酸片段，或第六方面所述的载体；或第八和第九方面所述方法制备获得的产品；或第十方面所述的药物组合物在制备预防和/或治疗肿瘤的药物中的用途；所述肿瘤优选间皮瘤、肺癌、乳腺癌、食管癌、胰腺癌、卵巢癌或胸膜癌；更优选上皮样恶性胸膜间皮瘤、肺腺癌。
在第十二个方面，本发明提供一种预防和/或治疗肿瘤的方法，包含向有此需要的患者施用有效量的任选自第一方面所述的抗体或抗原结合片段，或任选自第二方面所述的多特异性抗体，或第四方面所述免疫效应细胞，或第五方面所述的核酸片段，或第六方面所述的载体；或第八和第九方面所述方法制备获得的产品；或第十方面所述的药物组合物；所述肿瘤优选间皮瘤、肺癌、乳腺癌、食管癌、胰腺癌、卵巢癌或胸膜癌；更优选上皮样恶性胸膜间皮瘤、肺腺癌。
在第十三个方面，本发明提供一种试剂盒，其包含任选自第一方面所述的抗体或抗原结合片段，或任选自第二方面所述的多特异性抗体，或第四方面所述免疫效应细胞，或第五方面所述核酸片段，或第六方面所述载体，或第八和第九方面所述方法制备获得的产品，或第十方面所述药物组合物。
在第十四个方面，本发明提供一种检测MSLN表达的方法，在任选自第一方面所述的抗体或抗原结合片段与MSLN之间能够形成复合物的条件下，使待检测样品与任选自第一方面所述的抗体或抗原结合片段接触。
在第十五个方面，本发明提供一种体外抑制表达MSLN细胞增殖或迁移的方法，在任选自第一方面所述的抗体或抗原结合片段与MSLN之间能够形成复合物的条件下，使所述细胞与任选自第一方面所述的抗体或抗原结合片段接触。
术语定义和说明
除非本发明另外定义，与本发明相关的科学和技术术语应具有本领域普通技术人员所理解的含义。
此外，除非本文另有说明，本文单数形式的术语应包括复数形式，复数形式的术语应包括单数形式。更具体地，如在本说明书和所附权利要求中所使用的，除非另外明确指出，否则单数形式“一种”和“这种”包括复数指示物。
本文术语“包括”、“包含”和“具有”之间可互换使用，旨在表示方案的包含性，意味着所述方案可存在除所列出的元素之外的其他元素。同时应当理解，在本文中使用“包括”、“包含”和“具有”描述，也提供“由……组成”方案。示例性地，“一种组合物，包括A和B”，应当理解为以下技术方案：由A和B组成的组合物，以及除A和B外，还含有其他组分的组合物，均落入前述“一种组合物”的范围内。
术语“和/或”在本文使用时，包括“和”、“或”和“由所属术语链接的要素的全部或任何其他组合”的含义。
本文术语“MSLN”是指间皮素(Mesothelin，MSLN)，是一种存在于正常间皮细胞上的分化抗原，可表达于正常胸膜、心包和腹膜的间皮细胞中。在正常组织中表达有限，但MSLN被发现高表达在上皮样恶性胸膜间皮瘤、肺腺癌、乳腺癌、食管癌、胰腺肿瘤和卵巢癌等细胞上。术语“MSLN”包括任何人类和非人类动物物种的MSLN蛋白，并且具体地包括人类MSLN以及非人类哺乳动物的MSLN。
本文术语“特异性结合”是指抗原结合分子(例如抗体)通常以高亲和力特异性结合抗原和实质上相同的抗原，但不以高亲和力结合不相关抗原。亲和力通常以平衡解离常数(equilibrium dissociation constant，KD)来反映，其中较低KD表示较高亲和力。以抗体为例，高亲和力通常指具有约1×10 -6M或更低、约1×10 -7M或更低、约1×10 -8M或更低、约1×10 -9M或更低、约1×10 -10M或更低、1×10 -11M或更低或1×10 -12M或更低的KD。KD计算方式如下：KD＝Kd/Ka，其中Kd表示解离速率，Ka表示结合速率。可采用本领域周知的方法测量平衡解离常数KD，如表面等离子共振(例如Biacore)或平衡透析法测定，示例性地，可参见本文实施例5所示KD值获得方法。
本文术语“抗原结合分子”按最广义使用，是指特异性结合抗原的分子。示例性地，抗原结合分子包括但不限于抗体或抗体模拟物。“抗体模拟物”是指能够与抗原特异性结合，但与抗体结构无关的有机化合物或结合域，示例性地，抗体模拟物包括但不限于affibody、affitin、affilin、经设计的锚蛋白重复蛋白(DARPin)、核酸适体或Kunitz型结构域肽。
本文术语“抗体”按最广义使用，是指包含来自免疫球蛋白重链可变区的足够序列和/或来自免疫球蛋白轻链可变区的足够序列，从而能够特异性结合至抗原的多肽或多肽组合。本文“抗体”涵盖各种形式和各种结构，只要它们展现出期望的抗原结合活性。本文“抗体”包括具有移植的互补决定区(CDR)或CDR衍生物的替代蛋白质支架或人工支架。此类支架包括抗体衍生的支架(其包含引入以例如稳定化抗体三维结构的突变)以及包含例如生物相容性聚合物的全合成支架。参见，例如Korndorfer et al.,2003,Proteins:Structure,Function,and Bioinformatics,53(1):121-129(2003)；Roque et al.,Biotechnol.Prog.20:639-654(2004)。此类支架还可以包括非抗体衍生的支架，例如本领域已知可用于移植CDR的支架蛋白，包括但不限于肌腱蛋白、纤连蛋白、肽适体等。
本文“抗体”包括一种典型的“四链抗体”，其属于由两条重链(HC)和两条轻链(LC)组成的免疫球蛋白；重链是指这样的多肽链，其在N端到C端的方向上由重链可变区(VH)、重链恒定区CH1结构域、铰链区(HR)、重链恒定区CH2结构域、重链恒定区CH3结构域组成；并且，当所述全长抗体为IgE同种型时，任选地还包括重链恒定区CH4结构域；轻链是在N端到C端方向上由轻链可变区(VL)和轻链恒定区(CL)组成的多肽链；重链与重链之间、重链与轻链之间通过二硫键连接，形成“Y”字型结构。由于免疫球蛋白重链恒定区的氨基酸组成和排列顺序不同，故其抗原性也不同。据此，可将本文“免疫球蛋白”分为五类，或称为免疫球蛋白的同种型，即IgM、IgD、IgG、IgA和IgE，其相应的重链分别为μ链、δ链、γ链、α链和ε链。同一类Ig根据其铰链区氨基酸组成和重链二硫键的数目和位置的差别，又可分为不同的亚类，如IgG可分为IgG1、IgG2、IgG3、IgG4，IgA可分为IgA1和IgA2。轻链通过恒定区的不同分为κ链或λ链。五类Ig中第每类Ig都可以有κ链或λ链。
本文“抗体”可以来源于任何动物，包括但不限于人和非人动物，所述非人动物可选自灵长类动物、哺乳动物、啮齿动物和脊椎动物，例如骆驼科动物、大羊驼、原鸵、羊驼、羊、兔、小鼠、大鼠或软骨鱼纲(例如鲨)。
本文“抗体”包括但不限于单克隆抗体、多克隆抗体、单特异性抗体、多特异性抗体(例如双特异性抗体)、单价抗体、多价抗体、完整抗体、完整抗体的片段、裸抗体、缀合抗体、嵌合抗体、人源化抗体或全人抗体。
本文术语“单克隆抗体”是指从基本上同质的抗体群体获得的抗体，即，除了可能的变异体(例如含有天然存在的突变或在制剂的生产过程中产生，此类变体通常以少量存在)之外，包含所述群体的各个抗体是相同的和/或结合相同的表位。与通常包括针对不同决定簇(表位)的不同抗体的多克隆抗体制剂相反，单克隆抗体制剂中的每种单克隆抗体针对抗原上的单一决定簇。本文修饰语“单克隆”不应解释为需要通过任何特定方法产生所述抗体或抗原结合分子。举例来说，单克隆抗体可通过多种技术制得，包括(但不限于)杂交瘤技术、重组DNA方法、噬菌体库展示技术和利用含有全部或部分人免疫球蛋白基因座的转殖基因动物的方法和其它本领域已知的方法。
本文术语“天然抗体”是指通过多细胞生物体的免疫系统制造和配对的抗体。本文术语“工程化抗体”的抗体是指通过基因工程、抗体工程等技术获得的非天然抗体，示例性地，“工程化抗体”包括人源化抗体、小分子抗体(例如scFv等)、双特异性抗体等等。
本文术语“单特异性”是指表示具有一个或多个结合位点，其中每个结合位点结合相同抗原的相同表位。
本文术语“多特异性抗体”是指具有至少两个抗原结合位点，所述至少两个抗原结合位点中的每一个抗原结合位点与相同抗原的不同表位或与不同抗原的不同表位结合。因此，诸如“双特异性”、“三特异性”、“四特异性”等术语是指抗体/抗原结合分子可以结合的不同表位的数目。
本文术语“价”表示抗体/抗原结合分子中规定数目的结合位点的存在。因此,术语“单价”、“二价”、“四价”和“六价”分别表示抗体/抗原结合分子中一个结合位点、两个结合位点、四个结合位点和六个结合位点的存在。
本文“全长抗体”、“完好抗体”和“完整抗体”在本文中可互换使用，是指具有基本上与天然抗体结构相似的结构。
本文“抗原结合片段”和“抗体片段”在本文中可互换使用，其不具备完整抗体的全部结构，仅包含完整抗体的局部或局部的变体，所述局部或局部的变体具备结合抗原的能力。本文“抗原结合片段”或“抗体片段”包括但不限于Fab、Fab’、Fab’-SH、F(ab’) 2、Fd、Fv、scFv、双抗体(diabody)和单域抗体。
完整抗体的木瓜蛋白酶消化生成两个同一的抗原结合片段，称作“Fab”片段，每个含有重和轻链可变域，还有轻链的恒定域和重链的第一恒定域(CH1)。如此,本文术语“Fab片段”指包含轻链的VL域和恒定域(CL)的轻链片段,和重链的VH域和第一恒定域(CH1)的抗体片段。Fab’片段因在重链CH1域的羧基末端增加少数残基而与Fab片段不同,包括来自抗体铰链区的一个或多个半胱氨酸。Fab’-SH是其中恒定域的半胱氨酸残基携带游离硫醇基团 的Fab’片段。胃蛋白酶处理产生具有两个抗原结合位点(两个Fab片段)和Fc区的一部分的F(ab’) 2片段。
本文术语“Fd”是指由VH和CH1结构域组成的抗体。本文术语“Fv”是指由单臂VL和VH结构域组成的抗体片段。Fv片段通常被认为是，能形成完整的抗原结合位点的最小抗体片段。一般认为，六个CDR赋予抗体的抗原结合特异性。然而，即便是一个可变区(例如Fd片段，其仅仅含有三个对抗原特异的CDR)也能够识别并结合抗原，尽管其亲和力可能低于完整的结合位点。
本文术语“scFv”(single-chain variable fragment)是指包含VL和VH结构域的单个多肽链，其中所述VL和VH通过接头(linker)相连(参见，例如,Bird等人,Science242:423-426(1988)；Huston等人,Proc.Natl.Acad.Sci.USA 85:5879-5883(1988)；和Pluckthun，The Pharmacology of Monoclonal Antibodies，第113卷，Roseburg和Moore编，Springer-Verlag，纽约，第269-315页(1994))。此类scFv分子可具有一般结构：NH2-VL-接头-VH-COOH或NH2-VH-接头-VL-COOH。合适的现有技术接头由重复的GGGGS氨基酸序列或其变体组成。例如，可使用具有氨基酸序列(GGGGS) 4的接头，但也可使用其变体(Holliger等人(1993)，Proc.Natl.Acad.Sci.USA 90:6444-6448)。可用于本发明的其他接头由Alfthan等人(1995)，Protein Eng.8:725-731，Choi等人(2001)，Eur.J.Immunol.31:94-106，Hu等人(1996)，Cancer Res.56:3055-3061，Kipriyanov等人(1999)，J.Mol.Biol.293:41-56和Roovers等人(2001)，Cancer Immunol.描述。在一些情况下，scFv的VH与VL之间还可以存在二硫键，形成二硫键连接的Fv(dsFv)。
本文术语“双抗体(diabody)”，其VH和VL结构域在单个多肽链上表达，但使用太短的连接体以致不允许在相同链的两个结构域之间配对，从而迫使结构域与另一条链的互补结构域配对并且产生两个抗原结合部位(参见，例如,Holliger P.等人,Proc.Natl.Acad.Sci.USA 90:6444-6448(1993)，和Poljak R.J.等人,Structure 2:1121-1123(1994))。
本文术语“裸抗体”是指不与治疗剂或示踪剂缀合的抗体；术语“缀合抗体”是指与治疗剂或示踪剂缀合的抗体。
本文术语“嵌合抗体(Chimeric antibody)”是指，这样的抗体，其轻链或/和重链的一部分源自一个抗体(其可以源自某一特定物种或属于某一特定抗体类或亚类)，且轻链或/和重链的另一部分源自另一个抗体(其可以源自相同或不同的物种或属于相同或不同的抗体类或亚类)，但无论如何，其仍保留对目标抗原的结合活性(U.S.P 4,816,567 to Cabilly et al.；Morrison et al.,Proc.Natl.Acad.Sci.USA,81:6851 6855(1984))。例如，术语“嵌合抗体”可包括这样的抗体(例如人鼠嵌合抗体)，其中抗体的重链和轻链可变区来自第一抗体(例如鼠源抗体)，而抗体的重链和轻链恒定区来自第二抗体(例如人抗体)。
本文术语“人源化抗体”是指，经基因工程改造的非人源抗体，其氨基酸序列经修饰以提高与人源抗体的序列的同源性。通常而言，人源化抗体的全部或部分CDR区来自于非人源抗体(供体抗体)，全部或部分的非CDR区(例如，可变区FR和/或恒定区)来自于人源免疫球蛋白(受体抗体)。人源化抗体通常保留或部分保留了供体抗体的预期性质，包括但不限于，抗原特异性、亲和性、反应性、提高免疫细胞活性的能力、增强免疫应答的能力 等。
本文术语“全人抗体”是指具有其中FR和CDR二者都源自人种系免疫球蛋白序列的可变区的抗体。此外，如果抗体包含恒定区，则恒定区也源自人种系免疫球蛋白序列。本文全人抗体可以包括不由人种系免疫球蛋白序列编码的氨基酸残基(例如，通过体外随机或位点特异性诱变或通过体内体细胞突变引入的突变)。然而，本文“全人抗体”不包括其中来源于另一个哺乳动物物种(例如小鼠)的种系的CDR序列已被移植到人框架序列上的抗体。
本文术语“可变区”是指抗体重链或轻链中牵涉使抗体结合抗原的区域，“重链可变区”与“VH”、“HCVR”可互换使用，“轻链可变区”与“VL”、“LCVR”可互换使用。天然抗体的重链和轻链的可变域(分别是VH和VL)一般具有相似的结构,每个域包含四个保守的框架区(FR)和三个高变区(HVR)。参见例如Kindt et al.,Kuby Immunology,6th ed.,W.H.Freeman and Co.,p.91(2007)。单个VH或VL域可足以赋予抗原结合特异性。本文术语“互补决定区”与“CDR”可互换使用，通常指重链可变区(VH)或轻链可变区(VL)的高变区(HVR)，该部位因在空间结构上可与抗原表位形成精密的互补，故又称为互补决定区，其中，重链可变区CDR可缩写为HCDR，轻链可变区CDR可缩写为LCDR。本术语“构架区”或“FR区”可互换，是指抗体重链可变区或轻链可变区中除CDR以外的那些氨基酸残基。通常典型的抗体可变区由4个FR区和3个CDR区按以下顺序组成：FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4。
对于CDR的进一步描述，参考Kabat等人,J.Biol.Chem.,252:6609-6616(1977)；Kabat等人,美国卫生与公共服务部，“Sequences of proteins of immunological interest”(1991)；Chothia等人,J.Mol.Biol.196:901-917(1987)；Al-Lazikani B.等人,J.Mol.Biol.,273:927-948(1997)；MacCallum等人,J.Mol.Biol.262:732-745(1996)；Abhinandan和Martin,Mol.Immunol.,45:3832-3839(2008)；Lefranc M.P.等人,Dev.Comp.Immunol.,27:55-77(2003)；以及Honegger和Plückthun,J.Mol.Biol.,309:657-670(2001)。本文“CDR”可由本领域公知的方式加以标注和定义，包括但不限于Kabat编号系统、Chothia编号系统或IMGT编号系统，使用的工具网站包括但不限于AbRSA网站(http://cao.labshare.cn/AbRSA/cdrs.php)、abYsis网站(www.abysis.org/abysis/sequence_input/key_annotation/key_annotation.cgi)和IMGT网站(http://www.imgt.org/3Dstructure-DB/cgi/DomainGapAlign.cgi#results)。本文CDR包括不同定义方式的氨基酸残基的重叠(overlap)和子集。
本文术语“Kabat编号系统”通常是指由Elvin A.Kabat提出的免疫球蛋白比对及编号系统(参见，例如Kabat et al.,Sequences of Proteins of Immunological Interest,5th Ed.Public Health Service,National Institutes of Health,Bethesda,Md.,1991)。
本文术语“重链恒定区”是指抗体重链的羧基端部分，其不直接参与抗体与抗原的结合，但是表现出效应子功能，诸如与Fc受体的相互作用，其相对于抗体的可变结构域具有更保守的氨基酸序列。“重链恒定区”至少包含：CH1结构域，铰链区，CH2结构域，CH3结构域，或其变体或片段。“重链恒定区”包括“全长重链恒定区”和“重链恒定区片段”，前者具有基本上与天然抗体恒定区基本相似的结构，而后者仅包括“全长重链恒定区的一部分”。示例性地，典型的“全长抗体重链恒定区”由CH1结构域-铰链区-CH2结构域-CH3结构域组成；当抗体为IgE时，其还包括CH4结构域；当抗体为重链抗体时，则其不包括CH1 结构域。示例性地，典型的“重链恒定区片段”可选自CH1、Fc或CH3结构域。
本文术语“轻链恒定区”是指抗体轻链的羧基端部分，其不直接参与抗体与抗原的结合，所述轻链恒定区可选自恒定κ结构域或恒定λ结构域。
本文术语“Fc”是指完整抗体经木瓜蛋白酶水解而成的抗体羧基端部分，典型地，其包含抗体的CH3和CH2结构域。Fc区包括例如天然序列Fc区、重组Fc区和变体Fc区。尽管免疫球蛋白重链的Fc区的边界可以略微变化，但是人IgG重链的Fc区通常被定义为从Cys226位置的氨基酸残基或从Pro230延伸至其羧基末端。Fc区的C末端赖氨酸(根据Kabat编号系统的残基447)可以例如在抗体的产生或纯化过程中，或通过对编码抗体重链的核酸重组工程化而除去，因此，Fc区可包括或不包括Lys447。
本文术语“保守氨基酸”通常是指属于同一类或具有类似特征(例如电荷、侧链大小、疏水性、亲水性、主链构象和刚性)的氨基酸。示例性地，下述每组内的氨基酸属于彼此的保守氨基酸残基，组内氨基酸残基的替换属于保守氨基酸的替换：
示例性地，以下六组是被认为是互为保守性置换的氨基酸的实例：
1)丙氨酸(A)、丝氨酸(S)、苏氨酸(T)；
2)天冬氨酸(D)、谷氨酸(E)；
3)天冬酰胺(N)、谷氨酰胺(Q)；
4)精氨酸(R)、赖氨酸(K)、组氨酸(H)；
5)异亮氨酸(I)、亮氨酸(L)、甲硫氨酸(M)、缬氨酸(V)；和
6)苯丙氨酸(F)、酪氨酸(Y)、色氨酸(W)。
本文术语“同一性”可通过以下方式计算获得：为确定两个氨基酸序列或两个核酸序列的“同一性”百分数，将所述序列出于最佳比较目的比对(例如，可以为最佳比对而在第一和第二氨基酸序列或核酸序列之一或二者中引入空位或可以为比较目的而抛弃非同源序列)。随后比较在对应氨基酸位置或核苷酸位置处的氨基酸残基或核苷酸。当第一序列中的位置由第二序列中对应位置处的相同氨基酸残基或核苷酸占据时，则所述分子在这个位置处是相同的。
考虑到为最佳比对这两个序列而需要引入的空位的数目和每个空位的长度，两个序列之间的同一性百分数随所述序列共有的相同位置变化而变化。
可以利用数学算法实现两个序列间的序列比较和同一性百分数的计算。例如，使用已经集成至GCG软件包的GAP程序中的Needlema和Wunsch((1970)J.Mol.Biol.48:444-453)算法(在www.gcg.com可获得)，使用Blossum 62矩阵或PAM250矩阵和空位权重16、14、12、10、8、6或4和长度权重1、2、3、4、5或6，确定两个氨基酸序列之间的同一性百分数。又例如，使用GCG软件包中的GAP程序(在www.gcg.com可获得)，使用NWSgapdna.CMP矩阵和空位权重40、50、60、70或80和长度权重1、2、3、4、5或6，确定两个核苷酸序列之间的同一性百分数。特别优选的参数集合(和除非另外说明否则应当使用的一个参数集合)是采用空位罚分12、空位延伸罚分4和移码空位罚分5的Blossum62评分矩阵。
还可以使用PAM120加权余数表、空位长度罚分12，空位罚分4，利用已经并入ALIGN 程序(2.0版)的E.Meyers和W.Miller算法,((1989)CABIOS,4:11-17)确定两个氨基酸序列或核苷酸序列之间的同一性百分数。
额外地或备选地，可以进一步使用本发明所述的核酸序列和蛋白质序列作为“查询序列”以针对公共数据库执行检索，以例如鉴定其他家族成员序列或相关序列。例如，可以使用Altschul等人,(1990)J.Mol.Biol.215:403-10的NBLAST及XBLAST程序(版本2.0)执行此类检索。BLAST核苷酸检索可以用NBLAST程序，评分＝100、字长度＝12执行，以获得与本发明核酸(SEQ ID NO:1)分子同源的核苷酸序列。BLAST蛋白质检索可以用XBLAST程序、评分＝50、字长度＝3执行，以获得与本发明蛋白质分子同源的氨基酸序列。为了出于比较目的获得带空位的比对结果，可以如Altschul等人,(1997)Nucleic Acids Res.25:3389-3402中所述那样使用空位BLAST。当使用BLAST和空位BLAST程序时，可以使用相应程序(例如，XBLAST和NBLAST)的默认参数。参见www.ncbi.nlm.nih.gov。
本文术语“嵌合抗原受体(CAR)”是指经改造以在免疫效应细胞上表达并且特异性结合抗原的人工细胞表面受体，其包含至少(1)细胞外抗原结合结构域，例如抗体的可变重链或轻链，(2)锚定CAR进入免疫效应细胞的跨膜结构域，和(3)胞内信号传导结构域。CAR能够利用细胞外抗原结合结构域以非MHC限制性的方式将T细胞和其它免疫效应细胞重定向至所选择的靶标，例如癌细胞。
本文术语“核酸”包括包含核苷酸的聚合物的任何化合物和/或物质。每个核苷酸由碱基，特别是嘌呤或嘧啶碱基(即胞嘧啶(C)、鸟嘌呤(G)、腺嘌呤(A)、胸腺嘧啶(T)或尿嘧啶(U))、糖(即脱氧核糖或核糖)和磷酸基团组成。通常，核酸分子由碱基的序列描述，由此所述碱基代表核酸分子的一级结构(线性结构)。碱基的序列通常表示为5′至3′。在本文中，术语核酸分子涵盖脱氧核糖核酸(DNA)，包括例如互补DNA(cDNA)和基因组DNA、核糖核酸(RNA)，特别是信使RNA(mRNA)、DNA或RNA的合成形式，以及包含两种或更多种这些分子的混合的聚合物。核酸分子可以是线性的或环状的。此外，术语核酸分子包括有义链和反义链二者，以及单链和双链形式。而且，本文所述的核酸分子可含有天然存在的或非天然存在的核苷酸。非天然存在的核苷酸的例子包括具有衍生的糖或磷酸骨架键合或化学修饰的残基的修饰的核苷酸碱基。核酸分子还涵盖DNA和RNA分子，其适合作为载体用于在体外和/或体内，例如在宿主或患者中，直接表达本发明的抗体。此类DNA(例如cDNA)或RNA(例如mRNA)载体可以是未修饰的或修饰的。例如，可以对mRNA进行化学修饰以增强RNA载体的稳定性和/或被编码分子的表达，从而可以将mRNA注入到受试者内以在体内产生抗体(参见例如Stadler等人，Nature Medicine 2017，published online 2017年6月12日，doi：10.1038/nm.4356或EP 2 101 823 B1)。本文“分离的”核酸指已经与其天然环境的组分分开的核酸分子。分离的核酸包括在下述细胞中含有的核酸分子，所述细胞通常含有该核酸分子，但该核酸分子存在于染色体外或存在于不同于其天然染色体位置的染色体位置处。
本文术语“载体”是指能够扩增与其连接的另一个核酸的核酸分子。该术语包括作为自我复制型核酸结构的载体以及整合入已引入该载体的宿主细胞的基因组中的载体。某些载体能够指导与它们可操作连接的核酸的表达。这样的载体在本文中称为“表达载体”。
本文术语“宿主细胞”是指细胞中引入外源核酸的细胞，包括这种细胞的后代。宿主细 胞包括“转化体”和“经转化的细胞”，其包括原代的经转化的细胞和来源于其的后代，而不考虑传代的次数。后代在核酸内容物上可能与亲本细胞不完全相同，而是可以包含突变。本文中包括具有与在初始转化的细胞中筛选或选择的相同功能或生物学活性的突变体后代。
本文术语“药物组合物”是指这样的制剂，其以允许包含在其中的活性成分的生物学活性有效的形式存在，并且不含有对施用所述药物组合物的受试者具有不可接受的毒性的另外的成分。
本文术语“治疗”是指外科手术或药物处理(surgical or therapeutic treatment)，其目的是预防、减缓(减少)治疗对象中不希望的生理变化或病变，如癌症的进展。有益的或所希望的临床结果包括但不限于症状的减轻、疾病程度减弱、疾病状态稳定(即，未恶化)、疾病进展的延迟或减慢、疾病状态的改善或缓和、以及缓解(无论是部分缓解或完全缓解)，无论是可检测的或不可检测的。需要治疗的对象包括已患有病症或疾病的对象以及易于患上病症或疾病的对象或打算预防病症或疾病的对象。当提到减缓、减轻、减弱、缓和、缓解等术语时，其含义也包括消除、消失、不发生等情况。
本文术语“受试者”是指接受对如本发明所述的特定疾病或病症的治疗的生物体。对象和患者的实例包括接受疾病或病症治疗的哺乳动物，如人、灵长类动物(例如，猴)或非灵长类哺乳动物。
本文术语“有效量”指单独给予或与另一治疗剂组合给予细胞、组织或对象时能有效防止或缓解疾病病症或该疾病进展的治疗剂用量。“有效量”还指足以缓解症状，例如治疗、治愈、防止或缓解相关医学病症，或治疗、治愈、防止或缓解这些病症的速度增加的化合物用量。当将活性成分单独给予个体时，治疗有效剂量单指该成分。当应用某一组合时，治疗有效剂量指产生治疗作用的活性成分的组合用量，而无论是组合、连续或同时给予。
本文术语“癌症”指向或描述哺乳动物中典型地以不受调节的细胞生长为特征的生理状况。此定义中包括良性和恶性癌症。本文术语“肿瘤”或“瘤”是指所有赘生性(neoplastic)细胞生长和增殖,无论是恶性的还是良性的,及所有癌前(pre-cancerous)和癌性细胞和组织。术语“癌症”和“肿瘤”在本文中提到时并不互相排斥。
本文术语“EC50”是指半最大有效浓度，其包括在指定暴露时间之后诱导基线与最大值之间的半途响应的抗体浓度。EC50本质上代表其中观察到其最大作用的50％的抗体浓度，可通过本领域已知方法测量。
附图说明
图1为SDS-PAGE测定人MSLN蛋白的纯度情况
图2 A为ELISA检测人MSLN-R3-rFc蛋白与对照抗体的结合活性
B为ELISA检测人MSLN-FL-his蛋白与对照抗体的结合活性
C为ELISA检测人MSLN-R1-his蛋白与对照抗体的结合活性
D为ELISA检测人MSLN-R2-his蛋白与对照抗体的结合活性
E为ELISA检测人MSLN-R3-his蛋白与对照抗体的结合活性
图3为ELISA检测对照抗体与MSLN蛋白的结合活性
图4 A为对照抗体Tab106检测Hela细胞MSLN表达量的FACS结果
B为对照抗体Tab131检测Hela细胞MSLN表达量的FACS结果
C为对照抗体Tab142检测Hela细胞MSLN表达量的FACS结果
图5 A为对照抗体Tab106检测OVCAR3细胞MSLN表达量的FACS结果
B为对照抗体Tab131检测OVCAR3细胞MSLN表达量的FACS结果
C为对照抗体Tab142检测OVCAR3细胞MSLN表达量的FACS结果
图6 A为对照抗体Tab020检测人MSLN蛋白转染的CHO-K1-hMSLN-2C8细胞FACS筛选结果
B为对照抗体Tab020检测人MSLN蛋白转染的CHO-K1-Hmsln-2D11细胞FACS筛选结果
C为对照抗体Tab020检测人MSLN蛋白转染的CHO-K1-hMSLN-2C5细胞FACS筛选结果
图7为NB149抗血清检测HEK293T-猴MSLN细胞表达量的FACS结果
图8 A为对照抗体Tab020检测人MSLN蛋白转染的HEK293T-hMSLN-B8细胞FACS筛选结果
B为对照抗体Tab020检测人MSLN蛋白转染的HEK293T-hMSLN-2A4细胞FACS筛选结果
C为对照抗体Tab020检测人MSLN蛋白转染的HEK293T-hMSLN-2A7细胞FACS筛选结果
图9为对照抗体Tab106检测人MSLN-R3蛋白转染的HEK293T细胞FACS筛选结果
图10 A为FACS检测对照抗体与人肿瘤细胞OVCAR3肿瘤细胞的结合反应
B为FACS检测对照抗体与CHO-K1-hMSLN-2C8重组细胞的结合反应
C为FACS检测对照抗体与HEK293T-猴MSLN重组细胞的结合反应
图11 A为人MSLN-FL-his,MSLN-R3-his,MSLN-R3-3蛋白检测小鼠免疫后血清抗体效价情况；B,C为人MSLN-FL-his蛋白检测小鼠免疫后血清抗体效价情况
图12 A,B为人MSLN-R1-his蛋白检测小鼠免疫后血清抗体效价情况
图13 A,B为人MSLN-R2-his蛋白检测小鼠免疫后血清抗体效价情况
图14 A,B为人MSLN-R3-his蛋白检测小鼠免疫后血清抗体效价情况
图15 A,B为人MSLN-R3-3蛋白检测小鼠免疫后血清抗体效价情况
图16 A,B,C为小鼠免疫后用不同细胞检测血清抗体效价情况
图17 A为小鼠免疫后用OVCAR3细胞检测血清抗体效价情况
B为小鼠免疫后用HEK293T-hMSLN细胞检测血清抗体效价情况
C为小鼠免疫后用HEK293T-猴MSLN细胞检测血清抗体效价情况
D为小鼠免疫后用HEK293T细胞检测血清抗体效价情况
图18 A,B为小鼠免疫后用不同细胞检测血清抗体效价情况
图19 A.ELISA检测F1嵌合抗体与人MSLN-FL-his蛋白的结合反应
B.ELISA检测F1嵌合抗体与人MSLN-R1-his蛋白的结合反应
C.ELISA检测F1嵌合抗体与人MSLN-R2-his蛋白的结合反应
D.ELISA检测F1嵌合抗体与人MSLN-R3-his蛋白的结合反应
E.ELISA检测F1嵌合抗体与人MSLN-R3-3的结合反应
图20 A.ELISA检测F2嵌合抗体与人MSLN-FL-his蛋白的结合反应
B.ELISA检测F2嵌合抗体与人MSLN-R1-his蛋白的结合反应
C.ELISA检测F2嵌合抗体与人MSLN-R2-his蛋白的结合反应
D.ELISA检测F2嵌合抗体与人MSLN-R3-his蛋白的结合反应
E.ELISA检测F2嵌合抗体与人MSLN-R3-3的结合反应
图21 A.ELISA检测F3嵌合抗体与人MSLN-FL-his蛋白的结合反应
B.ELISA检测F3嵌合抗体与人MSLN-R1-his蛋白的结合反应
C.ELISA检测F3嵌合抗体与人MSLN-R2-his蛋白的结合反应
D.ELISA检测F3嵌合抗体与人MSLN-R3-his蛋白的结合反应
E.ELISA检测F3嵌合抗体与人MSLN-R3-3的结合反应
图22 A.ELISA检测F4,5,6嵌合抗体与人MSLN-FL-his蛋白的结合反应
B.ELISA检测F4,5,6嵌合抗体与人MSLN-R1-his蛋白的结合反应
C.ELISA检测F4,5,6嵌合抗体与人MSLN-R2-his蛋白的结合反应
D.ELISA检测F4,5,6嵌合抗体与人MSLN-R3-his蛋白的结合反应
E.ELISA检测F4,5,6嵌合抗体与人MSLN-R3-3的结合反应
图23 A,B.ELISA检测F7嵌合抗体与人MSLN-FL-his蛋白的结合反应
C,D.ELISA检测F7嵌合抗体与人MSLN-R1-his蛋白的结合反应
E,F.ELISA检测F7嵌合抗体与人MSLN-R2-his蛋白的结合反应
G,H.ELISA检测F7嵌合抗体与人MSLN-R3-his蛋白的结合反应
图24 A,B.ELISA检测F8嵌合抗体与人MSLN-FL-his蛋白的结合反应
C,D.ELISA检测F8嵌合抗体与人MSLN-R1-his蛋白的结合反应
E,F.ELISA检测F8嵌合抗体与人MSLN-R2-his蛋白的结合反应
G,H.ELISA检测F8嵌合抗体与人MSLN-R3-his蛋白的结合反应
图25 A.FACS检测F1嵌合抗体与OVCAR3细胞的结合反应
B.FACS检测F1嵌合抗体与HEK293T-hMSLN-B8细胞的结合反应
C.FACS检测F1嵌合抗体与HEK293T-hMSLN-R3细胞的结合反应
D.FACS检测F1嵌合抗体与HEK293T-猴MSLN细胞的结合反应
E.FACS检测F1嵌合抗体与A431细胞的结合反应
F.FACS检测F1嵌合抗体与293T细胞的结合反应
图26 A.FACS检测F2嵌合抗体与OVCAR3细胞的结合反应
B.FACS检测F2嵌合抗体与HEK293T-hMSLN-B8细胞的结合反应
C.FACS检测F2嵌合抗体与HEK293T-hMSLN-R3细胞的结合反应
D.FACS检测F2嵌合抗体与HEK293T-猴MSLN细胞的结合反应
E.FACS检测F2嵌合抗体与A431细胞的结合反应
F.FACS检测F2嵌合抗体与293T细胞的结合反应
图27 A.FACS检测F3嵌合抗体与OVCAR3细胞的结合反应
B.FACS检测F3嵌合抗体与HEK293T-hMSLN-B8细胞的结合反应
C.FACS检测F3嵌合抗体与HEK293T-hMSLN-R3细胞的结合反应
D.FACS检测F3嵌合抗体与HEK293T-猴MSLN细胞的结合反应
E.FACS检测F3嵌合抗体与A431细胞的结合反应
F.FACS检测F3嵌合抗体与293T细胞的结合反应
图28 A.FACS检测F4,F5,F6嵌合抗体与OVCAR3细胞的结合反应
B.FACS检测F4,F5,F6嵌合抗体与HEK293T-hMSLN-B8细胞的结合反应
C.FACS检测F4,F5,F6嵌合抗体与HEK293T-hMSLN-R3细胞的结合反应
D.FACS检测F4,F5,F6嵌合抗体与HEK293T-猴MSLN细胞的结合反应
E.FACS检测F4,F5,F6嵌合抗体与293T细胞的结合反应
F.FACS检测F4,F5,F6嵌合抗体与A431细胞的结合反应
图29 A,B.FACS检测F7嵌合抗体与OVCAR3细胞的结合反应
C,D.FACS检测F7嵌合抗体与HEK293T-hMSLN-R3细胞的结合反应
E,F.FACS检测F7嵌合抗体与HEK293T-猴MSLN细胞的结合反应
G,H.FACS检测F7嵌合抗体与293T细胞的结合反应
I,J.FACS检测F7嵌合抗体与A431细胞的结合反应
图30 A,B.FACS检测F8嵌合抗体与OVCAR3细胞的结合反应
C,D.FACS检测F8嵌合抗体与HEK293T-hMSLN-R3细胞的结合反应
E,F.FACS检测F8嵌合抗体与HEK293T-猴MSLN细胞的结合反应
G,H.FACS检测F8嵌合抗体与293T细胞的结合反应
I,J.FACS检测F8嵌合抗体与A431细胞的结合反应
图31～图37为竞争性ELISA方法检测嵌合抗体之间的抑制率
图38中A～H为ELISA检测人源化抗体与人MSLN全长蛋白的结合反应
图39中A～F为ELISA检测人源化抗体与人MSLN-R3蛋白的结合反应
图40中A～J为FACS检测人源化抗体与HEK293T-hMSLN-R3细胞的结合反应
图41中A～J为FACS检测人源化抗体与HEK293T空细胞的结合反应
图42中A～J为FACS检测人源化抗体与OVCAR3细胞的结合反应
图43中A～J为FACS检测人源化抗体与A431细胞的结合反应
图44中A～J为FACS检测人源化抗体与HEK293T-猴MSLN细胞的结合反应
具体实施方式
下面结合具体实施例来进一步描述本发明，本发明的优点和特点将会随着描述而更为清楚。实施例中未注明具体条件者，按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者，均为可以通过市售购买获得的常规产品。
本发明实施例仅是范例性的，并不对本发明的范围构成任何限制。本领域技术人员应该理解的是，在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换，但这些修改和替换均落入本发明的保护范围内。
实施例1 对照抗体制备、内源细胞鉴定和过表达细胞株的制备
1.1对照抗体的制备
YP218、YP3和YP223序列来自专利US2015252118A1，m912序列来自专利WO2009120769A1，Amatuximab序列来自专利US20140127237A1。将识别人MSLN R3表位的克隆YP218和识别人MSLN构象表位的克隆YP3的VH和VL序列重组到人IgG1CH和CL表达载体；识别人MSLN R2表位的克隆YP223的VH和VL序列重组到兔IgG1CH和CL表达载体；识别人MSLN R3表位的克隆m912和YP218的VH和VL通过3个GGGGS连接子连接后重组到人IgG1Fc的表达载体中，得重组质粒。质粒构建及抗体的表达纯化工作均由泰州市百英生物科技有限公司完成。
将Amatuximab、YP218人IgG1形式的抗体、YP223兔IgG1形式的抗体、YP3人IgG1形式的抗体、YP218scFv-人IgG1Fc(hFc)形式的抗体、和m912scFv-人IgG1Fc(hFc)形式的抗体分别命名为Tab142(Amatuximab)，Tab106(YP218，hIgG1形式)，Tab020(YP223，rabbitIgG1形式)，Tab107(YP3，hIgG1形式)、Tab108(YP218，scFv-hIgG1Fc形式)和Tab131(m912，scFv-hIgG1Fc形式)。
表1.对照抗体序列信息
Figure PCTCN2022093759-appb-000005
Figure PCTCN2022093759-appb-000006
1.2人MSLN-R3-rFc，MSLN-FL-his，MSLN-R1-his，MSLN-R2-his，MSLN-R3-his的制备
MSLN蛋白胞外具有3个类IgG样结构域，其中Region1(R1)位于最远膜端，Region3(R3)位于最近膜端，Amatuximab的抗原结合表位位于R1，YP218位于R3。将含有编码人MSLN蛋白(NCBI：AAH09272.1)胞外区氨基酸序列Glu296-Gly580(MSLN-FL)、 Glu296-Thr390(MSLN-R1)、Ser391-Asn486(MSLN-R2)和Met487-Ser598(MSLN-R3)的核苷酸序列分别克隆到pTT5载体(由通用生物系统(安徽)有限公司完成)并按已建立的标准分子生物学方法制备质粒，具体方法参见Sambrook,J.,Fritsch,E.F.,and Maniatis,T.(1989).Molecular Cloning:A Laboratory Manual,Second Edition(Plainview,New York:Cold Spring Harbor Laboratory Press)。对HEK293E细胞(购自苏州益研生物科技有限公司)进行瞬时转染(PEI，Polysciences，货号：24765-1)并使用FreeStyle TM 293(Thermofisher scientific，货号：12338018)在37℃下进行扩大培养。6天后收集细胞培养液，离心去除细胞成分，获得含人MSLN蛋白胞外区的培养上清液。将培养上清液上样到镍离子亲和层析柱HisTrap TM Excel(GE Healthcare，货号：GE17-3712-06)，同时用紫外(UV)检测仪监测紫外吸收值(A280nm)的变化。上样后用20mM PB，0.5M NaCl(pH7.4)清洗镍离子亲和层析柱直到紫外吸收值回到基线，然后用buffer A：20mM PB，0.5M NaCl(pH7.4)和buffer B：20mM PB，0.5M NaCl，500mM咪唑进行梯度洗脱(2％,4％,8％,16％,50％,100％)，收集从镍离子亲和层析柱上洗脱下来的带His标签的人MSLN蛋白。将培养上清液上样到蛋白A层析柱(蛋白A填料AT Protein A Diamond和层析柱BXK16/26均购自博格隆)，使用PBS磷酸盐缓冲液(pH7.4)清洗后再用20mM PB,1M NaCl,pH 7.2进行清洗，最后使用pH3.4的柠檬酸缓冲液进行洗脱，收集从蛋白A层析柱上洗脱下来的带rabbit Fc(rFc)标签的人MSLN蛋白。用PBS磷酸盐缓冲液(pH7.4)在4℃冰箱透析过夜。透析后的蛋白经0.22微米无菌过滤后分装于-80℃保存，即获得纯化的人MSLN胞外区蛋白，SDS-PAGE还原胶和非还原胶检测样品目的条带如图1所示。
人MSLN蛋白(NCBI：AAH09272.1)：
Figure PCTCN2022093759-appb-000007
对制备的上述人MSLN蛋白应用识别不同表位的阳性对照抗体进行ELISA检测，检测结果如图2和表2～表6所示，人MSLN-R3-rFc、MSLN-FL-his、MSLN-R1-his、MSLN-R2-his、MSLN-R3-his蛋白可与抗人MSLN抗体(购自Acro，货号#MSN-M30)或者与对照抗体有结合活性，与产品说明书或者文献报道的Tab142(Amatuximab)、Tab106(YP218)、Tab020(YP223)和Tab107(YP3)的结合表位一致，说明已经制备获得具有结合活性的上述蛋白。
表2.ELISA检测人MSLN-R3-rFc蛋白与抗体的结合反应
Figure PCTCN2022093759-appb-000008
Figure PCTCN2022093759-appb-000009
表3.ELISA检测人MSLN-FL-his蛋白与抗体的结合反应
Figure PCTCN2022093759-appb-000010
表4.ELISA检测人MSLN-R1-his蛋白与抗体的结合反应
Figure PCTCN2022093759-appb-000011
表5.ELISA检测人MSLN-R2-his蛋白与抗体的结合反应
Figure PCTCN2022093759-appb-000012
表6.ELISA检测人MSLN-R3-his蛋白与抗体的结合反应
Figure PCTCN2022093759-appb-000013
Figure PCTCN2022093759-appb-000014
对照抗体与人MSLN-FL-His蛋白，MSLN-R1-His蛋白，MSLN-R2-His蛋白，MSLN-R3-His蛋白和MSLN-R3-3多肽(R3-3是R3中更小的表位，购自：吉尔生化，货号：406676)的结合活性如表7和图3所示，结果说明，Tab020(YP223)，Tab142(Amatuximab)，Tab106(YP218)，Tab107(YP3)抗体与人MSLN-FL-his蛋白有很好的结合活性，同等实验条件下Tab131(m912 scFv-hFc)几乎与人MSLN-FL-his蛋白没有结合活性。
表7.ELISA检测对照抗体与人MSLN-FL-his蛋白的结合反应
Figure PCTCN2022093759-appb-000015
1.3内源性表达人MSLN蛋白的细胞株鉴定
将内源性表达人MSLN蛋白的细胞在T-75细胞培养瓶中扩大培养至对数生长期，离心弃去培养基上清，细胞沉淀用PBS洗涤2次。用20nM Tab106、Tab131和Tab142抗体作为一抗，FITC标记的二抗(购自Invitrogen，货号：A18830)经FACS(FACS Canto TM，购自BD公司)检测和分析。结果如表8，图4以及图5所示，说明内源表达人MSLN蛋白的细胞与Tab106、Tab131和Tab142均有结合活性。
表8.FACS检测肿瘤细胞MSLN表达量
Figure PCTCN2022093759-appb-000016
1.4表达人MSLN全长蛋白的CHO-K1重组细胞株的制备
编码人MSLN全长氨基酸序列(NCBI：AAH09272.1)的核苷酸序列被克隆到pcDNA3.1载体并制备质粒(由通用生物系统(安徽)有限公司完成)。对CHO-K1细胞系(购自中国科学院上海生命科学研究院)进行质粒转染(
Figure PCTCN2022093759-appb-000017
3000 Transfection Kit，购自Invitrogen，货号：L3000-015)后，在含10μg/mL嘌呤霉素和含10％(w/w)胎牛血清的DMEM/F12培养基中选择性培养2周，用兔抗人MSLN抗体(Tab020)和山羊抗兔IgG Fab抗体(cell signaling，货号：4414S)在流式细胞仪FACSAriaII(购自BD Biosciences)上分选阳性单克隆细胞到96孔板，置于37℃，5％(v/v)CO 2培养，大约2周后选择部分 单克隆孔进行扩增。对扩增后的克隆经流式细胞分析法进行筛选。选择长势较好、荧光强度较高、单克隆的细胞系继续扩大培养并液氮冻存。
具体选择结果如表9和图6所示，仅孵育二抗的作为对照。表9说明，已经制得一系列人MSLN阳性表达的CHO-K1单克隆细胞系。图6中，横坐标为细胞荧光强度，纵坐标为细胞数。结果说明，2C8、2D11、2C5为高水平表达人MSLN蛋白的重组CHO-K1细胞株。
表9.表达人MSLN全长蛋白的CHO-K1重组细胞系FACS检测结果
Figure PCTCN2022093759-appb-000018
1.5表达猴MSLN蛋白的重组HEK293T细胞株制备
编码猴MSLN全长氨基酸序列(NCBI：XP_028696439.1)的核苷酸序列被克隆到pcDNA3.1载体并制备质粒。对HEK293T细胞系(购自ATCC)进行质粒转染(
Figure PCTCN2022093759-appb-000019
3000 Transfection Kit，购自Invitrogen，货号：L3000-015)后，在含10μg/ml嘌呤霉素和含10％(w/w)胎牛血清的DMEM/F12培养基中选择性培养2周，用有限稀释法在96孔培养板中进行亚克隆，并置于37℃，5％(v/v)CO 2培养，大约2周后选择部分多克隆孔扩增到6孔板中。对扩增后的克隆用NB149抗血清经FACS流式细胞仪检测和分析，选择长势较好、荧光强度较高的细胞株继续扩大培养并液氮冻存。表达量的结果如表10和图7，显示经过嘌呤霉素加压筛选后的HEK293T-猴-MSLN具有相对单一的阳性峰，可用于FACS检测抗体与猴MSLN蛋白的交叉活性。
猴MSLN全长氨基酸序列(NCBI：XP_028696439.1)：
Figure PCTCN2022093759-appb-000020
表10.表达猴MSLN全长蛋白的HEK293T重组细胞系FACS检测结果
Figure PCTCN2022093759-appb-000021
1.6表达人MSLN蛋白的重组HEK293T细胞株制备
编码人MSLN全长氨基酸序列(NCBI：AAH09272.1)的核苷酸序列被克隆到pcDNA3.1载体并制备质粒。对HEK293T细胞系(购自ATCC)进行质粒转染(
Figure PCTCN2022093759-appb-000022
3000 Transfection Kit，购自Invitrogen，货号：L3000-015)后，在含5μg/mL嘌呤霉素和含10％(w/w)胎牛血清的DMEM培养基中选择性培养2周，用兔抗人MSLN抗体(Tab020) 和山羊抗兔IgG Fab抗体(cell signaling，货号：4414S)在流式细胞仪FACSAriaII(购自BD Biosciences)上分选阳性单克隆细胞到96孔板，并置于37℃，5％(v/v)CO 2培养，大约2周后选择部分单克隆孔进行扩增。对扩增后的克隆用Tab020抗体经FACS流式细胞仪检测和分析，选择长势较好、荧光强度较高的细胞株继续扩大培养并液氮冻存。表达量的结果如表11和图8，显示经过嘌呤霉素加压筛选后的HEK293T-人MSLN具有单一的阳性峰，B8、2A4、2A7为高水平表达人MSLN蛋白的重组HEK293T细胞株，可用于FACS检测抗体与人MSLN蛋白的结合活性。
表11.表达人MSLN全长蛋白的HEK293T重组细胞系FACS检测结果
Figure PCTCN2022093759-appb-000023
1.7表达人MSLN-R3蛋白的重组HEK293T细胞株制备
编码人MSLN-R3氨基酸序列(NCBI：AAH09272.1的Met487-Ser606)的核苷酸序列被克隆到pcDNA3.1载体并制备质粒。对HEK293T细胞系(购自ATCC)进行质粒转染(
Figure PCTCN2022093759-appb-000024
3000 Transfection Kit，购自Invitrogen，货号：L3000-015)后，在含5μg/mL嘌呤霉素和含10％(w/w)胎牛血清的DMEM培养基中选择性培养2周，用抗人MSLN-R3抗体(Tab106)和山羊抗人IgG H+L抗体(Jackson，货号：109605088)在流式细胞仪FACSAriaII(购自BD Biosciences)上分选阳性单克隆细胞到96孔板，并置于37℃，5％(v/v)CO 2培养，大约2周后选择部分单克隆孔进行扩增。对扩增后的克隆用Tab106抗体经FACS流式细胞仪检测和分析，选择长势较好、荧光强度较高的细胞株继续扩大培养并液氮冻存。表达量的结果如表12和图9，显示经过嘌呤霉素加压筛选后的HEK293T-人MSLN-R3具有相对单一的阳性峰，可用于FACS检测抗体与人MSLN-R3蛋白的结合活性。
表12.表达人MSLN-R3蛋白的HEK293T重组细胞系FACS检测结果
Figure PCTCN2022093759-appb-000025
1.8重组细胞系与对照抗体的结合实验
对照抗体与表达人MSLN或者猴MSLN的细胞结合活性如表13～表15和图10所示，IgG亚型对照为人IgG1。Tab142、Tab020、Tab106、Tab107与表达人MSLN蛋白的OVCAR3肿瘤细胞和CHO-K1-hMSLN-2C8重组细胞有很好的结合活性，Tab131的结合活性相对较弱。Tab142、Tab106、Tab107与HEK293T-猴MSLN重组细胞有结合活性，Tab020和Tab131在同等实验条件下几乎未检测出与猴MSLN的交叉结合活性。
表13.FACS检测对照抗体与OVCAR3肿瘤细胞的结合反应
Figure PCTCN2022093759-appb-000026
Figure PCTCN2022093759-appb-000027
表14.FACS检测对照抗体与CHO-K1-hMSLN-2C8重组细胞的结合反应
Figure PCTCN2022093759-appb-000028
表15.FACS检测对照抗体与HEK293T-猴MSLN重组细胞的结合反应
Figure PCTCN2022093759-appb-000029
实施例2 抗人MSLN杂交瘤单克隆抗体的制备
2.1动物免疫
抗人MSLN单克隆抗体通过免疫小鼠产生。实验用6～8周龄BALB/c AnNCrl小鼠(购自维通利华公司)或SJL/JorllcoCrl小鼠(购自上海斯莱克公司)，雌性。饲养环境：SPF级。小鼠购进后，实验室环境饲养1周，12/12小时光/暗周期调节，温度20-25℃；湿度40-60％。将已适应环境的小鼠按以下方案免疫。免疫抗原为(1)蛋白免疫原：人MSLN-FL-hFc蛋白，MSLN-FL-his蛋白，MSLN-R3-rFc蛋白(公司自制)，(2)转入不同MSLN蛋白的293T细胞作为免疫原：293T-hMSLN，293T-hMSLN R3，293T-hMSLN R3/mMSLN R1-2(公司自制)。免疫6组小鼠，分别用以上抗原单独免疫或者组合免疫(免疫方案见表16)，初次免疫时，免疫原用TiterMax(购自Sigma，货号T2684)乳化后皮下与腹腔分别注射0.1毫升，即每只小鼠注射50微克免疫原蛋白或者5E6个细胞。加强免疫时，免疫原用Imject Alum Adjuvant(购自Thermofisher scientific货号：77161)皮下与腹腔分别注射0.1毫升，即每只小鼠注射25微克免疫原。免疫频次每周一次，于融合前取血， 用ELISA和FACS方法检测小鼠血清中的抗体滴度。结果如图11～图18所示，经以上蛋白和细胞免疫的小鼠的免疫后血清对免疫原均有不同程度的结合，呈现抗原抗体反应，其中空白对照为1％(w/w)BSA，表中的数据为OD450nm和MFI值。
表16.小鼠免疫组别和免疫方案
Figure PCTCN2022093759-appb-000030
2.2脾细胞融合和杂交瘤筛选
加入ACK Lysing Buffer(购自Gibco，货号：A1049201)，裂解脾细胞中掺杂的红细胞，获得脾细胞悬液。用DMEM(购自Gibco，货号：11995-073)基础培养基1000转每分钟离心清洗细胞3次，然后按照活细胞数目2:1比率与小鼠骨髓瘤细胞SP2/0(购自ATCC，CRL-1581)混合，采用BTX ECM2001+高效电融合方法(参见METHODS IN ENZYMOLOGY,VOL.220)进行细胞融合。融合后的细胞稀释到含20％胎牛血清(ExCell Bio，货号FSD500)、1×HAT(购自Sigma，货号：H0262)的DMEM培养基中，所述百分比为质量百分比。然后按2×10 4/200微升每孔加入到96孔细胞培养板中，放入5％CO 2、37℃培养箱中，所述百分比为体积百分比。14天后用ELISA筛选细胞融合板上清，将ELISA阳性克隆扩增到24孔板，在含10％(w/w)HT(购自Sigma，货号：H0137)胎牛血清，DMEM在37℃，5％(v/v)CO 2条件下扩大培养。培养3天后取24孔板中扩大培养的培养液进行离心，收集上清液，对上清液进行抗体亚型分析，用ELISA、FACS确定对人MSLN蛋白和人MSLN阳性细胞的结合活性(结合活性的检测方法请分别参见实施例1.2和实施例1.3)。
根据24孔板筛选结果，挑选ELISA和FACS实验中阳性组的杂交瘤细胞为符合条件的阳性克隆，选择符合条件的杂交瘤细胞用有限稀释法在96孔板进行亚克隆，在含10％(w/w)FBS的DMEM培养基中(购自Gibco)，37℃，5％(v/v)CO 2条件下培养。亚克隆后10天用ELISA和FACS进行初步筛选，挑选单个阳性单克隆扩增到24孔板继续培养。
根据24孔板样品检测结果，挑选出最优的克隆，并于含10％(w/w)FBS的DMEM 培养基中(购自Gibco)在37℃，5％(v/v)CO 2条件下将该最优的克隆进行扩大培养，液氮冻存即得本发明杂交瘤细胞。
实施例3 杂交瘤阳性克隆轻链和重链可变区氨基酸序列测定
收集对数生长期杂交瘤细胞，用Trizol(Invitrogen,Cat No.15596-018)充分裂解细胞后于-80摄氏度保存待测。样品委托苏州金唯智生物生物科技有限公司完成杂交瘤阳性克隆轻重链可变区氨基酸序列测定。对测序结果使用MOE软件进行分析，根据可变区编码蛋白氨基酸序列构建进化树，根据序列相似性剔除在进化树上距离较近的序列后，筛选获得71个克隆，其中F1系列8个：S009-F1.2.12，S009-F1.7.14，S009-F1.25.10，S009-F1.35.24，S009-F1.56.1，S009-F1.57.1，S009-F1.59.1，S009-F1.62.9(见表17，SEQ ID NO：16-31)，F2系列10个：S009-F2.13.3，S009-F2.16.10，S009-F2.17.3，S009-F2.21.4，S009-F2.23.12，S009-F2.38.12，S009-F2.39.3，S009-F2.47.1，S009-F2-56.12，S009-F2.58.8(见表18，SEQ ID NO：32-51)，F3系列9个：S009-F3.7.3，S009-F3.16.1，S009-F3.23.1，S009-F3.38.10，S009-F3.45.21，S009-F3.51.8，S009-F3-63.5，S009-F3.74.20，S009-F3.80.22(见表19，SEQ ID NO：52-69)，F4系列2个：S009-F4-94.15，S009-F4-127.10(见表20，SEQ ID NO：70-73)，F5系列1个：S009-F5-9.16(见表20，SEQ ID NO：74-75)，F6系列2个：S009-F6-62.5，S009-F6-76.1(见表20，SEQ ID NO：76-79)，F7系列20个：S009-F7.2.3，S009-F7.6.17，S009-F7.11.11，S009-F7.12.13，S009-F7.18.10，S009-F7.21.16，S009-F7.23.19，S009-F7.25.19，S009-F7.26.15，S009-F7.30.5，S009-F7.33.24，S009-F7.41.18，S009-F7.44.20，S009-F7.48.1，S009-F7.53.2，S009-F7.61.21，S009-F7.65.13，S009-F7.66.12，S009-F7.67.12，S009-F7.69.8(见表21，SEQ ID NO：80-119)，F8系列19个：S009-F8-4.5，S009-F8-5.15，S009-F8-7.5，S009-F8-8.22，S009-F8-9.16，S009-F8-12.13，S009-F8-13.8，S009-F8-15.19，S009-F8-18.9，S009-F8-19.21，S009-F8-22.23，S009-F8-24.14，S009-F8-27.1，S009-F8-28.23，S009-F8-29.1，S009-F8-31.22，S009-F8-32.3，S009-F8-33.12，S009-F8-36.12(见表22，SEQ ID NO：120-157)。
表17.MSLN F1杂交瘤阳性克隆轻链和重链可变区氨基酸序列信息
Figure PCTCN2022093759-appb-000031
Figure PCTCN2022093759-appb-000032
表18.MSLN F2杂交瘤阳性克隆轻链和重链可变区氨基酸序列信息
Figure PCTCN2022093759-appb-000033
Figure PCTCN2022093759-appb-000034
Figure PCTCN2022093759-appb-000035
表19.MSLN F3杂交瘤阳性克隆轻链和重链可变区氨基酸序列信息
Figure PCTCN2022093759-appb-000036
Figure PCTCN2022093759-appb-000037
表20.MSLN F4,F5,F6杂交瘤阳性克隆轻链和重链可变区氨基酸序列信息
Figure PCTCN2022093759-appb-000038
表21.MSLN F7杂交瘤阳性克隆轻链和重链可变区氨基酸序列信息
Figure PCTCN2022093759-appb-000039
Figure PCTCN2022093759-appb-000040
Figure PCTCN2022093759-appb-000041
Figure PCTCN2022093759-appb-000042
表22.MSLN F8杂交瘤阳性克隆轻链和重链可变区氨基酸序列信息
Figure PCTCN2022093759-appb-000043
Figure PCTCN2022093759-appb-000044
Figure PCTCN2022093759-appb-000045
Figure PCTCN2022093759-appb-000046
由泰州市百英生物科技有限公司将71个克隆的重链可变区序列克隆到包含信号肽和人源抗体IgG1的重链恒定区的表达载体pcDNA3.4-B1HH1(重链恒定区序列：ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK，SEQ ID NO：158)。
将71个克隆的轻链可变区序列克隆到包含信号肽和人源抗体IgG1的Kappa轻链恒定区的表达载体pcDNA3.4-B1HLK(轻链恒定区序列：RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC，SEQ ID NO：159)，获得人鼠嵌合抗体的表达载体并按照实施例1.1的方法制备抗体。
表23 MSLN嵌合抗体VH和VL序列的Kabat分析结果
Figure PCTCN2022093759-appb-000047
Figure PCTCN2022093759-appb-000048
Figure PCTCN2022093759-appb-000049
Figure PCTCN2022093759-appb-000050
Figure PCTCN2022093759-appb-000051
Figure PCTCN2022093759-appb-000052
Figure PCTCN2022093759-appb-000053
Figure PCTCN2022093759-appb-000054
Figure PCTCN2022093759-appb-000055
Figure PCTCN2022093759-appb-000056
实施例4 MSLN人鼠嵌合抗体的鉴定
4.1酶联免疫吸附实验(ELISA)检测嵌合抗体与人MSLN蛋白的结合
为了检测MSLN人鼠嵌合抗体与人MSLN全长蛋白、MSLN-R1蛋白、MSLN-R2蛋白、MSLN-R3蛋白、MSLN-R3-3蛋白的结合活性，将实施例2获得的纯化的这些蛋白用PBS稀释到终浓度2μg/mL，然后以50μl/孔加到96孔ELISA板。用塑料膜封好4℃孵育过夜，第二天用PBST洗板2次，加入封闭液[PBS+2％(w/w)BSA]室温封闭2小时。倒掉封闭液，以50μl/孔加入100nM梯度稀释的嵌合抗体或阴性对照抗体。37℃孵育2小时后，用PBST洗板3次。加入HRP(辣根过氧化物酶)标记的二抗(购自Jackson，货号：109-035-088)，37℃孵育2小时后，用PBST洗板5次。加入TMB底物50μl/孔，室温孵育5-10分钟后，加入终止液(1.0N HCl)50μl/孔。用ELISA读板机(Multimode Plate Reader，EnSight，购自Perkin Elmer)读取OD450nm数值，嵌合抗体与人MSLN全长蛋白、MSLN-R1蛋白、MSLN-R2蛋白、MSLN-R3蛋白、MSLN-R3-3蛋白的结合活性ELISA检测结果如表24～表51和图19～图24。表24-51说明，纯化生产后的嵌合抗体与人MSLN全长蛋白、 MSLN-R1蛋白、MSLN-R2蛋白、MSLN-R3蛋白、MSLN-R3-3蛋白在ELISA水平上有不同程度的结合，根据体外ELISA实验抗原抗体结合的不同，F1-F8嵌合抗体可分为五类：
(1)只与人MSLN全长蛋白结合，如S009-F8.4.5；
(2)只与人MSLN-R3蛋白结合，如S009-F3.7.3、F3.38.10；
(3)同时与人MSLN全长蛋白和人MSLN-R1蛋白结合，如S009-F2.16.10；
(4)同时与人MSLN全长蛋白和人MSLN-R2蛋白结合，如S009-F7.2.3；
(5)同时与人MSLN全长蛋白和人MSLN-R3蛋白结合，如S009-F7.33.24、F7.44.20、F3.80.22(R3-3也结合)；弱结合R3，F2.23.12、F2.39.3。
阴性对照抗体hIgG1为针对鸡卵溶菌酶的抗体anti-hel-hIgG1(购自百英，货号：B117901)，表中的数据为OD 450nm值。
表24.ELISA检测F1嵌合抗体与人MSLN全长蛋白的结合反应
Figure PCTCN2022093759-appb-000057
表25.ELISA检测F1嵌合抗体与人MSLN-R1蛋白的结合反应
Figure PCTCN2022093759-appb-000058
表26.ELISA检测F1嵌合抗体与人MSLN-R2蛋白的结合反应
Figure PCTCN2022093759-appb-000059
Figure PCTCN2022093759-appb-000060
表27.ELISA检测F1嵌合抗体与人MSLN-R3蛋白的结合反应
Figure PCTCN2022093759-appb-000061
表28.ELISA检测F1嵌合抗体与人MSLN-R3-3蛋白的结合反应
Figure PCTCN2022093759-appb-000062
表29.ELISA检测F2嵌合抗体与人MSLN全长蛋白的结合反应
Figure PCTCN2022093759-appb-000063
Figure PCTCN2022093759-appb-000064
表30.ELISA检测F2嵌合抗体与人MSLN-R1蛋白的结合反应
Figure PCTCN2022093759-appb-000065
表31.ELISA检测F2嵌合抗体与人MSLN-R2蛋白的结合反应
Figure PCTCN2022093759-appb-000066
Figure PCTCN2022093759-appb-000067
表32.ELISA检测F2嵌合抗体与人MSLN-R3蛋白的结合反应
Figure PCTCN2022093759-appb-000068
表33.ELISA检测F2嵌合抗体与人MSLN-R3-3蛋白的结合反应
Figure PCTCN2022093759-appb-000069
表34.ELISA检测F3嵌合抗体与人MSLN全长蛋白的结合反应
Figure PCTCN2022093759-appb-000070
Figure PCTCN2022093759-appb-000071
表35.ELISA检测F3嵌合抗体与人MSLN-R1蛋白的结合反应
Figure PCTCN2022093759-appb-000072
表36.ELISA检测F3嵌合抗体与人MSLN-R2蛋白的结合反应
Figure PCTCN2022093759-appb-000073
表37.ELISA检测F3嵌合抗体与人MSLN-R3蛋白的结合反应
Figure PCTCN2022093759-appb-000074
Figure PCTCN2022093759-appb-000075
表38.ELISA检测F3嵌合抗体与人MSLN-R3-3蛋白的结合反应
Figure PCTCN2022093759-appb-000076
表39.ELISA检测F4,F5,F6嵌合抗体与人MSLN全长蛋白的结合反应
Figure PCTCN2022093759-appb-000077
表40.ELISA检测F4,F5,F6嵌合抗体与人MSLN-R1蛋白的结合反应
Figure PCTCN2022093759-appb-000078
Figure PCTCN2022093759-appb-000079
表41.ELISA检测F4,F5,F6嵌合抗体与人MSLN-R2蛋白的结合反应
Figure PCTCN2022093759-appb-000080
表42.ELISA检测F4,F5,F6嵌合抗体与人MSLN-R3蛋白的结合反应
Figure PCTCN2022093759-appb-000081
表43.ELISA检测F4,F5,F6嵌合抗体与人MSLN-R3-3蛋白的结合反应
Figure PCTCN2022093759-appb-000082
表44.ELISA检测F7嵌合抗体与人MSLN全长蛋白的结合反应
Figure PCTCN2022093759-appb-000083
表45.ELISA检测F7嵌合抗体与人MSLN-R1蛋白的结合反应
Figure PCTCN2022093759-appb-000084
Figure PCTCN2022093759-appb-000085
表46.ELISA检测F7嵌合抗体与人MSLN-R2蛋白的结合反应
Figure PCTCN2022093759-appb-000086
表47.ELISA检测F7嵌合抗体与人MSLN-R3蛋白的结合反应
Figure PCTCN2022093759-appb-000087
Figure PCTCN2022093759-appb-000088
表48.ELISA检测F8嵌合抗体与人MSLN全长蛋白的结合反应
Figure PCTCN2022093759-appb-000089
表49.ELISA检测F8嵌合抗体与人MSLN-R1蛋白的结合反应
Figure PCTCN2022093759-appb-000090
Figure PCTCN2022093759-appb-000091
表50.ELISA检测F8嵌合抗体与人MSLN-R2蛋白的结合反应
Figure PCTCN2022093759-appb-000092
表51.ELISA检测F8嵌合抗体与人MSLN-R3蛋白的结合反应
Figure PCTCN2022093759-appb-000093
Figure PCTCN2022093759-appb-000094
4.2流式细胞实验(FACS)检测嵌合抗体与不同MSLN表达细胞的结合
将所需细胞在T-75细胞培养瓶中扩大培养至对数生长期，对于贴壁细胞OVCAR3,A431,HEK293T-hMSLN-B8,HEK293T-hMSLN-R3,HEK293T-猴MSLN,293T吸除培养基，用PBS缓冲液洗涤2次，然后用胰酶消化细胞，终止消化后用PBS缓冲液洗涤细胞2次；对上一步的细胞进行细胞计数后将细胞沉淀用[PBS+2％(w/w)BSA]封闭液重悬至2×10 6个细胞/毫升，按50μl/孔加入到96孔FACS反应板中，加入嵌合抗体待测样品50μl/孔，冰上孵育2小时。用PBS缓冲液离心洗涤3次，加入50μl/孔山羊抗人IgG H+L抗体(Jackson，货号：109605088)，冰上孵育1小时。用PBST缓冲液离心洗涤5次，用FACS(FACS CantoII，购自BD公司)检测和分析结果。通过软件(Flowjo)进行数据分析，得到细胞的平均荧光密度(MFI)。再通过软件(GraphPad Prism8)分析，进行数据分析，分析结果如表52～表57以及图25～图30所示，
(1)嵌合抗体均可结合293T-hMSLN.B8细胞，
(2)大部分可结合OVCAR3，
(3)和HEK293T-hMSLN-R3部分结合。
(4)嵌合抗体与过表达猴MSLN的293T细胞大部分均有结合活性，
使用同样的方法同时检测了嵌合抗体与内源A431以及293T细胞的结合，
(5)所有嵌合抗体均不结合A431细胞以及293T细胞，具有很好的特异性。
表52.FACS检测F1嵌合抗体与细胞的结合反应
Figure PCTCN2022093759-appb-000095
1.NB:no binding；
2.WB:worse binding
表53.FACS检测F2嵌合抗体与细胞的结合反应
Figure PCTCN2022093759-appb-000096
Figure PCTCN2022093759-appb-000097
表54.FACS检测F3嵌合抗体与细胞的结合反应
Figure PCTCN2022093759-appb-000098
表55.FACS检测F4,F5,F6嵌合抗体与细胞的结合反应
Figure PCTCN2022093759-appb-000099
Figure PCTCN2022093759-appb-000100
表56.FACS检测F7嵌合抗体与细胞的结合反应
Figure PCTCN2022093759-appb-000101
Figure PCTCN2022093759-appb-000102
表57.FACS检测F8嵌合抗体与细胞的结合反应
Figure PCTCN2022093759-appb-000103
实施例5 MSLN抗体亲和力测定
5.1嵌合抗体与人MSLN-FL-His蛋白亲和力测定
使用Protein A芯片(GE Helthcare；29-127-558)捕获抗人MSLN嵌合抗体。样品和运行缓冲液是HBS-EP+(10mM HEPES,150mM NaCl,3mM EDTA,0.05％surfactant P20)(GE Healthcare；BR-1006-69)。流经池设置为25℃。样品块设置为16℃。两者都用运行缓冲液预处理。在每一个循环中，首先用Protein A芯片捕获待测抗体，然后注入单一浓度的人MSLN-FL-his蛋白，记录抗体和抗原蛋白的结合和解离过程，最后用Glycine pH1.5(GE Helthcare；BR-1003-54)完成芯片再生。通过注射溶液中不同浓度的人MSLN-FL-his持续240秒来测量结合，其中流速为30μL/分钟，从200nM起始(测试的实际浓度见详细结果)，以1：1稀释，总共5个浓度。监测解离相长达600秒，并通过从样品溶液切换到运行缓冲液触发。通过用10mM甘氨酸溶液(pH 1.5)以30μL/分钟的流速洗涤30秒，再生表面。通过减去从山羊抗人Fc表面获得的响应来校正本体折射率(Bulk refractive index)差异。也减去空白注射(＝双重参照)。为了计算表观KD和其他动力学参数，使用Langmuir 1：1模 型。人MSLN嵌合抗体与人MSLN-FL-his蛋白的结合速率(Ka)、解离速率(Kd)及结合亲和力(KD)如表58～表59所示，其中抗体Tab106、Tab108、Tab142作为对照。结果表明，大部分人MSLN嵌合抗体与人MSLN蛋白的亲和力不低于7.45E-7M，其中S009-F3.7.3，S009-F3.16.1，S009-F3.38.10，S009-F8-9.16与人MSLN-R3蛋白结合，未显示SPR检测数据。
表58.SPR(biacore)检测F1,F2,F3,F4,F5,F6嵌合抗体与人MSLN的亲和力
抗体名称 ka(1/Ms) kd(1/s) KD(M)
S009-F1.2.12 9.06E+04 1.43E-03 1.58E-08
S009-F1.7.14 5.53E+05 7.09E-03 1.28E-08
S009-F1.25.10 3.60E+03 6.70E-04 1.86E-07
S009-F1.35.24 9.31E+04 8.51E-05 9.14E-10
S009-F1.56.1 7.99E+05 7.10E-04 8.89E-10
S009-F1.59.1 1.64E+03 9.22E-04 5.63E-07
S009-F1.62.9 4.67E+02 3.48E-04 7.45E-07
S009-F2.13.3 2.19E+05 1.89E-03 8.65E-09
S009-F2.16.10 1.09E+06 1.64E-03 1.51E-09
S009-F2.17.3 6.41E+04 1.74E-04 2.72E-09
S009-F2.21.4 7.80E+05 2.27E-02 2.91E-08
S009-F2.23.12 8.19E+04 7.14E-04 8.71E-09
S009-F2.38.12 3.54E+05 1.09E-02 3.08E-08
S009-F2.39.3 4.00E+04 1.22E-04 3.06E-09
S009-F2.47.1 2.01E+06 1.03E-02 5.13E-09
S009-F2-56.12 7.24E+04 3.12E-03 4.31E-08
S009-F2.58.8 2.36E+05 1.23E-04 5.24E-10
S009-F3.23.1 1.02E+03 7.03E-04 6.89E-07
S009-F3.45.21 5.52E+05 8.30E-04 1.50E-09
S009-F3.51.8 2.47E+03 3.50E-04 1.42E-07
S009-F3-63.5 4.56E+03 4.78E-04 1.05E-07
S009-F3.74.20 1.03E+04 5.04E-05 4.92E-09
S009-F3.80.22 2.20E+03 3.32E-04 1.51E-07
S009-F4-94.15 1.54E+05 1.85E-04 1.20E-09
S009-F4-127.10 2.53E+03 4.33E-04 1.71E-07
S009-F6-62.5 1.44E+05 1.73E-02 1.20E-07
S009-F6-76.1 3.67E+04 3.69E-04 1.01E-08
Tab108 3.77E+05 1.26E-04 3.33E-10
表59.SPR(biacore)检测F7,F8嵌合抗体与人MSLN的亲和力
Figure PCTCN2022093759-appb-000104
Figure PCTCN2022093759-appb-000105
实施例6 抗体抗原结合表位竞争实验(epitope binning)
6.1 ELISA竞争法
为了鉴定抗体对抗原的结合位点，采用竞争ELISA的方法对MSLN嵌合抗体进行分组。参照实施例5(5.1)的方法使用2μg/mL嵌合抗体包被ELISA板，人MSLN蛋白从30μg/mL开始进行梯度稀释，计算出EC80作为竞争性ELISA中的浓度。
用PBS稀释嵌合抗体至2μg/mL，以50μL/孔包被96孔高吸附酶标板，4℃过夜包被后用250μL封闭液(含有2％(w/w)BSA的PBS)进行室温两小时封闭，加入40μg/mL待检测的抗体后，再加入每个待检测抗体对应的EC80浓度的人MSLN-FL-his蛋白，孵育2小 时，用PBS洗5次后加入HRP标记的anti-His二抗(购自Genescript，货号：A00612)，孵育1小时，洗板5次。加入TMB底物50μL每孔，室温孵育10分钟后，加入终止液(1.0M HCl)50μL每孔。用ELISA读板机(Insight，购自PerkinElmer)读取OD450nm数值，根据OD450nm数值，利用公式计算出抗体相互之间的竞争率，结果如图31～图37所示，竞争率的数值越高，表示两个抗体结合的抗原表位越是接近。
实施例7 MSLN抗体的人源化
将嵌合抗体F2.23.12、F2.39.3、F7.44.20、F7.33.24、F3.80.22和F3.38.10进行人源化。
通过比对IMGT(http://imgt.cines.fr)人类抗体重轻链可变区种系基因数据库，分别挑选与鼠源抗体同源性高的重链和轻链可变区种系基因作为模板，将鼠源抗体的CDR分别移植到相应的人源模板中，形成次序为FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4的可变区序列。基于抗体的三维结构，对包埋残基、与CDR区有直接相互作用的残基以及对VL和VH的构象有重要影响的构架区的残基进行回复突变，即得到人源化单克隆抗体。其中抗体的CDR氨基酸残基由Kabat编号系统确定并注释。
7.1 S009-F2.39.3的人源化
抗体S009-F2.39.3的人源化轻链模板为IGKV4-1*01/IGKV2-29*02和IGKJ4*01，人源化重链模板为IGHV1-46*01和IGHJ1*01，将鼠源抗体S009-F2.39.3的CDR分别移植到其人源模板中，即获得对应的人源化版本。根据需要，将S009-F2.39.3的人源化抗体的FR区序列中关键氨基酸进行回复突变为鼠源抗体对应的氨基酸，以保证原有的亲和力。具体回复突变设计见表60。
表60 S009-F2.39.3的人源化抗体回复突变设计
Figure PCTCN2022093759-appb-000106
注：Graft代表将鼠源抗体CDR植入人种系模板FR区序列；P49S表示将Graft第49位P突变成S，其它依此类推。回复突变氨基酸的编号为自然顺序编号。
S009-F2.39.3人源化抗体可变区具体序列如下：
S009-F2.39.3.VL1氨基酸序列如SEQ ID NO：565所示：
Figure PCTCN2022093759-appb-000107
S009-F2.39.3.VL2氨基酸序列如SEQ ID NO：566所示：
Figure PCTCN2022093759-appb-000108
S009-F2.39.3.VL3氨基酸序列如SEQ ID NO：567所示：
Figure PCTCN2022093759-appb-000109
S009-F2.39.3.VL4氨基酸序列如SEQ ID NO：568所示：
Figure PCTCN2022093759-appb-000110
S009-F2.39.3.VH1氨基酸序列如SEQ ID NO：569所示：
Figure PCTCN2022093759-appb-000111
S009-F2.39.3.VH2氨基酸序列如SEQ ID NO：570所示：
Figure PCTCN2022093759-appb-000112
S009-F2.39.3.VH3氨基酸序列如SEQ ID NO：571所示：
Figure PCTCN2022093759-appb-000113
人源化轻链模板IGKV4-1*01氨基酸序列如SEQ ID NO：572所示：
Figure PCTCN2022093759-appb-000114
人源化轻链模板IGKV2-29*02氨基酸序列如SEQ ID NO：573所示：
Figure PCTCN2022093759-appb-000115
人源化轻链模板IGKJ4*01氨基酸序列如SEQ ID NO：574所示：
Figure PCTCN2022093759-appb-000116
人源化重链模板IGHV1-46*01氨基酸序列如SEQ ID NO：575所示：
Figure PCTCN2022093759-appb-000117
人源化重链模板IGHJ1*01氨基酸序列如SEQ ID NO：576所示：
Figure PCTCN2022093759-appb-000118
根据Kabat编号系统，上述人源化抗体VH和VL序列分析结果如表61所示。
表61 S009-F2.39.3人源化抗体VH和VL序列的Kabat分析结果
Figure PCTCN2022093759-appb-000119
7.2 S009-F2.23.12的人源化
抗体S009-F2.23.12的人源化轻链模板为IGKV1-33*01和IGKJ4*01，人源化重链模板为IGHV1-46*01和IGHJ6*01，将鼠源抗体S009-F2.23.12的CDR分别移植到其人源模板中，即获得对应的人源化版本。根据需要，将S009-F2.23.12的人源化抗体的FR区序列中关键氨基酸进行回复突变为鼠源抗体对应的氨基酸，以保证原有的亲和力(抗体存在易发 生化学修饰的位点，我们对这些位点进行点突变以消除修饰风险)。具体回复突变设计见表62。
表62 S009-F2.23.12的人源化抗体回复突变设计
Figure PCTCN2022093759-appb-000120
注：Graft代表将鼠源抗体CDR植入人种系模板FR区序列；Y49H表示将Graft第49位Y突变成H，其它依此类推。回复突变氨基酸的编号为自然顺序编号。
S009-F2.23.12人源化抗体可变区具体序列如下：
S009-F2.23.12.VL1氨基酸序列如SEQ ID NO：577所示：
Figure PCTCN2022093759-appb-000121
S009-F2.23.12.VL2氨基酸序列如SEQ ID NO：578所示：
Figure PCTCN2022093759-appb-000122
S009-F2.23.12.VL3氨基酸序列如SEQ ID NO：579所示：
Figure PCTCN2022093759-appb-000123
S009-F2.23.12.VL4氨基酸序列如SEQ ID NO：580所示：
Figure PCTCN2022093759-appb-000124
S009-F2.23.12.VH1氨基酸序列如SEQ ID NO：581所示：
Figure PCTCN2022093759-appb-000125
S009-F2.23.12.VH2氨基酸序列如SEQ ID NO：582所示：
Figure PCTCN2022093759-appb-000126
S009-F2.23.12.VH3氨基酸序列如SEQ ID NO：583所示：
Figure PCTCN2022093759-appb-000127
S009-F2.23.12.VH4氨基酸序列如SEQ ID NO：584所示：
Figure PCTCN2022093759-appb-000128
人源化轻链模板IGKV1-33*01氨基酸序列如SEQ ID NO：585所示：
Figure PCTCN2022093759-appb-000129
人源化轻链模板IGKJ4*01氨基酸序列如SEQ ID NO：574所示：
Figure PCTCN2022093759-appb-000130
人源化重链模板IGHV1-46*01氨基酸序列如SEQ ID NO：575所示：
Figure PCTCN2022093759-appb-000131
人源化重链模板IGHJ6*01氨基酸序列如SEQ ID NO：586所示：
Figure PCTCN2022093759-appb-000132
根据Kabat编号系统，上述人源化抗体VH和VL序列分析结果如表63所示。
表63 S009-F2.23.12人源化抗体VH和VL序列的Kabat分析结果
Figure PCTCN2022093759-appb-000133
7.3 S009-F7.44.20的人源化
抗体S009-F7.44.20的人源化轻链模板为IGKV3-11*01/IGKV6-21*01和IGKJ4*01，人源化重链模板为IGHV1-46*01和IGHJ6*01，将鼠源抗体S009-F7.44.20的CDR分别移植到其人源模板中，即获得对应的人源化版本。根据需要，将S009-F7.44.20的人源化抗体的FR区序列中关键氨基酸进行回复突变为鼠源抗体对应的氨基酸，以保证原有的亲和力(抗体存在易发生化学修饰的位点，我们对这些位点进行点突变已消除修饰风险)。具体回复突变设计见表64。
表64 S009-F7.44.20的人源化抗体回复突变设计
Figure PCTCN2022093759-appb-000134
注：Graft代表将鼠源抗体CDR植入人种系模板FR区序列；K50Y表示将Graft第50位K突变成Y，其它依此类推。回复突变氨基酸的编号为自然顺序编号。
S009-F7.44.20人源化抗体可变区具体序列如下：
S009-F7.44.20.VL1氨基酸序列如SEQ ID NO：589所示：
Figure PCTCN2022093759-appb-000135
S009-F7.44.20.VL2氨基酸序列如SEQ ID NO：590所示：
Figure PCTCN2022093759-appb-000136
S009-F7.44.20.VL3氨基酸序列如SEQ ID NO：591所示：
Figure PCTCN2022093759-appb-000137
S009-F7.44.20.VL4氨基酸序列如SEQ ID NO：592所示：
Figure PCTCN2022093759-appb-000138
S009-F7.44.20.VH1氨基酸序列如SEQ ID NO：593所示：
Figure PCTCN2022093759-appb-000139
S009-F7.44.20.VH1a氨基酸序列如SEQ ID NO：594所示：
Figure PCTCN2022093759-appb-000140
S009-F7.44.20.VH2氨基酸序列如SEQ ID NO：595所示：
Figure PCTCN2022093759-appb-000141
S009-F7.44.20.VH2a氨基酸序列如SEQ ID NO：596所示：
Figure PCTCN2022093759-appb-000142
人源化轻链模板IGKV3-11*01氨基酸序列如SEQ ID NO：597所示：
Figure PCTCN2022093759-appb-000143
人源化轻链模板IGKV6-21*01氨基酸序列如SEQ ID NO：598所示：
Figure PCTCN2022093759-appb-000144
人源化轻链模板IGKJ4*01氨基酸序列如SEQ ID NO：574所示：
Figure PCTCN2022093759-appb-000145
人源化重链模板IGHV1-46*01氨基酸序列如SEQ ID NO：575所示：
Figure PCTCN2022093759-appb-000146
人源化重链模板IGHJ6*01氨基酸序列如SEQ ID NO：586所示：
Figure PCTCN2022093759-appb-000147
根据Kabat编号系统，上述人源化抗体VH和VL序列分析结果如表65所示。
表65 S009-F7.44.20人源化抗体VH和VL序列的Kabat分析结果
Figure PCTCN2022093759-appb-000148
7.4 S009-F7.33.24的人源化
抗体S009-F7.33.24的人源化轻链模板为IGKV2-29*02/IGKV4-1*01和IGKJ4*01，人源化重链模板为IGHV1-3*01和IGHJ1*01，将鼠源抗体S009-F7.33.24的CDR分别移植到其人源模板中，即获得对应的人源化版本。根据需要，将S009-F7.33.24的人源化抗体的FR区序列中关键氨基酸进行回复突变为鼠源抗体对应的氨基酸，以保证原有的亲和力(抗体存在易发生化学修饰的位点，我们对这些位点进行点突变已消除修饰风险)。具体回复突变设计见表66。
表66 S009-F7.33.24的人源化抗体回复突变设计
Figure PCTCN2022093759-appb-000149
注：Graft代表将鼠源抗体CDR植入人种系模板FR区序列；P43S表示将Graft第43位P突变成S，其它依此类推。回复突变氨基酸的编号为自然顺序编号。
S009-F7.33.24人源化抗体可变区具体序列如下：
S009-F7.33.24.VL1氨基酸序列如SEQ ID NO：601所示：
Figure PCTCN2022093759-appb-000150
S009-F7.33.24.VL2氨基酸序列如SEQ ID NO：602所示：
Figure PCTCN2022093759-appb-000151
S009-F7.33.24.VL3氨基酸序列如SEQ ID NO：603所示：
Figure PCTCN2022093759-appb-000152
S009-F7.33.24.VH1氨基酸序列如SEQ ID NO：604所示：
Figure PCTCN2022093759-appb-000153
S009-F7.33.24.VH1a氨基酸序列如SEQ ID NO：605所示：
Figure PCTCN2022093759-appb-000154
S009-F7.33.24.VH2氨基酸序列如SEQ ID NO：606所示：
Figure PCTCN2022093759-appb-000155
S009-F7.33.24.VH2a氨基酸序列如SEQ ID NO：607所示：
Figure PCTCN2022093759-appb-000156
人源化轻链模板IGKV2-29*02氨基酸序列如SEQ ID NO：573所示：
Figure PCTCN2022093759-appb-000157
人源化轻链模板IGKV4-1*01氨基酸序列如SEQ ID NO：572所示：
Figure PCTCN2022093759-appb-000158
人源化轻链模板IGKJ4*01氨基酸序列如SEQ ID NO：574所示：
Figure PCTCN2022093759-appb-000159
人源化重链模板IGHV1-3*01氨基酸序列如SEQ ID NO：608所示：
Figure PCTCN2022093759-appb-000160
人源化重链模板IGHJ1*01氨基酸序列如SEQ ID NO：576所示：
Figure PCTCN2022093759-appb-000161
根据Kabat编号系统，上述人源化抗体VH和VL序列分析结果如表67所示。
表67 S009-F7.33.24人源化抗体VH和VL序列的Kabat分析结果
Figure PCTCN2022093759-appb-000162
Figure PCTCN2022093759-appb-000163
7.5 S009-F3.80.22的人源化
抗体S009-F3.80.22的人源化轻链模板为IGKV2-40*01和IGKJ2*01，人源化重链模板为IGHV1-69-2*01和IGHJ6*01，将鼠源抗体S009-F3.80.22的CDR分别移植到其人源模板中，即获得对应的人源化版本。根据需要，将S009-F3.80.22的人源化抗体的FR区序列中关键氨基酸进行回复突变为鼠源抗体对应的氨基酸，以保证原有的亲和力(抗体存在易发生化学修饰的位点，我们对这些位点进行点突变已消除修饰风险)。具体回复突变设计见表68。
表68 S009-F3.80.22的人源化抗体回复突变设计
Figure PCTCN2022093759-appb-000164
注：Graft代表将鼠源抗体CDR植入人种系模板FR区序列；Y41F表示将Graft第41位Y突变成F，其它依此类推。回复突变氨基酸的编号为自然顺序编号。
S009-F3.80.22人源化抗体可变区具体序列如下：
S009-F3.80.22.VL1氨基酸序列如SEQ ID NO：611所示：
Figure PCTCN2022093759-appb-000165
S009-F3.80.22.VL1a氨基酸序列如SEQ ID NO：612所示：
Figure PCTCN2022093759-appb-000166
S009-F3.80.22.VL2氨基酸序列如SEQ ID NO：613所示：
Figure PCTCN2022093759-appb-000167
S009-F3.80.22.VL2a氨基酸序列如SEQ ID NO：614所示：
Figure PCTCN2022093759-appb-000168
S009-F3.80.22.VH1氨基酸序列如SEQ ID NO：615所示：
Figure PCTCN2022093759-appb-000169
S009-F3.80.22.VH2氨基酸序列如SEQ ID NO：616所示：
Figure PCTCN2022093759-appb-000170
S009-F3.80.22.VH3氨基酸序列如SEQ ID NO：617所示：
Figure PCTCN2022093759-appb-000171
S009-F3.80.22.VH4氨基酸序列如SEQ ID NO：618所示：
Figure PCTCN2022093759-appb-000172
人源化轻链模板IGKV2-40*01氨基酸序列如SEQ ID NO：619所示：
Figure PCTCN2022093759-appb-000173
人源化轻链模板IGKJ2*01氨基酸序列如SEQ ID NO：620所示：
Figure PCTCN2022093759-appb-000174
人源化重链模板IGHV1-69-2*01氨基酸序列如SEQ ID NO：621所示：
Figure PCTCN2022093759-appb-000175
人源化重链模板IGHJ6*01氨基酸序列如SEQ ID NO：586所示：
Figure PCTCN2022093759-appb-000176
根据Kabat编号系统，上述人源化抗体VH和VL序列分析结果如表69所示。
表69 S009-F3.80.22人源化抗体VH和VL序列的Kabat分析结果
Figure PCTCN2022093759-appb-000177
7.6 S009-F3.38.10的人源化
抗体S009-F3.38.10的人源化轻链模板为IGKV4-1*01/IGKV2-40*01和IGKJ2*01，人源化重链模板为IGHV1-3*01和IGHJ6*01，将鼠源抗体S009-F3.38.10的CDR分别移植到其人源模板中，即获得对应的人源化版本。根据需要，将S009-F3.38.10的人源化抗体的FR区序列中关键氨基酸进行回复突变为鼠源抗体对应的氨基酸，以保证原有的亲和力，(抗体存在易发生化学修饰的位点，我们对这些位点进行点突变已消除修饰风险)。具体回复突变设计见表70。
表70 S009-F3.38.10的人源化抗体回复突变设计
Figure PCTCN2022093759-appb-000178
Figure PCTCN2022093759-appb-000179
注：Graft代表将鼠源抗体CDR植入人种系模板FR区序列；P48S表示将Graft第48位P突变成S，其它依此类推。回复突变氨基酸的编号为自然顺序编号。
S009-F3.38.10人源化抗体可变区具体序列如下：
S009-F3.38.10.VL1氨基酸序列如SEQ ID NO：624所示：
Figure PCTCN2022093759-appb-000180
S009-F3.38.10.VL2氨基酸序列如SEQ ID NO：625所示：
Figure PCTCN2022093759-appb-000181
S009-F3.38.10.VH1氨基酸序列如SEQ ID NO：626所示：
Figure PCTCN2022093759-appb-000182
S009-F3.38.10.VH2氨基酸序列如SEQ ID NO：627所示：
Figure PCTCN2022093759-appb-000183
S009-F3.38.10.VH3氨基酸序列如SEQ ID NO：628所示：
Figure PCTCN2022093759-appb-000184
S009-F3.38.10.VH3a氨基酸序列如SEQ ID NO：629所示：
Figure PCTCN2022093759-appb-000185
S009-F3.38.10.VH4氨基酸序列如SEQ ID NO：630所示：
Figure PCTCN2022093759-appb-000186
S009-F3.38.10.VH5氨基酸序列如SEQ ID NO：631所示：
Figure PCTCN2022093759-appb-000187
人源化轻链模板IGKV4-1*01氨基酸序列如SEQ ID NO：572所示：
Figure PCTCN2022093759-appb-000188
人源化轻链模板IGKV2-40*01氨基酸序列如SEQ ID NO：619所示：
Figure PCTCN2022093759-appb-000189
人源化轻链模板IGKJ2*01氨基酸序列如SEQ ID NO：620所示：
Figure PCTCN2022093759-appb-000190
人源化重链模板IGHV1-3*01氨基酸序列如SEQ ID NO：608所示：
Figure PCTCN2022093759-appb-000191
人源化重链模板IGHJ6*01氨基酸序列如SEQ ID NO：586所示：
Figure PCTCN2022093759-appb-000192
根据Kabat编号系统，上述人源化抗体VH和VL序列分析结果如表71所示。
表71 S009-F3.38.10人源化抗体VH和VL序列的Kabat分析结果
Figure PCTCN2022093759-appb-000193
7.7对照抗体的制备
阳性对照抗体和阴性对照抗体均由泰州市百英生物科技有限公司完成质粒构建及抗体的生产纯化。
阳性对照：YP218序列来自专利US2015252118A1(VH-SEQ ID NO：13；VL-SEQ ID NO：15)，构建为VH-(G4S)3-VL-his和VL-(G4S)3-VH-his形式的抗体，分别命名为Tab110和Tab111。阴性对照：MSLN人源化抗体的同型阴性对照为不结合MSLN蛋白的无关抗体m971，其重链可变区和轻链可变区序列来自专利US 8591889B(VH-SEQ ID NO：3，第1-124位；VL-SEQ ID NO：4，第1-107位)，构建成VH-(G4S)3-VL-his的形式，命名为Tab084(NC)。
7.8 Anti-MSLN人源化抗体的制备
Anti-MSLN人源化抗体以VH-(G4S)3-VL-his或VL-(G4S)3-VH-his形式的进行表达。抗体表达纯化由泰州市百英生物科技有限公司负责。将纯化的人源化抗体进行蛋白浓度、纯度、内毒素(Lonza试剂盒)等检测分析，人源化抗体的纯度差异较大，选择纯度>50％的抗体进行更多的活性验证。
实施例8 Anti-MSLN人源化抗体与MSLN蛋白的结合能力鉴定
本发明分别从上述Anti-MSLN人源化抗体轻链和重链可变区的回复突变设计中，选择不同的轻链和重链序列进行交叉组合，以VH-(G4S)3-VL-his或VL-(G4S)3-VH-his形式的 进行表达，最终获得以下Anti-MSLN人源化抗体。
表72 Anti-MSLN人源化抗体对应的可变区编号
抗体名称 对应可变区 抗体名称 对应可变区
F2.39.3-H1 VH1+VL1 F7.44.20-H15 VH2a+VL3
F2.39.3-H2 VH1+VL2 F7.44.20-H16 VH2a+VL4
F2.39.3-H5 VH2+VL1 F7.33.24-H1 VH1+VL1
F2.39.3-H6 VH2+VL2 F7.33.24-H2 VH1+VL2
F2.39.3-H8 VH2+VL4 F7.33.24-H3 VH1+VL3
F2.39.3-H9 VH3+VL1 F7.33.24-H4 VH1a+VL1
F2.23.12-H1 VH1+VL1 F7.33.24-H5 VH1a+VL2
F2.23.12-H4 VH1+VL4 F7.33.24-H6 VH1a+VL3
F2.23.12-H5 VH2+VL1 F7.33.24-H7 VH2+VL1
F2.23.12-H8 VH2+VL4 F7.33.24-H8 VH2+VL2
F2.23.12-H13 VH4+VL1 F7.33.24-H9 VH2+VL3
F2.23.12-H16 VH4+VL4 F7.33.24-H10 VH2a+VL1
F7.44.20-H1 VH1+VL1 F7.33.24-H11 VH2a+VL2
F7.44.20-H2 VH1+VL2 F7.33.24-H12 VH2a+VL3
F7.44.20-H3 VH1+VL3 F3.80.22-H1 VL1+VH1
F7.44.20-H4 VH1+VL4 F3.80.22-H2 VL1+VH2
F7.44.20-H5 VH1a+VL1 F3.80.22-H3 VL1+VH3
F7.44.20-H6 VH1a+VL2 F3.80.22-H4 VL1+VH4
F7.44.20-H7 VH1a+VL3 F3.80.22-H5 VL1a+VH1
F7.44.20-H8 VH1a+VL4 F3.80.22-H6 VL1a+VH2
F7.44.20-H9 VH2+VL1 F3.80.22-H7 VL1a+VH3
F7.44.20-H10 VH2+VL2 F3.80.22-H8 VL1a+VH4
F7.44.20-H11 VH2+VL3 F3.80.22-H10 VL2+VH2
F7.44.20-H12 VH2+VL4 F3.80.22-H17 VH1+VL1a
F7.44.20-H13 VH2a+VL1 F3.38.10-L1H5 VL1+VH5
F7.44.20-H14 VH2a+VL2 F3.38.10-L2H3a VL2+VH3a
8.1酶联免疫吸附实验(ELISA)检测抗体与人MSLN蛋白的结合
为检测Anti-MSLN人源化抗体与人MSLN蛋白的结合活性，将人MSLN-hFc蛋白(Acro,CAT#MSN-H5253)用PBS稀释到终浓度2μg/mL，然后以50μl/孔加到96孔ELISA板，用塑料膜封好4℃孵育过夜，第二天用PBST洗板2次，加入封闭液[PBS+2％(w/w)BSA]室温封闭2小时。倒掉封闭液，PBST洗板2次，按50μl/孔加入起始浓度100nM，1:10梯度稀释的待测抗体或对照抗体。37℃孵育2小时后，用PBST洗板3次。加入HRP(辣根过氧化物酶)标记的Anti-his二抗(购自Genscript，货号：A00612)，37℃孵育半小时后，用PBST洗板5次。按50μl/孔加入TMB底物，室温孵育10～15分钟后，按50μl/孔加入终止液(1.0N HCl)。用ELISA读板机(Multimode Plate Reader，EnSight，购自Perkin Elmer)读取OD450nm数值。实验结果如图38中A～H，图39中A～F和表73-80所示。其中阴性对照为不结合MSLN蛋白的无关抗体m971，其重链可变区和轻链可变区序列来自专利US8591889B，构建成VH-(G4S)3-VL-his的形式，命名为Tab084(NC)；阳性对照为构建为VH-(G4S)3-VL-his和VL-(G4S)3-VH-his形式的YP218抗体，分别命名为Tab110和Tab111。 表中的数据为OD450nm值。结果说明，除F3.38.10与人MSLN全长蛋白无结合活性以外，其余经检测的Anti-MSLN人源化抗体与人MSLN全长蛋白和人MSLN-R3蛋白均有结合活性。
表73.F2.39.3人源化抗体与人MSLN全长蛋白在ELISA水平上的结合反应
Figure PCTCN2022093759-appb-000194
表74.F2.23.12人源化抗体与人MSLN全长蛋白在ELISA水平上的结合反应
Figure PCTCN2022093759-appb-000195
表75.F7.44.20人源化抗体与人MSLN全长蛋白在ELISA水平上的结合反应
Figure PCTCN2022093759-appb-000196
Figure PCTCN2022093759-appb-000197
表76.F7.33.24人源化抗体与人MSLN全长蛋白在ELISA水平上的结合反应
Figure PCTCN2022093759-appb-000198
表77.F3.38.10人源化抗体与人MSLN全长蛋白在ELISA水平上的结合反应
Figure PCTCN2022093759-appb-000199
表78.F7.44.20人源化抗体与人MSLN-R3蛋白在ELISA水平上的结合反应
Figure PCTCN2022093759-appb-000200
Figure PCTCN2022093759-appb-000201
表79.F7.33.24人源化抗体与人MSLN-R3蛋白在ELISA水平上的结合反应
Figure PCTCN2022093759-appb-000202
表80.F3.38.10人源化抗体与人MSLN-R3蛋白在ELISA水平上的结合反应
Figure PCTCN2022093759-appb-000203
Figure PCTCN2022093759-appb-000204
8.2流式细胞实验(FACS)检测抗体与表达人MSLN-R3-HEK293T重组细胞结合
将所需细胞在T-175细胞培养瓶中扩大培养至对数生长期，吸除培养基，用PBS缓冲液洗涤2次，用胰酶消化细胞，然后用完全培养基终止消化，并吹打细胞至单细胞悬液。细胞计数后，离心，细胞沉淀用PBS洗涤2次，将细胞沉淀用FACS缓冲液(PBS+2％胎牛血清)重悬至2×10 6细胞/mL，按每孔50μl加入到96孔FACS反应板中，按50μl/孔加入待测抗体或对照抗体(200nM为起始浓度，5倍梯度稀释)，与细胞悬液混匀，4℃孵育1小时。用PBS缓冲液离心洗涤3次，加入每孔50μl iFluor 647标记的Anti-His二抗(购自Genescript，货号：A01802-100)，4℃孵育1小时。用PBS缓冲液离心洗涤3次，100μl PBS重悬后用FACS(FACS Canto TM，购自BD公司)检测和分析结果。通过软件(CellQuest)进行数据分析，得到细胞的平均荧光密度(MFI)。再通过软件(GraphPad Prism8)分析，进行数据拟合，计算EC50。分析结果如图40中A～J，图41中A～J以及表81-85所示，其中Tab084为阴性对照(NC)；Tab110和Tab111为阳性对照。结果可见Anti-MSLN人源化抗体与表达人MSLN-R3蛋白的HEK293T重组细胞均有结合活性，且不与HEK293T空细胞结合，表明Anti-MSLN人源化抗体特异性结合人MSLN-R3膜蛋白。
表81.F2.39.3和F2.23.12人源化抗体与HEK293T-hMSLN-R3的结合反应
Figure PCTCN2022093759-appb-000205
表82.F7.44.20人源化抗体与HEK293T-hMSLN-R3的结合反应
Figure PCTCN2022093759-appb-000206
Figure PCTCN2022093759-appb-000207
表83.F7.33.24人源化抗体与HEK293T-hMSLN-R3的结合反应
Figure PCTCN2022093759-appb-000208
表84.F3.80.22人源化抗体与HEK293T-hMSLN-R3的结合反应
Figure PCTCN2022093759-appb-000209
Figure PCTCN2022093759-appb-000210
表85.F3.38.10人源化抗体与HEK293T-hMSLN-R3的结合反应
Figure PCTCN2022093759-appb-000211
8.3流式细胞实验(FACS)检测抗体与表达人MSLN的OVCAR3肿瘤细胞的结合
检测细胞和待测抗体的准备以及检测方法参照实施例2.2。分析结果如图42中A～J，图43中A～J以及表86-90所示，其中Tab084为阴性对照(NC)；Tab110和Tab111为阳性对照。结果可见F3.80.22人源化抗体无结合活性，F3.38.10人源化抗体弱(无)结合活性，其余检测的Anti-MSLN人源化抗体与表达人MSLN蛋白的OVCAR3肿瘤细胞均有结合活性，且不与不表达人MSLN蛋白A431细胞结合，表明Anti-MSLN人源化抗体可较好的特异性结合OVCAR3细胞。
表86.F2.39.3和F2.23.12人源化抗体与OVCAR3的结合反应
Figure PCTCN2022093759-appb-000212
Figure PCTCN2022093759-appb-000213
表87.F7.44.20人源化抗体与OVCAR3的结合反应
Figure PCTCN2022093759-appb-000214
表88.F7.33.24人源化抗体与OVCAR3的结合反应
Figure PCTCN2022093759-appb-000215
Figure PCTCN2022093759-appb-000216
表89.F3.80.22人源化抗体与OVCAR3的结合反应
Figure PCTCN2022093759-appb-000217
表90.F3.38.10人源化抗体与OVCAR3的结合反应
Figure PCTCN2022093759-appb-000218
实施例9 Anti-MSLN人源化抗体与HEK293T-猴MSLN细胞交叉结合活性的鉴定
收集HEK293T-猴MSLN细胞，按照实施例2.2的方法进行FACS检测与数据分析。分析结果如图44中A～J以及表91-95所示，其中Tab084为阴性对照(NC)；Tab110和Tab110为阳性对照。结果可见F3.80.22人源化抗体无结合活性，F3.38.10人源化抗体弱结合活性，其余检测的Anti-MSLN人源化抗体与HEK293T-猴MSLN细胞均有较好的结合活性。
表91.F2.39.3和F2.23.12人源化抗体与HEK293-猴MSLN的结合反应
Figure PCTCN2022093759-appb-000219
Figure PCTCN2022093759-appb-000220
表92.F7.44.20人源化抗体与HEK293-猴MSLN的结合反应
Figure PCTCN2022093759-appb-000221
表93.F7.33.24人源化抗体与HEK293-猴MSLN的结合反应
Figure PCTCN2022093759-appb-000222
Figure PCTCN2022093759-appb-000223
表94.F3.80.22人源化抗体与HEK293-猴MSLN的结合反应
Figure PCTCN2022093759-appb-000224
表95.F3.38.10人源化抗体与HEK293-猴MSLN的结合反应
Figure PCTCN2022093759-appb-000225
实施例10 Anti-MSLN人源化抗体亲和力测定
应用BIAcore 8K仪器，采用抗人抗体捕获法检测抗体与抗原的结合强度。首先，根据Human Antibody Capture Kit试剂盒(Cytiva；29-2346-00)的指导，应用氨基偶联法，将Anti-Human IgG抗体固定到CM5芯片(Cytiva；29-1496-03)上，以HBS-EP+pH7.4(10mM HEPES,150mM NaCl,3mM EDTA,0.05％surfactant P20)(Cytiva；BR-1006-69)为流动相，将NHS和EDC混合后，活化芯片约600s，用10mM乙酸钠pH5.0将Anti-Human IgG抗体稀释至15μg/mL，注射420s，最后用乙醇胺对剩余的活化位点进行封闭。然后，采用多循环动力学法测定抗体与抗原的亲和力，在每一个循环中，首先用抗人抗体捕获MSLN-hFc或CD3e-hFc重组蛋白，然后注入单一浓度的待测抗体，记录抗体和抗原蛋白的结合和解离过程，最后用3M MgCl 2完成芯片再生，其中流动相为HBS-EP+pH7.4，流 速30μL/min，再生时间30s，检测温度25℃。最后，根据1:1结合模型，对数据进行分析，拟合抗体抗原结合动力学参数，包括结合速率常数ka、解离速率常数kd、平衡解离常数KD、最大结合信号Rmax。
结果表明，F3.38.10-L1H5与人MSLN蛋白的结合信号未检测到。其余Anti-MSLN人源化分子与人MSLN蛋白的亲和力不低于3.11E-8。
表96 SPR(biacore)检测Anti-MSLN人源化抗体与人MSLN蛋白的亲和力
Figure PCTCN2022093759-appb-000226

Claims (27)

  1. 特异性结合MSLN的抗体或抗原结合片段，其特征在于，所述抗体或抗原结合片段包含：
    (a)SEQ ID NO：594-596、604-607、615-618、626-631、569-571、581-584、593、16、18、20、22、24、26、28、30、32、34、36、38、40、42、44、46、48、50、52、54、56、58、60、62、64、66、68、70、72、74、76、78、80、82、84、86、88、90、92、94、96、98、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、136、138、140、142、144、146、148、150、152、154或156任一项所示VH的HCDR1、HCDR2和HCDR3，或与所述HCDR1、HCDR2和/或HCDR3具有至少70％同一性或具有1、2、3或更多个氨基酸插入、缺失和/或替换，所述替换优选为保守氨基酸的替换；
    和/或，(b)SEQ ID NO：589-592、601-603、611-614、624-625、565-568、577-580、17、19、21、23、25、27、29、31、33、35、37、39、41、43、45、47、49、51、53、55、57、59、61、63、65、67、69、71、73、75、77、79、81、83、85、87、89、91、93、95、97、99、101、103、105、107、109、111、113、115、117、119、121、123、125、127、129、131、133、135、137、139、141、143、145、147、149、151、153、155或157任一项所示VL的LCDR1、LCDR2和LCDR3，或与所述LCDR1、LCDR2和/或LCDR3具有至少70％同一性或具有1、2、3或更多个氨基酸插入、缺失和/或替换，所述替换优选为保守氨基酸的替换；
    优选的，所述HCDR1～3和/或LCDR1～3根据Kabat编号系统确定，更优选地，所述HCDR1～3和/或所述LCDR1～3包含表23所示序列。
  2. 根据权利要求1所述的抗体或抗原结合片段，其特征在于，所述HCDR1～3选自以下VH1-VH77的任意序列组合或者与所述序列组合相比具有至少70％同一性或具有1、2、3或更多个氨基酸插入、缺失和/或替换的序列组合，所述替换优选为保守氨基酸的替换：
    Figure PCTCN2022093759-appb-100001
    Figure PCTCN2022093759-appb-100002
    所述LCDR1～3选自以下VL1-VL67的任意序列组合或者与所述序列组合相比具有至少70％同一性或具有1、2、3或更多个氨基酸插入、缺失和/或替换的序列组合，所述替换优选为保守氨基酸的替换：
    Figure PCTCN2022093759-appb-100003
    Figure PCTCN2022093759-appb-100004
  3. 根据权利要求2所述的抗体或抗原结合部分，其特征在于，所述抗体或抗原结合片段包括选自以下的序列组合：VH1+VL1、VH2+VL2、VH3+VL3、VH4+VL4、VH5+VL5、VH6+VL6、VH7+VL7、VH8+VL8、VH9+VL9、VH10+VL10、VH11+VL11、VH12+VL12、VH13+VL13、VH14+VL14、VH15+VL15、VH16+VL16、VH17+VL17、VH18+VL18、VH19+VL19、VH19+VL20、VH20+VL21、VH21+VL22、VH22+VL23、VH23+VL24、VH24+VL25、VH25+VL26、VH26+VL27、VH27+VL28、VH28+VL29、VH29+VL30、VH30+VL31、VH31+VL32、VH32+VL33、VH33+VL34、VH34+VL35、VH35+VL36、VH36+VL37、VH37+VL38、VH38+VL39、VH39+VL38、VH40+VL40、VH41+VL38、 VH42+VL41、VH43+VL42、VH44+VL43、VH45+VL38、VH46+VL44、VH47+VL45、VH48+VL46、VH49+VL47、VH50+VL48、VH51+VL49、VH52+VL50、VH53+VL51、VH54+VL52、VH55+VL14、VH56+VL53、VH57+VL54、VH58+VL55、VH59+VL56、VH60+VL57、VH61+VL58、VH62+VL59、VH63+VL14、VH64+VL60、VH65+VL60、VH66+VL61、VH67+VL62、VH68+VL63、VH69+VL64、VH70+VL65、VH72+VL13、VH73+VL43、VH74+VL43、VH75+VL41、VH76+VL41、VH26+VL66或VH77+VL22、以及与所述序列组合之序列相比具有至少70％同一性或具有1、2、3或更多个氨基酸插入、缺失和/或替换的序列组合，所述替换优选为保守氨基酸的替换。
  4. 根据权利要求1～3任一项所述的抗体或抗原结合部分，其特征在于，所述抗体或抗原结合片段包含：(1)与SEQ ID NO：16、18、20、22、24、26、28、30、32、34、36、38、40、42、44、46、48、50、52、54、56、58、60、62、64、66、68、70、72、74、76、78、80、82、84、86、88、90、92、94、96、98、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、136、138、140、142、144、146、148、150、152、154、156、569-571、581-584、593-596、604-607、615-618或626-631任一项所示VH相比具有至少80％、85％、90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或100％同一性的序列，或具有至多20个、19个、18个、17个、16个、15个、14个、13个、12个、11个、10个、9个、8个、7个、6个、5个、4个、3个、2个或1个突变的序列；所述突变可选自插入、缺失和/或替换，所述替换优选为保守氨基酸的替换；
    和/或，(2)与SEQ ID NO：17、19、21、23、25、27、29、31、33、35、37、39、41、43、45、47、49、51、53、55、57、59、61、63、65、67、69、71、73、75、77、79、81、83、85、87、89、91、93、95、97、99、101、103、105、107、109、111、113、115、117、119、121、123、125、127、129、131、133、135、137、139、141、143、145、147、149、151、153、155、157、565-568、577-580、589-592、601-603、611-614或624-625任一项所示VL相比具有至少80、85％、90％、91％、92％、93％、94％、95％、96％、97％、98％、99％或100％同一性的序列，或具有至多20个、19个、18个、17个、16个、15个、14个、13个、12个、11个、10个、9个、8个、7个、6个、5个、4个、3个、2个或1个突变的序列；所述突变可选自插入、缺失和/或替换，所述替换优选为保守氨基酸的替换。
  5. 根据权利要求1～4任一项所述的抗体或抗原结合部分，其特征在于，所述抗体或抗原结合部分包含：(1)SEQ ID NO：16所示序列和SEQ ID NO：17所示序列；
    (2)SEQ ID NO：18所示序列和SEQ ID NO：19所示序列；
    (3)SEQ ID NO：20所示序列和SEQ ID NO：21所示序列；
    (4)SEQ ID NO：22所示序列和SEQ ID NO：23所示序列；
    (5)SEQ ID NO：24所示序列和SEQ ID NO：25所示序列；
    (6)SEQ ID NO：26所示序列和SEQ ID NO：27所示序列；
    (7)SEQ ID NO：28所示序列和SEQ ID NO：29所示序列；
    (8)SEQ ID NO：30所示序列和SEQ ID NO：31所示序列；
    (9)SEQ ID NO：32所示序列和SEQ ID NO：33所示序列；
    (10)SEQ ID NO：34所示序列和SEQ ID NO：35所示序列；
    (11)SEQ ID NO：36所示序列和SEQ ID NO：37所示序列；
    (12)SEQ ID NO：38所示序列和SEQ ID NO：39所示序列；
    (13)SEQ ID NO：40所示序列和SEQ ID NO：41所示序列；
    (14)SEQ ID NO：42所示序列和SEQ ID NO：43所示序列；
    (15)SEQ ID NO：44所示序列和SEQ ID NO：45所示序列；
    (16)SEQ ID NO：46所示序列和SEQ ID NO：47所示序列；
    (17)SEQ ID NO：48所示序列和SEQ ID NO：49所示序列；
    (18)SEQ ID NO：50所示序列和SEQ ID NO：51所示序列；
    (19)SEQ ID NO：52所示序列和SEQ ID NO：53所示序列；
    (20)SEQ ID NO：54所示序列和SEQ ID NO：55所示序列；
    (21)SEQ ID NO：56所示序列和SEQ ID NO：57所示序列；
    (22)SEQ ID NO：58所示序列和SEQ ID NO：59所示序列；
    (23)SEQ ID NO：60所示序列和SEQ ID NO：61所示序列；
    (24)SEQ ID NO：62所示序列和SEQ ID NO：63所示序列；
    (25)SEQ ID NO：64所示序列和SEQ ID NO：65所示序列；
    (26)SEQ ID NO：66所示序列和SEQ ID NO：67所示序列；
    (27)SEQ ID NO：68所示序列和SEQ ID NO：69所示序列；
    (28)SEQ ID NO：70所示序列和SEQ ID NO：71所示序列；
    (29)SEQ ID NO：72所示序列和SEQ ID NO：73所示序列；
    (30)SEQ ID NO：74所示序列和SEQ ID NO：75所示序列；
    (31)SEQ ID NO：76所示序列和SEQ ID NO：77所示序列；
    (32)SEQ ID NO：78所示序列和SEQ ID NO：79所示序列；
    (33)SEQ ID NO：80所示序列和SEQ ID NO：81所示序列；
    (34)SEQ ID NO：82所示序列和SEQ ID NO：83所示序列；
    (35)SEQ ID NO：84所示序列和SEQ ID NO：85所示序列；
    (36)SEQ ID NO：86所示序列和SEQ ID NO：87所示序列；
    (37)SEQ ID NO：88所示序列和SEQ ID NO：89所示序列；
    (38)SEQ ID NO：90所示序列和SEQ ID NO：91所示序列；
    (39)SEQ ID NO：92所示序列和SEQ ID NO：93所示序列；
    (40)SEQ ID NO：94所示序列和SEQ ID NO：95所示序列；
    (41)SEQ ID NO：96所示序列和SEQ ID NO：97所示序列；
    (42)SEQ ID NO：98所示序列和SEQ ID NO：99所示序列；
    (43)SEQ ID NO：100所示序列和SEQ ID NO：101所示序列；
    (44)SEQ ID NO：102所示序列和SEQ ID NO：103所示序列；
    (45)SEQ ID NO：104所示序列和SEQ ID NO：105所示序列；
    (46)SEQ ID NO：106所示序列和SEQ ID NO：107所示序列；
    (47)SEQ ID NO：108所示序列和SEQ ID NO：109所示序列；
    (48)SEQ ID NO：110所示序列和SEQ ID NO：111所示序列；
    (49)SEQ ID NO：112所示序列和SEQ ID NO：113所示序列；
    (50)SEQ ID NO：114所示序列和SEQ ID NO：115所示序列；
    (51)SEQ ID NO：116所示序列和SEQ ID NO：117所示序列；
    (52)SEQ ID NO：118所示序列和SEQ ID NO：119所示序列；
    (53)SEQ ID NO：120所示序列和SEQ ID NO：121所示序列；
    (54)SEQ ID NO：122所示序列和SEQ ID NO：123所示序列；
    (55)SEQ ID NO：124所示序列和SEQ ID NO：125所示序列；
    (56)SEQ ID NO：126所示序列和SEQ ID NO：127所示序列；
    (57)SEQ ID NO：128所示序列和SEQ ID NO：129所示序列；
    (58)SEQ ID NO：130所示序列和SEQ ID NO：131所示序列；
    (59)SEQ ID NO：132所示序列和SEQ ID NO：133所示序列；
    (60)SEQ ID NO：134所示序列和SEQ ID NO：135所示序列；
    (61)SEQ ID NO：136所示序列和SEQ ID NO：137所示序列；
    (62)SEQ ID NO：138所示序列和SEQ ID NO：139所示序列；
    (63)SEQ ID NO：140所示序列和SEQ ID NO：141所示序列；
    (64)SEQ ID NO：142所示序列和SEQ ID NO：143所示序列；
    (65)SEQ ID NO：144所示序列和SEQ ID NO：145所示序列；
    (66)SEQ ID NO：146所示序列和SEQ ID NO：147所示序列；
    (67)SEQ ID NO：148所示序列和SEQ ID NO：149所示序列；
    (68)SEQ ID NO：150所示序列和SEQ ID NO：151所示序列；
    (69)SEQ ID NO：152所示序列和SEQ ID NO：153所示序列；
    (70)SEQ ID NO：154所示序列和SEQ ID NO：155所示序列；
    (71)SEQ ID NO：156所示序列和SEQ ID NO：157所示序列；
    (72)SEQ ID NO：569所示序列和SEQ ID NO：565所示序列；
    (73)SEQ ID NO：569所示序列和SEQ ID NO：566所示序列；
    (74)SEQ ID NO：570所示序列和SEQ ID NO：565所示序列；
    (75)SEQ ID NO：570所示序列和SEQ ID NO：566所示序列；
    (76)SEQ ID NO：570所示序列和SEQ ID NO：568所示序列；
    (77)SEQ ID NO：571所示序列和SEQ ID NO：565所示序列；
    (78)SEQ ID NO：581所示序列和SEQ ID NO：577所示序列；
    (79)SEQ ID NO：581所示序列和SEQ ID NO：580所示序列；
    (80)SEQ ID NO：582所示序列和SEQ ID NO：577所示序列；
    (81)SEQ ID NO：582所示序列和SEQ ID NO：580所示序列；
    (82)SEQ ID NO：584所示序列和SEQ ID NO：577所示序列；
    (83)SEQ ID NO：584所示序列和SEQ ID NO：580所示序列；
    (84)SEQ ID NO：593所示序列和SEQ ID NO：589所示序列；
    (85)SEQ ID NO：593所示序列和SEQ ID NO：590所示序列；
    (86)SEQ ID NO：593所示序列和SEQ ID NO：591所示序列；
    (87)SEQ ID NO：593所示序列和SEQ ID NO：592所示序列；
    (88)SEQ ID NO：594所示序列和SEQ ID NO：589所示序列；
    (89)SEQ ID NO：594所示序列和SEQ ID NO：590所示序列；
    (90)SEQ ID NO：594所示序列和SEQ ID NO：591所示序列；
    (91)SEQ ID NO：594所示序列和SEQ ID NO：592所示序列；
    (92)SEQ ID NO：595所示序列和SEQ ID NO：589所示序列；
    (93)SEQ ID NO：595所示序列和SEQ ID NO：590所示序列；
    (94)SEQ ID NO：595所示序列和SEQ ID NO：591所示序列；
    (95)SEQ ID NO：595所示序列和SEQ ID NO：592所示序列；
    (96)SEQ ID NO：596所示序列和SEQ ID NO：589所示序列；
    (97)SEQ ID NO：596所示序列和SEQ ID NO：590所示序列；
    (98)SEQ ID NO：596所示序列和SEQ ID NO：591所示序列；
    (99)SEQ ID NO：596所示序列和SEQ ID NO：592所示序列；
    (100)SEQ ID NO：604所示序列和SEQ ID NO：601所示序列；
    (101)SEQ ID NO：604所示序列和SEQ ID NO：602所示序列；
    (102)SEQ ID NO：604所示序列和SEQ ID NO：603所示序列；
    (103)SEQ ID NO：605所示序列和SEQ ID NO：601所示序列；
    (104)SEQ ID NO：605所示序列和SEQ ID NO：602所示序列；
    (105)SEQ ID NO：605所示序列和SEQ ID NO：603所示序列；
    (106)SEQ ID NO：606所示序列和SEQ ID NO：601所示序列；
    (107)SEQ ID NO：606所示序列和SEQ ID NO：602所示序列；
    (108)SEQ ID NO：606所示序列和SEQ ID NO：603所示序列；
    (109)SEQ ID NO：607所示序列和SEQ ID NO：601所示序列；
    (110)SEQ ID NO：607所示序列和SEQ ID NO：602所示序列；
    (111)SEQ ID NO：607所示序列和SEQ ID NO：603所示序列；
    (112)SEQ ID NO：611所示序列和SEQ ID NO：615所示序列；
    (113)SEQ ID NO：611所示序列和SEQ ID NO：616所示序列；
    (114)SEQ ID NO：611所示序列和SEQ ID NO：617所示序列；
    (115)SEQ ID NO：611所示序列和SEQ ID NO：618所示序列；
    (116)SEQ ID NO：612所示序列和SEQ ID NO：615所示序列；
    (117)SEQ ID NO：612所示序列和SEQ ID NO：616所示序列；
    (118)SEQ ID NO：612所示序列和SEQ ID NO：617所示序列；
    (119)SEQ ID NO：612所示序列和SEQ ID NO：618所示序列；
    (120)SEQ ID NO：613所示序列和SEQ ID NO：616所示序列；
    (121)SEQ ID NO：624所示序列和SEQ ID NO：631所示序列；
    (122)SEQ ID NO：625所示序列和SEQ ID NO：629所示序列；
    (123)与上述(1)至(122)所示序列具有至少70％、75％、80％、85％、90％、95％、96％、97％、98％、99％或更高一致性的序列。
  6. 根据权利要求1～5任一项所述的抗体或抗原结合片段，其特征在于，所述抗体或抗原结合片段包含或不包含抗体重链恒定区和/或轻链可变区；可选的，所述抗体重链恒定区可选自人、羊驼、小鼠、大鼠、兔或羊；可选地，所述抗体重链恒定区可选自IgG、IgM、IgA、IgE或IgD，所述IgG可选自IgG1，IgG2，IgG3或IgG4；可选地，所述重链恒定区可选自Fc区、CH3区、不存在CH1片段的重链恒定区或完整重链恒定区；优选地，所述重链恒定区具有如SEQ ID NO：158所示氨基酸序列；优选地，所述轻链恒定区具有如SEQ ID NO：159所示氨基酸序列。
  7. 根据权利要求1～6任一项所述的抗体或抗原结合片段，其特征在于，所述抗体或抗原结合片段特异性结合人MSLN蛋白；优选地，与人MSLN的解离常数(KD)不大于8.00E-7M。
  8. 根据权利要求1～7任一项所述的抗体或抗原结合片段，其特征在于，所述抗体或抗原结合片段为：
    (1)嵌合抗体或其片段；
    (2)人源化抗体或其片段；或，
    (3)全人抗体或其片段。
  9. 根据权利要求1～8任一项所述抗体或抗原结合片段，其特征在于，所述抗体或抗原结合片段选自单克隆抗体、多克隆抗体、天然抗体、工程化抗体、单特异性抗体、多特异性抗体(例如双特异性抗体)、单价抗体、多价抗体、完整抗体、完整抗体的片段、裸 抗体、缀合抗体、嵌合抗体、人源化抗体、全人抗体、Fab、Fab’、Fab’-SH、F(ab’)2、Fd、Fv、scFv、双抗体(diabody)或单域抗体。
  10. 根据权利要求1～9任一项所述的抗体或抗原结合片段，其特征在于，所述抗体或抗原结合片段还偶联有治疗剂或示踪剂；优选地，所述治疗剂选自药物、毒素、放射性同位素、化疗药或免疫调节剂，所述示踪剂选自放射学造影剂、顺磁离子、金属、荧光标记、化学发光标记、超声造影剂和光敏剂。
  11. 一种多特异性分子，其特征在于，所述多特异性分子包含权利要求1～10中任一项所述的抗体或抗原结合片段；优选地，所述多特异性分子进一步包含特异性结合MSLN以外的抗原或结合与权利要求1～10任一项所述抗体或抗原结合片段不同的MSLN表位的抗体或抗原结合片段。
  12. 根据权利要求11所述的多特异性分子，其特征在于，所述MSLN以外的抗原为T细胞、B细胞、自然杀伤细胞、树突状细胞、巨噬细胞、单核细胞或嗜中性细胞表面上的抗原；优选地，所述MSLN以外的抗原选自：CD3、CD3γ、CD3δ、CD3ε、CD3ζ、CD16、CD16A、CD32B、PD-1、PD-2、PD-L1、VEGF、NKG2D、CD19、CD20、CD40、CD47、4-1BB、CD137、EGFR、EGFRvIII、TNF-alpha、CD33、HER2、HER3、HAS、CD5、CD27、EphA2、EpCAM、MUC1、MUC16、CEA、Claudin18.2、叶酸受体、Claudin6、WT1、NY-ESO-1、MAGE3、ASGPR1或CDH16。
  13. 根据权利要求11或12所述的多特异性分子，其特征在于，所述多特异性分子为串联scFv、双功能抗体(Db)、单链双功能抗体(scDb)、双重亲和力再靶向(DART)抗体、F(ab')2、双重可变域(DVD)抗体、臼包杵(KiH)抗体、对接及锁定(DNL)抗体、化学交联抗体、杂多聚抗体或异结合物抗体。
  14. 一种嵌合抗原受体(CAR)，其特征在于，所述嵌合抗原受体至少包含细胞外抗原结合结构域、跨膜结构域和胞内信号传导结构域，所述细胞外抗原结合结构域包含权利要求1～10任一项所述抗体或抗原结合片段。
  15. 一种免疫效应细胞，其特征在于，所述免疫效应细胞表达权利要求14所述的嵌合抗原受体，或包含编码权利要求14所述嵌合抗原受体的核酸片段；优选地，所述免疫效应细胞选自T细胞、NK细胞(natural killer cell)、NKT细胞(natural killer T cell)、DNT细胞(double negative T cell)、单核细胞、巨噬细胞、树突状细胞或肥大细胞，所述T细胞优选自细胞毒性T细胞、调节性T细胞或辅助性T细胞；优选地，所述免疫效应细胞为自体免疫效应细胞或同种异体免疫效应细胞。
  16. 一种分离的核酸片段，其特征在于，所述核酸片段编码权利要求1～10任一项所述的抗体或抗原结合片段，或权利要求11～13任一项所述多特异性分子，或权利要求14所述的嵌合抗原受体。
  17. 一种载体(vector)，其特征在于，所述载体包含权利要求16所述的核酸片段。
  18. 一种宿主细胞，其特征在于，所述宿主细胞包含权利要求17所述的载体；优选地，所述细胞为原核细胞或真核细胞，例如细菌(大肠杆菌)、真菌(酵母)、昆虫细胞或哺乳动物细胞(CHO细胞系或293T细胞系)。
  19. 一种制备权利要求1～10任一项所述抗体或抗原结合片段或权利要求11～13任一项所述多特异性分子的方法，其特征在于，所述方法包括培养权利要求18所述细胞，以及分离所述细胞表达的抗体或抗原结合片段，或分离所述细胞表达的多特异性分子。
  20. 一种制备权利要求15所述免疫效应细胞的方法，其特征在于，所述方法包括将编码权利要求14所述CAR的核酸片段导入所述免疫效应细胞，可选地，所述方法还包括启动所述免疫效应细胞表达权利要求14所述CAR。
  21. 一种药物组合物，其特征在于，所述药物组合物包含权利要求1～10任一项所述的抗体或抗原结合片段，或权利要求11～13任一项所述的多特异性抗体，或权利要求15所述免疫效应细胞，或权利要求16所述的核酸片段，或权利要求17所述载体；或权利要求19～20任一项所述方法制备获得的产品；可选地，所述药物组合物还包含药学上可接受的运载体(carrier)、稀释剂或助剂；可选地，所述药物组合物还包含额外的抗肿瘤剂。
  22. 权利要求1～10任一项所述的抗体或抗原结合片段，或权利要求11～13任一项所述的多特异性分子，或权利要求15所述免疫效应细胞，或权利要求16所述的核酸片段，或权利要求17所述载体；或权利要求19～20任一项所述方法制备获得的产品；或权利要求21所述药物组合物在制备预防和/或治疗肿瘤的药物中的用途；所述肿瘤优选间皮瘤、肺癌、乳腺癌、食管癌、胰腺癌、卵巢癌或胸膜癌；更优选上皮样恶性胸膜间皮瘤、肺腺癌。
  23. 一种预防和/或治疗肿瘤的方法，包含向有此需要的患者施用有效量的权利要求1～10任一项所述的抗体或抗原结合片段，或权利要求11～13任一项所述的多特异性抗体，或权利要求15所述免疫效应细胞，或权利要求16所述的核酸片段，或权利要求17所述载体，或权利要求19～20任一项所述方法制备获得的产品，或权利要求21所述药物组合物；所述肿瘤优选间皮瘤、肺癌、乳腺癌、食管癌、胰腺癌、卵巢癌或胸膜癌；更优选上皮样恶性胸膜间皮瘤、肺腺癌。
  24. 权利要求1～10任一项所述的抗体或抗原结合片段，或权利要求11～13任一项所述的多特异性抗体，或权利要求15所述免疫效应细胞，或权利要求16所述的核酸片段，或权利要求17所述载体，或权利要求19～20任一项所述方法制备获得的产品，或权利要求21所述药物组合物，其特征在于，用于预防和/或治疗肿瘤；所述肿瘤优选间皮瘤、肺癌、乳腺癌、食管癌、胰腺癌、卵巢癌或胸膜癌；更优选上皮样恶性胸膜间皮瘤、肺腺癌。
  25. 一种试剂盒，其包含权利要求1～10任一项所述的抗体或抗原结合片段，或权利要求11～13任一项所述的多特异性抗体，或权利要求15所述免疫效应细胞，或权利要求16所述的核酸片段，或权利要求17所述载体，或权利要求19～20任一项所述方法制备获得的产品，或权利要求21所述药物组合物。
  26. 一种检测MSLN表达的方法，其特征在于，在权利要求1～10任一项所述的抗体或抗原结合片段与MSLN之间能够形成复合物的条件下，使待检测样品与权利要求1～10任一项所述的抗体或抗原结合片段接触。
  27. 一种体外抑制表达MSLN细胞增殖或迁移的方法，其特征在于，在权利要求1～10任一项所述的抗体或抗原结合片段与MSLN之间能够形成复合物的条件下，使所述细胞与 权利要求1～10任一项所述的抗体或抗原结合片段接触。
PCT/CN2022/093759 2021-05-19 2022-05-19 抗msln抗体及其应用 WO2022242703A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280035947.9A CN117396515A (zh) 2021-05-19 2022-05-19 抗msln抗体及其应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110543185 2021-05-19
CN202110543185.0 2021-05-19
CN202111321146 2021-11-09
CN202111321146.2 2021-11-09

Publications (1)

Publication Number Publication Date
WO2022242703A1 true WO2022242703A1 (zh) 2022-11-24

Family

ID=84140244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/093759 WO2022242703A1 (zh) 2021-05-19 2022-05-19 抗msln抗体及其应用

Country Status (2)

Country Link
CN (1) CN117396515A (zh)
WO (1) WO2022242703A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117024596A (zh) * 2023-08-18 2023-11-10 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
US11981745B2 (en) 2021-10-06 2024-05-14 Link Immunotherapeutics, Inc. Anti-mesothelin antigen-binding molecules and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107840891A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗msln抗体及其应用
WO2019078698A2 (ko) * 2017-10-20 2019-04-25 주식회사 녹십자 항 -msln항체 및 이를포함하는 암치료용 약학적 조성물
US20190218294A1 (en) * 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
CN110698562A (zh) * 2019-10-31 2020-01-17 浙江蓝盾药业有限公司 抗人msln单克隆抗体
CN111349165A (zh) * 2020-05-25 2020-06-30 南京蓝盾生物科技有限公司 抗人msln单克隆抗体及其应用
CN111560072A (zh) * 2020-07-16 2020-08-21 上海恒润达生生物科技有限公司 抗人msln抗体以及靶向msln的免疫效应细胞

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190218294A1 (en) * 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
CN107840891A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗msln抗体及其应用
WO2019078698A2 (ko) * 2017-10-20 2019-04-25 주식회사 녹십자 항 -msln항체 및 이를포함하는 암치료용 약학적 조성물
CN110698562A (zh) * 2019-10-31 2020-01-17 浙江蓝盾药业有限公司 抗人msln单克隆抗体
CN111349165A (zh) * 2020-05-25 2020-06-30 南京蓝盾生物科技有限公司 抗人msln单克隆抗体及其应用
CN111560072A (zh) * 2020-07-16 2020-08-21 上海恒润达生生物科技有限公司 抗人msln抗体以及靶向msln的免疫效应细胞

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11981745B2 (en) 2021-10-06 2024-05-14 Link Immunotherapeutics, Inc. Anti-mesothelin antigen-binding molecules and uses thereof
CN117024596A (zh) * 2023-08-18 2023-11-10 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像

Also Published As

Publication number Publication date
CN117396515A (zh) 2024-01-12

Similar Documents

Publication Publication Date Title
US11230603B2 (en) Anti-GARP protein
TW201800419A (zh) Ｌａｇ－３抗體、其抗原結合片段及其醫藥用途
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
CN112969716B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
WO2022242703A1 (zh) 抗msln抗体及其应用
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
CN110790839B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CN116239698A (zh) 双功能融合蛋白及其医药用途
US20220242953A1 (en) Cd3 antibody and pharmaceutical use thereof
WO2022262859A1 (zh) 抗人msln人源化抗体及其应用
WO2022105811A1 (zh) Cd19人源化抗体及其应用
WO2022121941A1 (zh) 抗人msln的抗体及其用途
WO2022135536A1 (zh) Cd3人源化抗体及其应用
WO2022127844A1 (zh) Cd5抗体及其应用
WO2022105914A1 (zh) Cd70抗体及其应用
WO2023125888A1 (zh) 一种gprc5d抗体及其应用
WO2023280297A1 (zh) Cd19抗体及其应用
WO2023036326A1 (zh) 抗人cd3抗体及其应用
CN113637075B (zh) 双特异性抗原结合分子及其医药用途
WO2023125349A1 (zh) 抗gucy2c抗体及其应用
WO2023104138A1 (zh) Bcma抗体及其应用
WO2022152282A1 (zh) 抗人cd22的单克隆抗体及其用途
CN114437215B (zh) 抗人cd38抗体及其制备方法和用途
WO2023186100A1 (zh) 抗ror1的抗体及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22804023

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280035947.9

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22804023

Country of ref document: EP

Kind code of ref document: A1